<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>TOPAMAX - topiramate tablet, coated </strong><br>PD-Rx Pharmaceuticals, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use TOPAMAX<span class="Sup">®</span> safely and effectively. See full prescribing information for TOPAMAX<span class="Sup">®</span><br><br> TOPAMAX (topiramate) TABLETS for oral use<br><br> TOPAMAX (topiramate capsules) SPRINKLE CAPSULES for oral use<br><br> Initial U.S. Approval – 1996</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div>
<a name="id802c3fb-c628-4483-876f-7bb13fb840b2"></a><table width="75%">
<col align="left" valign="top" width="75%">
<col align="right" valign="top" width="25%">
<tbody class="Headless">
<tr class="Botrule First Toprule">
<td align="left">•   Indications and Usage (<a href="#S1.1">1.1</a>)</td>
<td align="right">07/2011</td>
</tr>
<tr>
<td align="left">•   Dosage and Administration (<a href="#S2.1">2.1</a>)</td>
<td align="right">07/2011</td>
</tr>
<tr>
<td align="left">•   <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic Acidosis</span> (<a href="#S5.3">5.3</a>)</td>
<td align="right">07/2011</td>
</tr>
<tr class="Botrule Last">
<td align="left">•   <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">Hypothermia</span> with Concomitant Valproic Acid (VPA) Use (<a href="#S5.11">5.11</a>)</td>
<td align="right">07/2011</td>
</tr>
</tbody>
</table>
</div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div>
<p class="Highlighta">TOPAMAX<span class="Sup">®</span> is an antiepileptic (AED) agent indicated for: </p>
<ul class="Disc">
<li>Monotherapy <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>: Initial monotherapy in patients ≥ 2 years of age with partial onset or primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span> (<a href="#S1.1">1.1</a>)</li>
<li>Adjunctive therapy <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>: Adjunctive therapy for adults and pediatric patients (2 to 16 years of age) with partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span>, and in patients ≥2 years of age with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with Lennox-Gastaut syndrome (LGS) (<a href="#S1.2">1.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span>: Treatment for adults for prophylaxis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> (<a href="#S1.3">1.3</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta">See <a href="#S2.1">DOSAGE AND ADMINISTRATION, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span>: Monotherapy and Adjunctive Therapy Use for additional details (2.1)</a> </p>
<a name="ic7fabc44-536d-4826-8257-10d788bd48cc"></a><table width="80%">
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="25%">
<col align="left" valign="top" width="25%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left"></th>
<th class="Rrule" align="left">Initial Dose</th>
<th class="Rrule" align="left">Titration</th>
<th class="Rrule" align="left">Recommended Dose</th>
</tr></thead>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> monotherapy: children 2 to &lt;10 years (<a href="#S2.1">2.1</a>)</td>
<td class="Rrule" align="left">25 mg/day administered nightly for the first week</td>
<td class="Rrule" align="left">The dosage should be titrated over 5–7 weeks</td>
<td class="Rrule" align="left">Daily doses in two divided doses based on weight (Table 2)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> monotherapy: adults and pediatric patients ≥10 years (<a href="#S2.1">2.1</a>)</td>
<td class="Rrule" align="left">50 mg/day in two divided doses</td>
<td class="Rrule" align="left">The dosage should be increased weekly by increments of 50 mg for the first 4 weeks then 100 mg for weeks 5 to 6.</td>
<td class="Rrule" align="left">400 mg/day in two divided doses</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> adjunctive therapy: adults with partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or LGS (<a href="#S2.1">2.1</a>)</td>
<td class="Rrule" align="left">25 to 50 mg/day</td>
<td class="Rrule" align="left">The dosage should be increased weekly to an effective dose by increments of 25 to 50 mg.</td>
<td class="Rrule" align="left">200–400 mg/day in two divided doses</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> adjunctive therapy: adults with primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span> (<a href="#S2.1">2.1</a>)</td>
<td class="Rrule" align="left">25 to 50 mg/day</td>
<td class="Rrule" align="left">The dosage should be increased weekly to an effective dose by increments of 25 to 50 mg. </td>
<td class="Rrule" align="left">400 mg/day in two divided doses</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> adjunctive therapy: pediatric patients with partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span> or LGS (<a href="#S2.1">2.1</a>)</td>
<td class="Rrule" align="left">25 mg/day (or less, based on a range of 1 to 3 mg/kg/day) nightly for the first week</td>
<td class="Rrule" align="left">The dosage should be increased at 1- or 2-week intervals by increments of 1 to 3 mg/kg/day (administered in two divided doses). Dose titration should be guided by clinical outcome.</td>
<td class="Rrule" align="left">5 to 9 mg/kg/day in two divided doses</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> (<a href="#S2.2">2.2</a>) </td>
<td class="Rrule" align="left">25 mg/day administered nightly for the first week</td>
<td class="Rrule" align="left">The dosage should be increased weekly by increments of 25 mg. Dose and titration should be guided by clinical outcome.</td>
<td class="Rrule" align="left">100 mg/day administered in two divided doses</td>
</tr>
</tbody>
</table>
</div>
<div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc">
<li>Tablets: 25 mg, 50 mg,  100 mg, and 200 mg (<a href="#S3">3</a>)</li>
<li>Sprinkle Capsules: 15 mg and 25 mg (<a href="#S3">3</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">None.  (<a href="#section-4">4</a>)</p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Acute <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">myopia</span> and secondary <span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">angle closure glaucoma</span>: Untreated elevated intraocular pressure can lead to permanent visual loss. The primary treatment to reverse symptoms is discontinuation of TOPAMAX<span class="Sup">®</span> as rapidly as possible (<a href="#S5.1">5.1</a>)</li>
<li>Oligohidrosis and <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">hyperthermia</span>: Monitor decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> and increased body temperature, especially in pediatric patients (<a href="#S5.2">5.2</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic acidosis</span>: Baseline and periodic measurement of serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> is recommended. Consider dose reduction or discontinuation of TOPAMAX<span class="Sup">®</span> if clinically appropriate (<a href="#S5.3">5.3</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal behavior</span> and ideation: Antiepileptic drugs increase the risk of <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> or ideation (<a href="#S5.4">5.4</a>)</li>
<li>Cognitive/neuropsychiatric: TOPAMAX<span class="Sup">®</span> may cause cognitive dysfunction. Patients should use caution when operating machinery including automobiles. <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span> and mood problems may occur in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> populations (<a href="#S5.5">5.5</a>)</li>
<li>Fetal Toxicity: TOPAMAX<span class="Sup">®</span> use during pregnancy can cause <span class="product-label-link" type="condition" conceptid="133861" conceptname="Cleft lip">cleft lip</span> and/or palate (<a href="#S5.6">5.6</a>)</li>
<li>Withdrawal of AEDs: Withdrawal of TOPAMAX<span class="Sup">®</span> should be done gradually (<a href="#S5.7">5.7</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> and <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> associated with or without concomitant valproic acid use: Patients with inborn errors of metabolism or reduced mitochondrial activity may have an increased risk of hyper-ammonemia. Measure <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> if encephalopathic symptoms occur (<a href="#S5.9">5.9</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Kidney stones</span>: Use with other carbonic anhydrase inhibitors, other drugs causing <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, or in patients on a ketogenic diet should be avoided (<a href="#S5.10">5.10</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">Hypothermia</span> has been reported with and without <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> during topiramate treatment with concomitant valproic acid use (<a href="#S5.11">5.11</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common (≥5% more frequent than placebo or low-dose TOPAMAX<span class="Sup">®</span> in monotherapy) adverse reactions in controlled, <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> clinical trials were <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, psychomotor slowing, difficulty with memory, difficulty with concentration/attention, cognitive problems, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, mood problems, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>. The most common (≥5% more frequent than placebo) adverse reactions in controlled, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> clinical trials were <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> and <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">taste perversion</span> (<a href="#S6">6</a>) .  </p>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Janssen Pharmaceuticals, Inc. at 1-800-JANSSEN (1-800-526-7736) or FDA at 1-800-FDA-1088 or <span class="Italics">WWW.FDA.GOV/MEDWATCH</span>. </span> </p>
</div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div>
<p class="Highlighta">Summary of antiepileptic drug (AED) interactions with TOPAMAX<span class="Sup">®</span> (<a href="#S7.1">7.1</a>) </p>
<a name="if8794ccf-679d-4c62-8957-75c846702dfd"></a><table width="75%">
<col align="left" valign="top" width="33%">
<col align="left" valign="top" width="34%">
<col align="left" valign="top" width="33%">
<thead><tr class="First Last">
<th align="left">AED Co-administered</th>
<th align="left">AED Concentration</th>
<th align="left">Topiramate Concentration</th>
</tr></thead>
<tfoot>
<tr class="Botrule First Last"><td align="left" colspan="3">NC = Less than 10% change in plasma concentration.<br> NE = Not Evaluated</td></tr>
<tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd> = Plasma concentration increased 25% in some patients, generally those on a twice a day dosing regimen of phenytoin.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd> = Is not administered but is an active metabolite of carbamazepine.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left">Phenytoin</td>
<td align="left">NC or 25% increase<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a>
</td>
<td align="left">48% decrease</td>
</tr>
<tr>
<td align="left">Carbamazepine (CBZ)</td>
<td align="left">NC</td>
<td align="left">40% decrease</td>
</tr>
<tr>
<td align="left">CBZ epoxide<a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a>
</td>
<td align="left">NC</td>
<td align="left">NE</td>
</tr>
<tr>
<td align="left">Valproic acid</td>
<td align="left">11% decrease</td>
<td align="left">14% decrease</td>
</tr>
<tr>
<td align="left">Phenobarbital</td>
<td align="left">NC</td>
<td align="left">NE</td>
</tr>
<tr>
<td align="left">Primidone</td>
<td align="left">NC</td>
<td align="left">NE</td>
</tr>
<tr class="Last">
<td align="left">Lamotrigine</td>
<td align="left">NC at TPM doses up to 400 mg/day</td>
<td align="left">13% decrease</td>
</tr>
</tbody>
</table>
<ul class="Disc">
<li>Oral contraceptives: Decreased contraceptive efficacy and increased breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> should be considered, especially at doses greater than 200 mg/day (<a href="#S7.3">7.3)</a>
</li>
<li>Metformin is contraindicated with <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, an effect of TOPAMAX<span class="Sup">®</span> (<a href="#S7.4">7.4</a>)</li>
<li>Lithium levels should be monitored when co-administered with high-dose TOPAMAX<span class="Sup">®</span> (<a href="#S7.5">7.5</a>)</li>
<li>Other carbonic anhydrase inhibitors: Monitor the patient for the appearance or worsening of <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> (<a href="#S7.6">7.6</a>)</li>
</ul>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span>: In renally impaired patients (creatinine clearance less than 70 mL/min/1.73 m<span class="Sup">2</span>), one-half of the adult dose is recommended (<a href="#S2.4">2.4</a>)</li>
<li>Patients undergoing hemodialysis: Topiramate is cleared by hemodialysis. Dosage adjustment is necessary to avoid rapid drops in topiramate plasma concentration during hemodialysis (<a href="#S2.6">2.6</a>)</li>
<li>Pregnancy: Increased risk of <span class="product-label-link" type="condition" conceptid="133861" conceptname="Cleft lip">cleft lip</span> and/or palate. Pregnancy registry available (<a href="#S8.1">8.1</a>) </li>
<li>Nursing mothers: Caution should be exercised when administered to a nursing mother (<a href="#S8.3">8.3</a>)</li>
<li>Geriatric use: Dosage adjustment may be necessary for elderly with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (<a href="#S8.5">8.5</a>)</li>
</ul></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
</div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
</div>
<div><div>
<div></div>
<div></div>
<div></div>
</div></div>
<div>
<div><div>
<div></div>
<div></div>
</div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 1/2012</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h2><a href="#section-1.1" class="toc">1.1	Monotherapy <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></a></h2>
<h2><a href="#section-1.2" class="toc">1.2	Adjunctive Therapy <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></a></h2>
<h2><a href="#section-1.3" class="toc">1.3	<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></a></h2>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	<span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></a></h2>
<h2><a href="#section-2.2" class="toc">2.2	<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></a></h2>
<h2><a href="#section-2.3" class="toc">2.3	Administration of TOPAMAX<span class="Sup">®</span> Sprinkle Capsules</a></h2>
<h2><a href="#section-2.4" class="toc">2.4	Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-2.5" class="toc">2.5	Geriatric Patients (Ages 65 Years and Over)</a></h2>
<h2><a href="#section-2.6" class="toc">2.6	Patients Undergoing Hemodialysis</a></h2>
<h2><a href="#section-2.7" class="toc">2.7	Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Disease</span></a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Acute <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">Myopia</span> and Secondary <span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">Angle Closure Glaucoma</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Oligohidrosis and <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">Hyperthermia</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3	<span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic Acidosis</span></a></h2>
<h2><a href="#section-5.4" class="toc">5.4	<span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation</a></h2>
<h2><a href="#section-5.5" class="toc">5.5	Cognitive/Neuropsychiatric Adverse Reactions</a></h2>
<h2><a href="#section-5.6" class="toc">5.6	Fetal Toxicity</a></h2>
<h2><a href="#section-5.7" class="toc">5.7	Withdrawal of Antiepileptic Drugs (AEDs)</a></h2>
<h2><a href="#section-5.8" class="toc">5.8	Sudden Unexplained <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> (SUDEP)</a></h2>
<h2><a href="#section-5.9" class="toc">5.9	<span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> and <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span> (Without and With Concomitant Valproic Acid [VPA] Use)</a></h2>
<h2><a href="#section-5.10" class="toc">5.10	<span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Kidney Stones</span></a></h2>
<h2><a href="#section-5.11" class="toc">5.11	<span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">Hypothermia</span> with Concomitant Valproic Acid (VPA) Use</a></h2>
<h2><a href="#section-5.12" class="toc">5.12	<span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></a></h2>
<h2><a href="#section-5.13" class="toc">5.13	Adjustment of Dose in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span></a></h2>
<h2><a href="#section-5.14" class="toc">5.14	Decreased Hepatic Function</a></h2>
<h2><a href="#section-5.15" class="toc">5.15	Monitoring: Laboratory Tests</a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Monotherapy <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Adjunctive Therapy <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></a></h2>
<h2><a href="#section-6.3" class="toc">6.3	Incidence in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> Controlled Clinical Trials – Adjunctive Therapy – Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>, Primary Generalized Tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">Clonic Seizures</span>, and Lennox-Gastaut Syndrome</a></h2>
<h2><a href="#section-6.4" class="toc">6.4	Other Adverse Reactions Observed During Double-Blind <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> Adjunctive Therapy Trials</a></h2>
<h2><a href="#section-6.5" class="toc">6.5	Incidence in Study 119 – Add-On Therapy– Adults with Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></a></h2>
<h2><a href="#section-6.6" class="toc">6.6	Other Adverse Reactions Observed During All <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> Clinical Trials</a></h2>
<h2><a href="#section-6.7" class="toc">6.7	<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></a></h2>
<h2><a href="#section-6.8" class="toc">6.8	Other Adverse Reactions Observed During <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Clinical Trials</a></h2>
<h2><a href="#section-6.9" class="toc">6.9	Postmarketing and Other Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">7.1	Antiepileptic Drugs</a></h2>
<h2><a href="#section-7.2" class="toc">7.2	CNS Depressants</a></h2>
<h2><a href="#section-7.3" class="toc">7.3	Oral Contraceptives</a></h2>
<h2><a href="#section-7.4" class="toc">7.4	Metformin</a></h2>
<h2><a href="#section-7.5" class="toc">7.5	Lithium</a></h2>
<h2><a href="#section-7.6" class="toc">7.6	Other Carbonic Anhydrase Inhibitors</a></h2>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2	Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6	Race and Gender Effects</a></h2>
<h2><a href="#section-8.7" class="toc">8.7	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h2><a href="#section-8.8" class="toc">8.8	Patients Undergoing Hemodialysis</a></h2>
<h2><a href="#section-8.9" class="toc">8.9	Women of Childbearing Potential</a></h2>
<h1><a href="#section-9" class="toc">9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></a></h1>
<h2><a href="#section-9.1" class="toc">9.1 Controlled Substance</a></h2>
<h2><a href="#section-9.2" class="toc">9.2 Abuse</a></h2>
<h2><a href="#section-9.3" class="toc">9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></a></h2>
<h1><a href="#section-10" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-11" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-12" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">12.1	Mechanism of Action</a></h2>
<h2><a href="#section-12.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-12.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-13" class="toc">13 NON-CLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-13.1" class="toc">13.1	Carcinogenesis, Mutagenesis, and Impairment of Fertility</a></h2>
<h1><a href="#section-14" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-14.1" class="toc">14.1	Monotherapy <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> Controlled Trial</a></h2>
<h2><a href="#section-14.2" class="toc">14.2	Adjunctive Therapy <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> Controlled Trials</a></h2>
<h2><a href="#section-14.3" class="toc">14.3	<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Prophylaxis</a></h2>
<h1><a href="#section-15" class="toc">16	HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-16" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-16.1" class="toc">17.1	<span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></a></h2>
<h2><a href="#section-16.2" class="toc">17.2	Oligohydrosis and <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">Hyperthermia</span></a></h2>
<h2><a href="#section-16.3" class="toc">17.3	<span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic Acidosis</span></a></h2>
<h2><a href="#section-16.4" class="toc">17.4	<span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation</a></h2>
<h2><a href="#section-16.5" class="toc">17.5	Interference with Cognitive and Motor Performance</a></h2>
<h2><a href="#section-16.6" class="toc">17.6	Fetal Toxicity</a></h2>
<h2><a href="#section-16.7" class="toc">17.7	<span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> and <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span></a></h2>
<h2><a href="#section-16.8" class="toc">17.8	<span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Kidney Stones</span></a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.1"></a><a name="section-1.1"></a><p></p>
<h2>1.1	Monotherapy <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange">TOPAMAX<span class="Sup">®</span> (topiramate) Tablets and TOPAMAX<span class="Sup">®</span> (topiramate capsules) Sprinkle Capsules are indicated as initial monotherapy in patients 2 years of age and older with partial onset or primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span>. Safety and effectiveness in patients who were converted to monotherapy from a previous regimen of other anticonvulsant drugs have not been established in controlled trials<span class="Italics"> [see <a href="#S14.1">Clinical Studies (14.1)</a>]</span>.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.2"></a><a name="section-1.2"></a><p></p>
<h2>1.2	Adjunctive Therapy <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></h2>
<p class="First">TOPAMAX<span class="Sup">®</span> Tablets and TOPAMAX<span class="Sup">®</span> Sprinkle Capsules are indicated as adjunctive therapy for adults and pediatric patients ages 2 to 16 years with partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span>, and in patients 2 years of age and older with <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with Lennox-Gastaut syndrome <span class="Italics">[see <a href="#S14.2">Clinical Studies (14.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S1.3"></a><a name="section-1.3"></a><p></p>
<h2>1.3	<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></h2>
<p class="First">TOPAMAX<span class="Sup">®</span> Tablets and TOPAMAX<span class="Sup">®</span> Sprinkle Capsules are indicated for adults for the prophylaxis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> <span class="Italics">[see <a href="#S14.3">Clinical Studies (14.3)</a>]</span>. The usefulness of TOPAMAX<span class="Sup">® </span>in the acute treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> has not been studied.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	<span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></h2>
<p class="First">It is not necessary to monitor topiramate plasma concentrations to optimize TOPAMAX<span class="Sup">®</span> (topiramate) therapy.</p>
<p>On occasion, the addition of TOPAMAX<span class="Sup">®</span> to phenytoin may require an adjustment of the dose of phenytoin to achieve optimal clinical outcome. Addition or withdrawal of phenytoin and/or carbamazepine during adjunctive therapy with TOPAMAX<span class="Sup">®</span> may require adjustment of the dose of TOPAMAX<span class="Sup">®</span>.</p>
<p>Because of the bitter taste, tablets should not be broken.</p>
<p>TOPAMAX<span class="Sup">®</span> can be taken without regard to meals.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.1"></a><p></p>
<p class="First"><span class="Bold Italics">Monotherapy Use</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.1.1"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Adults and Pediatric Patients 10 Years and Older</span></p>
<p>The recommended dose for TOPAMAX<span class="Sup">®</span> monotherapy in adults and pediatric patients 10 years of age and older is 400 mg/day in two divided doses. Approximately 58% of patients randomized to 400 mg/day achieved this maximal dose in the monotherapy controlled trial; the mean dose achieved in the trial was 275 mg/day. The dose should be achieved by titration according to the following schedule (Table 1):</p>
<a name="table1"></a><table width="60%">
<caption><span>Table 1: Monotherapy Titration Schedule for Adults and Pediatric Patients 10 years and older</span></caption>
<col align="left" valign="top" width="34%">
<col align="left" valign="top" width="33%">
<col align="left" valign="top" width="33%">
<thead><tr class="First Last">
<th align="left"></th>
<th align="left">Morning Dose</th>
<th align="left">Evening Dose</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">Week 1</td>
<td align="left">25 mg</td>
<td align="left">25 mg</td>
</tr>
<tr>
<td align="left">Week 2</td>
<td align="left">50 mg</td>
<td align="left">50 mg</td>
</tr>
<tr>
<td align="left">Week 3</td>
<td align="left">75 mg</td>
<td align="left">75 mg</td>
</tr>
<tr>
<td align="left">Week 4</td>
<td align="left">100 mg</td>
<td align="left">100 mg</td>
</tr>
<tr>
<td align="left">Week 5</td>
<td align="left">150 mg</td>
<td align="left">150 mg</td>
</tr>
<tr class="Last">
<td align="left">Week 6</td>
<td align="left">200 mg</td>
<td align="left">200 mg</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.1.2"></a><p></p>
<p class="First" style="border-left:1px solid;"><span class="XmChange">Children Ages 2 to &lt;10 Years</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Dosing of topiramate as initial monotherapy in children 2 to &lt; 10 years of age with partial onset or primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span> was based on a pharmacometric bridging approach <span class="Italics">[see <a href="#S14.1">Clinical Studies (14.1)</a>]</span>.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Dosing in patients 2 to &lt;10 years is based on weight. During the titration period, the initial dose of TOPAMAX<span class="Sup">®</span> should be 25 mg/day administered nightly for the first week. Based upon tolerability, the dosage can be increased to 50 mg/day (25 mg twice daily) in the second week. Dosage can be increased by 25–50 mg/day each subsequent week as tolerated. Titration to the minimum maintenance dose should be attempted over 5–7 weeks of the total titration period. Based upon tolerability and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> control, additional titration to a higher dose (up to the maximum maintenance dose) can be attempted at 25–50 mg/day weekly increments. The total daily dose should not exceed the maximum maintenance dose for each range of body weight (Table 2).</span></p>
<a name="table2"></a><table width="60%">
<caption><span>Table 2:  Monotherapy Target Total Daily Maintenance Dosing for Patients 2 to  &lt;10 Years</span></caption>
<col align="center" valign="bottom" width="34%">
<col align="center" valign="bottom" width="33%">
<col align="center" valign="bottom" width="33%">
<thead><tr class="First Last">
<th align="center" valign="middle"><span class="XmChange">Weight (kg)</span></th>
<th align="center" valign="middle">Total Daily  Dose (mg/day)<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a> Minimum Maintenance Dose</th>
<th align="center" valign="middle">Total Daily  Dose (mg/day)<a href="#footnote-1" class="Sup">*</a> Maximum Maintenance Dose</th>
</tr></thead>
<tfoot><tr><td colspan="3" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Administered in two equally divided doses</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="center"><span class="XmChange">Up to 11</span></td>
<td align="center">150</td>
<td align="center">250</td>
</tr>
<tr>
<td align="center"><span class="XmChange">12 – 22</span></td>
<td align="center">200</td>
<td align="center">300</td>
</tr>
<tr>
<td align="center"><span class="XmChange">23 – 31</span></td>
<td align="center">200</td>
<td align="center">350</td>
</tr>
<tr>
<td align="center"><span class="XmChange">32 – 38</span></td>
<td align="center">250</td>
<td align="center">350</td>
</tr>
<tr class="Last">
<td align="center"><span class="XmChange">Greater than 38</span></td>
<td align="center">250</td>
<td align="center">400</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.2"></a><p></p>
<p class="First"><span class="Bold Italics">Adjunctive Therapy Use</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.2.1"></a><p></p>
<p class="First">Adults 17 Years of Age and Over - Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>, Primary Generalized Tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">Clonic Seizures</span>, or Lennox-Gastaut Syndrome</p>
<p>The recommended total daily dose of TOPAMAX<span class="Sup">®</span> as adjunctive therapy in adults with partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> is 200 to 400 mg/day in two divided doses, and 400 mg/day in two divided doses as adjunctive treatment in adults with primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span>. It is recommended that therapy be initiated at 25 to 50 mg/day followed by titration to an effective dose in increments of 25 to 50 mg/day every week. Titrating in increments of 25 mg/day every week may delay the time to reach an effective dose. Doses above 400 mg/day (600, 800 or 1,000 mg/day) have not been shown to improve responses in dose-response studies in adults with partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. Daily doses above 1,600 mg have not been studied.</p>
<p>In the study of primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span>, the initial titration rate was slower than in previous studies; the assigned dose was reached at the end of 8 weeks <span class="Italics">[see <a href="#S14.1">Clinical Studies (14.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-2.1.2.2"></a><p></p>
<p class="First">Pediatric Patients Ages 2 – 16 Years – Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>, Primary Generalized Tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">Clonic Seizures</span>, or Lennox-Gastaut Syndrome</p>
<p>The recommended total daily dose of TOPAMAX<span class="Sup">®</span> as adjunctive therapy for pediatric patients with partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span>, or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with Lennox-Gastaut syndrome is approximately 5 to 9 mg/kg/day in two divided doses. Titration should begin at 25 mg/day (or less, based on a range of 1 to 3 mg/kg/day) nightly for the first week. The dosage should then be increased at 1- or 2-week intervals by increments of 1 to 3 mg/kg/day (administered in two divided doses), to achieve optimal clinical response. Dose titration should be guided by clinical outcome.</p>
<p>In the study of primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span>, the initial titration rate was slower than in previous studies; the assigned dose of 6 mg/kg/day was reached at the end of 8 weeks<span class="Italics"> [see <a href="#S14.1">Clinical Studies (14.1)</a>]</span>.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></h2>
<p class="First">The recommended total daily dose of TOPAMAX<span class="Sup">®</span> as treatment for adults for prophylaxis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> is 100 mg/day administered in two divided doses (Table 3). The recommended titration rate for topiramate for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> prophylaxis to 100 mg/day is:</p>
<a name="table3"></a><table width="60%">
<caption><span>Table 3: <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Prophylaxis Titration Schedule for Adults</span></caption>
<col align="left" valign="top" width="34%">
<col align="left" valign="top" width="33%">
<col align="left" valign="top" width="33%">
<thead><tr class="First Last">
<th align="left"></th>
<th align="left">Morning Dose</th>
<th align="left">Evening Dose</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left">Week 1</td>
<td align="left">None</td>
<td align="left">25 mg</td>
</tr>
<tr>
<td align="left">Week 2</td>
<td align="left">25 mg</td>
<td align="left">25 mg</td>
</tr>
<tr>
<td align="left">Week 3</td>
<td align="left">25 mg</td>
<td align="left">50 mg</td>
</tr>
<tr class="Last">
<td align="left">Week 4</td>
<td align="left">50 mg</td>
<td align="left">50 mg</td>
</tr>
</tbody>
</table>
<p>Dose and titration rate should be guided by clinical outcome. If required, longer intervals between dose adjustments can be used.</p>
<p>TOPAMAX<span class="Sup">® </span>can be taken without regard to meals.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.3"></a><a name="section-2.3"></a><p></p>
<h2>2.3	Administration of TOPAMAX<span class="Sup">®</span> Sprinkle Capsules</h2>
<p class="First">TOPAMAX<span class="Sup">®</span> (topiramate capsules) Sprinkle Capsules may be swallowed whole or may be administered by carefully opening the capsule and sprinkling the entire contents on a small amount (teaspoon) of soft food. This drug/food mixture should be swallowed immediately and not chewed. It should not be stored for future use.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.4"></a><a name="section-2.4"></a><p></p>
<h2>2.4	Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">In renally impaired subjects (creatinine clearance less than 70 mL/min/1.73 m<span class="Sup">2</span>), one-half of the usual adult dose is recommended. Such patients will require a longer time to reach steady-state at each dose.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.5"></a><a name="section-2.5"></a><p></p>
<h2>2.5	Geriatric Patients (Ages 65 Years and Over)</h2>
<p class="First">Dosage adjustment may be indicated in the elderly patient when <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (creatinine clearance rate &lt;70 mL/min/1.73 m<span class="Sup">2</span>) is evident <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.6"></a><a name="section-2.6"></a><p></p>
<h2>2.6	Patients Undergoing Hemodialysis</h2>
<p class="First">Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than a normal individual. Accordingly, a prolonged period of dialysis may cause topiramate concentration to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> below that required to maintain an anti-<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> effect. To avoid rapid drops in topiramate plasma concentration during hemodialysis, a supplemental dose of topiramate may be required. The actual adjustment should take into account 1) the duration of dialysis period, 2) the clearance rate of the dialysis system being used, and 3) the effective renal clearance of topiramate in the patient being dialyzed.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S2.7"></a><a name="section-2.7"></a><p></p>
<h2>2.7	Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Disease</span></h2>
<p class="First">In hepatically impaired patients, topiramate plasma concentrations may be increased. The mechanism is not well understood.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">TOPAMAX<span class="Sup">®</span> (topiramate) Tablets are available as debossed, coated, round tablets in the following strengths and colors:</p>
<p>25 mg cream (debossed "OMN" on one side; "25" on the other)</p>
<p>50 mg light-yellow (debossed "OMN" on one side; "50" on the other)</p>
<p>100 mg yellow (debossed "OMN" on one side; "100" on the other)</p>
<p>200 mg salmon (debossed "OMN" on one side; "200" on the other)</p>
<p>TOPAMAX<span class="Sup">®</span> (topiramate capsules) Sprinkle Capsules contain small, white to off-white spheres. The gelatin capsules are white and clear.</p>
<p>They are marked as follows:</p>
<p>15 mg capsule with "TOP" and "15 mg" on the side</p>
<p>25 mg capsule with "TOP" and "25 mg" on the side</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">None.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Acute <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">Myopia</span> and Secondary <span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">Angle Closure Glaucoma</span></h2>
<p class="First">A syndrome consisting of acute <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">myopia</span> associated with secondary <span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">angle closure glaucoma</span> has been reported in patients receiving TOPAMAX<span class="Sup">®</span> (topiramate). Symptoms include acute onset of decreased visual acuity and/or <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span>. Ophthalmologic findings can include <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">myopia</span>, anterior chamber shallowing, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">ocular hyperemia</span> (<span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>), and <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>. <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">Mydriasis</span> may or may not be present. This syndrome may be associated with supraciliary <span class="product-label-link" type="condition" conceptid="4215818" conceptname="Effusion">effusion</span> resulting in anterior displacement of the lens and iris, with secondary <span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">angle closure glaucoma</span>. Symptoms typically occur within 1 month of initiating TOPAMAX<span class="Sup">®</span> therapy. In contrast to primary narrow angle <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>, which is rare under 40 years of age, secondary <span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">angle closure glaucoma</span> associated with topiramate has been reported in pediatric patients as well as adults. The primary treatment to reverse symptoms is discontinuation of TOPAMAX<span class="Sup">®</span> as rapidly as possible, according to the judgment of the treating physician. Other measures, in conjunction with discontinuation of TOPAMAX<span class="Sup">®</span>, may be helpful.</p>
<p>Elevated intraocular pressure of any etiology, if left untreated, can lead to serious sequelae including permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">vision loss</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Oligohidrosis and <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">Hyperthermia</span></h2>
<p class="First">Oligohidrosis (decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>), infrequently resulting in hospitalization, has been reported in association with TOPAMAX<span class="Sup">®</span> use. Decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> and an elevation in body temperature above normal characterized these cases. Some of the cases were reported after exposure to elevated environmental temperatures.</p>
<p>The majority of the reports have been in pediatric patients. Patients, especially pediatric patients, treated with TOPAMAX<span class="Sup">®</span> should be monitored closely for evidence of decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> and increased body temperature, especially in hot weather. Caution should be used when TOPAMAX<span class="Sup">®</span> is prescribed with other drugs that predispose patients to heat-related disorders; these drugs include, but are not limited to, other carbonic anhydrase inhibitors and drugs with anticholinergic activity.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	<span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic Acidosis</span></h2>
<p class="First">Hyperchloremic, non-<span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span>, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> (i.e., decreased serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> below the normal reference range in the absence of chronic <span class="product-label-link" type="condition" conceptid="4006309" conceptname="Respiratory alkalosis">respiratory alkalosis</span>) is associated with TOPAMAX<span class="Sup">®</span> treatment. This <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> is caused by renal <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> loss due to the inhibitory effect of topiramate on carbonic anhydrase. Such <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">electrolyte imbalance</span> has been observed with the use of topiramate in placebo-controlled clinical trials and in the post-marketing period. Generally, topiramate-induced <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> occurs early in treatment although cases can occur at any time during treatment. <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">Bicarbonate</span> decrements are usually mild-moderate (average decrease of 4 mEq/L at daily doses of 400 mg in adults and at approximately 6 mg/kg/day in pediatric patients); rarely, patients can experience severe decrements to values below 10 mEq/L. Conditions or therapies that predispose patients to <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> (such as <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span>, severe <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">respiratory disorders</span>, <span class="product-label-link" type="condition" conceptid="373748" conceptname="Grand mal status">status epilepticus</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, ketogenic diet, or specific drugs) may be additive to the <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> lowering effects of topiramate.</p>
<p>In adults, the incidence of persistent treatment-emergent decreases in serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> (levels of &lt;20 mEq/L at two consecutive visits or at the final visit) in controlled clinical trials for adjunctive treatment of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> was 32% for 400 mg/day, and 1% for placebo. <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic acidosis</span> has been observed at doses as low as 50 mg/day. The incidence of persistent treatment-emergent decreases in serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> in adults in the <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> controlled clinical trial for monotherapy was 15% for 50 mg/day and 25% for 400 mg/day. The incidence of a markedly abnormally low serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> (i.e., absolute value &lt;17 mEq/L and &gt;5 mEq/L decrease from pretreatment) in the adjunctive therapy trials was 3% for 400 mg/day, and 0% for placebo and in the monotherapy trial was 1% for 50 mg/day and 7% for 400 mg/day. Serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> levels have not been systematically evaluated at daily doses greater than 400 mg/day.</p>
<p>In pediatric patients (2 to 16 years of age), the incidence of persistent treatment-emergent decreases in serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> in placebo-controlled trials for adjunctive treatment of Lennox-Gastaut syndrome or refractory partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> was 67% for TOPAMAX<span class="Sup">®</span> (at approximately 6 mg/kg/day), and 10% for placebo. The incidence of a markedly abnormally low serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> (i.e., absolute value &lt;17 mEq/L and &gt;5 mEq/L decrease from pretreatment) in these trials was 11% for TOPAMAX<span class="Sup">®</span> and 0% for placebo. Cases of moderately severe <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> have been reported in patients as young as 5 months old, especially at daily doses above 5 mg/kg/day.</p>
<p style="border-left:1px solid;"><span class="XmChange">Although not approved for use in patients under 2 years of age with partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, a controlled trial that examined this population revealed that topiramate produced a <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> that is notably greater in magnitude than that observed in controlled trials in older children and adults. The mean treatment difference (25 mg/kg/day topiramate-placebo) was -5.9 mEq/L for <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span>. The incidence of <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> (defined by a serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> &lt;20 mEq/L) was 0% for placebo, 30% for 5 mg/kg/day, 50% for 15 mg/kg/day, and 45% for 25 mg/kg/day. The incidence of markedly abnormal changes (i.e., &lt;17 mEq/L and &gt;5 mEq/L decrease from baseline of ≥20 mEq/L) was 0% for placebo, 4% for 5 mg/kg/day, 5% for 15 mg/kg/day, and 5% for 25 mg/kg/day <span class="Italics">[see </span><span class="Italics"><a href="#S8.4">Use in Special Populations (8.4)</a>].</span></span></p>
<p style="border-left:1px solid;"><span class="XmChange">In pediatric patients (6 to 15 years of age), the incidence of persistent treatment-emergent decreases in serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> in the <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> controlled clinical trial for monotherapy was 9% for 50 mg/day and 25% for 400 mg/day. The incidence of a markedly abnormally low serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> (i.e., absolute value &lt;17 mEq/L and &gt;5 mEq/L decrease from pretreatment) in this trial was 1% for 50 mg/day and 6% for 400 mg/day. In adult patients (≥16 years of age), the incidence of persistent treatment-emergent decreases in serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> in the <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> controlled clinical trial for monotherapy was 14% for 50 mg/day and 25% for 400 mg/day. The incidence of a markedly abnormally low serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> (i.e., absolute value &lt;17 mEq/L and &gt;5 mEq/L decrease from pretreatment) in this trial for adults was 1% for 50 mg/day and 6% for 400 mg/day.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">The incidence of persistent treatment-emergent decreases in serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> in placebo-controlled trials for adults for prophylaxis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> was 44% for 200 mg/day, 39% for 100 mg/day, 23% for 50 mg/day, and 7% for placebo. The incidence of a markedly abnormally low serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> (i.e., absolute value &lt;17 mEq/L and &gt;5 mEq/L decrease from pretreatment) in these trials was 11% for 200 mg/day, 9% for 100 mg/day, 2% for 50 mg/day, and &lt;1% for placebo.</span></p>
<p style="border-left:1px solid;"><span class="XmChange">Some manifestations of acute or chronic <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> may include <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, nonspecific symptoms such as <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, or more severe sequelae including <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span> or <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>. Chronic, untreated <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> may increase the risk for <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">nephrolithiasis</span> or <span class="product-label-link" type="condition" conceptid="4171974" conceptname="Nephrocalcinosis">nephrocalcinosis</span>, and may also result in <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span> (referred to as <span class="product-label-link" type="condition" conceptid="4189941" conceptname="Rickets">rickets</span> in pediatric patients) and/or <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span> with an increased risk for <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fractures</span>. Chronic <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> in pediatric patients may also reduce growth rates. A reduction in growth rate may eventually decrease the maximal height achieved. The effect of topiramate on growth and bone-related sequelae has not been systematically investigated in long-term, placebo-controlled trials. Long-term, open-label treatment of infants/toddlers, with intractable <span class="product-label-link" type="condition" conceptid="374915" conceptname="Localization-related epilepsy">partial epilepsy</span>, for up to 1 year, showed reductions from baseline in Z SCORES for length, weight, and head circumference compared to age and sex-matched normative data, although these patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> are likely to have different growth rates than normal infants. Reductions in Z SCORES for length and weight were correlated to the degree of <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span> <span class="Italics">[see <a href="#S8.4">Use in Specific Populations (8.4)</a>]</span>. Topiramate treatment that causes <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> during pregnancy can possibly produce adverse effects on the fetus and might also cause <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> in the neonate from possible transfer of topiramate to the fetus <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a> and 											<a href="#S8.1"> Use in Specific Populations (8.1)</a>]</span>.</span></p>
<p>Measurement of baseline and periodic serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> during topiramate treatment is recommended. If <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> develops and persists, consideration should be given to reducing the dose or discontinuing topiramate (using dose tapering). If the decision is made to continue patients on topiramate in the face of persistent <span class="product-label-link" type="condition" conceptid="435517" conceptname="Acidosis">acidosis</span>, alkali treatment should be considered.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	<span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation</h2>
<p class="First">Antiepileptic drugs (AEDs), including TOPAMAX<span class="Sup">®</span>, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Patients treated with any AED for any indication should be monitored for the emergence or worsening of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior.</p>
<p>Pooled analyses of 199 placebo-controlled clinical trials (mono- and adjunctive therapy) of 11 different AEDs showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI:1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. In these trials, which had a median treatment duration of 12 weeks, the estimated incidence rate of <span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">suicidal behavior</span> or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicides</span> in drug-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about drug effect on <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span>.</p>
<p>The increased risk of suicidal thoughts or behavior with AEDs was observed as early as one week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed.</p>
<p>The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age (5 to 100 years) in the clinical trials analyzed.</p>
<p>Table 4 shows absolute and relative risk by indication for all evaluated AEDs.</p>
<a name="table4"></a><table width="90%">
<caption><span>Table 4: Risk by Indication for Antiepileptic Drugs in the Pooled Analysis</span></caption>
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<col align="left" valign="top" width="20%">
<thead><tr class="First Last">
<th align="left">Indication</th>
<th align="left">Placebo Patients with Events per 1000 Patients</th>
<th align="left">Drug Patients with Events per 1000 Patients</th>
<th align="left">Relative Risk: Incidence of Events in Drug Patients/Incidence in Placebo Patients</th>
<th align="left">Risk Difference: Additional Drug Patients with Events per 1000 Patients</th>
</tr></thead>
<tbody>
<tr class="First">
<td align="left"><span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></td>
<td align="left">1.0</td>
<td align="left">3.4</td>
<td align="left">3.5</td>
<td align="left">2.4</td>
</tr>
<tr>
<td align="left">Psychiatric</td>
<td align="left">5.7</td>
<td align="left">8.5</td>
<td align="left">1.5</td>
<td align="left">2.9</td>
</tr>
<tr>
<td align="left">Other</td>
<td align="left">1.0</td>
<td align="left">1.8</td>
<td align="left">1.9</td>
<td align="left">0.9</td>
</tr>
<tr class="Last">
<td align="left">Total</td>
<td align="left">2.4</td>
<td align="left">4.3</td>
<td align="left">1.8</td>
<td align="left">1.9</td>
</tr>
</tbody>
</table>
<p>The relative risk for suicidal thoughts or behavior was higher in clinical trials for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> than in clinical trials for psychiatric or other conditions, but the absolute risk differences were similar for the <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and psychiatric indications.</p>
<p>Anyone considering prescribing TOPAMAX<span class="Sup">®</span> or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Should suicidal thoughts and behavior emerge during treatment, the prescriber needs to consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.</p>
<p>Patients, their caregivers, and families should be informed that AEDs increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, any unusual changes in mood or behavior or the emergence of suicidal thoughts, or behavior or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	Cognitive/Neuropsychiatric Adverse Reactions</h2>
<p class="First">Adverse reactions most often associated with the use of TOPAMAX<span class="Sup">®</span> were related to the central nervous system and were observed in both the <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> populations. In adults, the most frequent of these can be classified into three general categories: 1) Cognitive-related dysfunction (e.g., <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, psychomotor slowing, difficulty with concentration/attention, difficulty with memory, speech or language problems, particularly word-finding difficulties); 2) Psychiatric/behavioral disturbances (e.g., <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or mood problems); and 3) <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> or <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.5.1"></a><p></p>
<p class="First"><span class="Bold">Adult Patients</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.5.1.1"></a><p></p>
<p class="First">Cognitive-Related Dysfunction</p>
<p>The majority of cognitive-related adverse reactions were mild to moderate in severity, and they frequently occurred in isolation. Rapid titration rate and higher initial dose were associated with higher incidences of these reactions. Many of these reactions contributed to withdrawal from treatment <span class="Italics">[see <a href="#S6">Adverse Reactions (6)</a>]</span>.</p>
<p>In the add-on <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> controlled trials (using rapid titration such as 100–200 mg/day weekly increments), the proportion of patients who experienced one or more cognitive-related adverse reactions was 42% for 200 mg/day, 41% for 400 mg/day, 52% for 600 mg/day, 56% for 800 and 1,000 mg/day, and 14% for placebo. These dose-related adverse reactions began with a similar frequency in the titration or in the maintenance phase, although in some patients the events began during titration and persisted into the maintenance phase. Some patients who experienced one or more cognitive-related adverse reactions in the titration phase had a dose-related recurrence of these reactions in the maintenance phase.</p>
<p>In the monotherapy <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> controlled trial, the proportion of patients who experienced one or more cognitive-related adverse reactions was 19% for TOPAMAX<span class="Sup">®</span> 50 mg/day and 26% for 400 mg/day.</p>
<p>In the 6-month <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> prophylaxis controlled trials using a slower titration regimen (25 mg/day weekly increments), the proportion of patients who experienced one or more cognitive-related adverse reactions was 19% for TOPAMAX<span class="Sup">®</span> 50 mg/day, 22% for 100 mg/day (the recommended dose), 28% for 200 mg/day, and 10% for placebo. These dose-related adverse reactions typically began in the titration phase and often persisted into the maintenance phase, but infrequently began in the maintenance phase. Some patients experienced a recurrence of one or more of these cognitive adverse reactions and this recurrence was typically in the titration phase. A relatively small proportion of topiramate-treated patients experienced more than one concurrent cognitive adverse reaction. The most common cognitive adverse reactions occurring together included difficulty with memory along with difficulty with concentration/attention, difficulty with memory along with language problems, and difficulty with concentration/attention along with language problems. Rarely, topiramate-treated patients experienced three concurrent cognitive reactions.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.5.1.2"></a><p></p>
<p class="First">Psychiatric/Behavioral Disturbances</p>
<p>Psychiatric/behavioral disturbances (<span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or mood) were dose-related for both the <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> populations <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.5.1.3"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span>/<span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></p>
<p><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> were the adverse reactions most frequently reported during clinical trials of TOPAMAX<span class="Sup">®</span> for adjunctive <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. For the adjunctive <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> population, the incidence of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> did not differ substantially between 200 mg/day and 1,000 mg/day, but the incidence of <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> was dose-related and increased at dosages above 400 mg/day. For the monotherapy <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> population in the 50 mg/day and 400 mg/day groups, the incidence of <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> was dose-related (9% for the 50 mg/day group and 15% for the 400 mg/day group) and the incidence of <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> was comparable in both treatment groups (14% each). For the <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> population, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> were dose-related and more common in the titration phase.</p>
<p>Additional nonspecific CNS events commonly observed with topiramate in the add-on <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> population included <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> or <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.5.2"></a><p></p>
<p class="First"><span class="Bold">Pediatric Patients</span></p>
<p>In double-blind adjunctive therapy and monotherapy <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> clinical studies, the incidences of cognitive/neuropsychiatric adverse reactions in pediatric patients were generally lower than observed in adults. These reactions included psychomotor slowing, difficulty with concentration/attention, speech disorders/related speech problems, and language problems. The most frequently reported neuropsychiatric reactions in pediatric patients during adjunctive therapy double-blind studies were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>. The most frequently reported neuropsychiatric reactions in pediatric patients in the 50 mg/day and 400 mg/day groups during the monotherapy double-blind study were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.</p>
<p>No patients discontinued treatment due to any adverse reactions in the adjunctive <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> double-blind trials. In the monotherapy <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> double-blind trial, 1 pediatric patient (2%) in the 50 mg/day group and 7 pediatric patients (12%) in the 400 mg/day group discontinued treatment due to any adverse reactions. The most common adverse reaction associated with discontinuation of therapy was difficulty with concentration/attention; all occurred in the 400 mg/day group.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	Fetal Toxicity</h2>
<p class="First">TOPAMAX<span class="Sup">®</span> can cause fetal harm when administered to a pregnant woman. Data from pregnancy registries indicate that infants exposed to topiramate <span class="Italics">in utero</span> have an increased risk for <span class="product-label-link" type="condition" conceptid="133861" conceptname="Cleft lip">cleft lip</span> and/or <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> (oral clefts). When multiple species of pregnant animals received topiramate at clinically relevant doses, structural malformations, including craniofacial defects, and reduced fetal weights occurred in offspring <span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>.</p>
<p>Consider the benefits and the risks of TOPAMAX<span class="Sup">®</span> when administering this drug in women of childbearing potential, particularly when TOPAMAX<span class="Sup">®</span> is considered for a condition not usually associated with permanent injury or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> <span class="Italics">[see <a href="#S8.9">Use in Specific Populations (8.9)</a> and <a href="#S17.8">Patient Counseling Information (17.8)</a>]</span>. TOPAMAX<span class="Sup">®</span> should be used during pregnancy only if the potential benefit outweighs the potential risk. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus<span class="Italics"> [see <a href="#S8.1">Use in Specific Populations (8.1)</a> and <a href="#S8.9">(8.9)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7	Withdrawal of Antiepileptic Drugs (AEDs)</h2>
<p class="First">In patients with or without a history of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, antiepileptic drugs, including TOPAMAX<span class="Sup">®</span>, should be gradually withdrawn to minimize the potential for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> or increased <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> frequency <span class="Italics">[see <a href="#S14">Clinical Studies (14)</a>]</span>. In situations where rapid withdrawal of TOPAMAX<span class="Sup">®</span> is medically required, appropriate monitoring is recommended.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8	Sudden Unexplained <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> (SUDEP)</h2>
<p class="First">During the course of premarketing development of topiramate tablets, 10 sudden and unexplained <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> were recorded among a cohort of treated patients (2796 subject years of exposure). This represents an incidence of 0.0035 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> per patient year. Although this rate exceeds that expected in a healthy population matched for age and sex, it is within the range of estimates for the incidence of sudden unexplained <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> in patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> not receiving TOPAMAX<span class="Sup">®</span> (ranging from 0.0005 for the general population of patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, to 0.003 for a clinical trial population similar to that in the TOPAMAX<span class="Sup">®</span> program, to 0.005 for patients with refractory <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9	<span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> and <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span> (Without and With Concomitant Valproic Acid [VPA] Use)</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.9.1"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span>/<span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span> Without Concomitant Valproic Acid (VPA)</p>
<p>Topiramate treatment has produced <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> (in some instances dose-related) in clinical investigational programs of adolescents (12–16 years) who were treated with topiramate monotherapy for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> prophylaxis (incidence above the upper limit of normal, 22% for placebo, 26% for 50 mg/day, 41% for 100 mg/day) and in very young pediatric patients (1–24 months) who were treated with adjunctive topiramate for partial onset <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (8% for placebo, 10% for 5 mg/kg/day, 0% for 15 mg/kg/day, 9% for 25 mg/kg/day). TOPAMAX<span class="Sup">®</span> is not approved as monotherapy for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> prophylaxis in adolescent patients or as adjunctive treatment of partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in pediatric patients less than 2 years old. In some patients, <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> was markedly increased (≥50% above upper limit of normal). In adolescent patients, the incidence of markedly increased <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> was 6% for placebo, 6% for 50 mg, and 12% for 100 mg topiramate daily. The <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> associated with topiramate treatment occurred with and without <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> in placebo-controlled trials and in an open-label, extension trial. Dose-related <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> was also observed in the extension trial in pediatric patients up to 2 years old. Clinical symptoms of <span class="product-label-link" type="condition" conceptid="4143108" conceptname="Hyperammonemic encephalopathy">hyperammonemic encephalopathy</span> often include acute alterations in level of consciousness and/or cognitive function with <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> with and without <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> has also been observed in post-marketing reports in patients who were taking topiramate without concomitant valproic acid (VPA).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.9.2"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span>/<span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span> With Concomitant Valproic Acid (VPA)</p>
<p>Concomitant administration of topiramate and valproic acid (VPA) has been associated with <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> with or without <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> in patients who have tolerated either drug alone based upon post-marketing reports. Although <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> may be asymptomatic, clinical symptoms of <span class="product-label-link" type="condition" conceptid="4143108" conceptname="Hyperammonemic encephalopathy">hyperammonemic encephalopathy</span> often include acute alterations in level of consciousness and/or cognitive function with <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. In most cases, symptoms and signs abated with discontinuation of either drug. This adverse reaction is not due to a <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span>.</p>
<p>Although TOPAMAX<span class="Sup">®</span> is not indicated for use in infants/toddlers (1–24 months), VPA clearly produced a dose-related increase in the incidence of treatment-emergent <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> (above the upper limit of normal, 0% for placebo, 12% for 5 mg/kg/day, 7% for 15 mg/kg/day, 17% for 25 mg/kg/day) in an investigational program. Markedly increased, dose-related <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> (0% for placebo and 5 mg/kg/day, 7% for 15 mg/kg/day, 8% for 25 mg/kg/day) also occurred in these infants/toddlers. Dose-related <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> was similarly observed in a long-term  extension trial in these very young, pediatric patients <span class="Italics">[see <a href="#S8.4">Use in Specific Populations (8.4)</a>]</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> with and without <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> has also been observed in post-marketing reports in patients taking topiramate with VPA.</p>
<p>The <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> associated with topiramate treatment appears to be more common when topiramate is used concomitantly with VPA.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-5.9.3"></a><p></p>
<p class="First">Monitoring for <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span></p>
<p>Patients with inborn errors of metabolism or reduced hepatic mitochondrial activity may be at an increased risk for <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> with or without <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>. Although not studied, topiramate treatment or an interaction of concomitant topiramate and valproic acid treatment may exacerbate existing defects or unmask deficiencies in susceptible persons.</p>
<p>In patients who develop unexplained <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or changes in mental status associated with any topiramate treatment, <span class="product-label-link" type="condition" conceptid="4143108" conceptname="Hyperammonemic encephalopathy">hyperammonemic encephalopathy</span> should be considered and an <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> level should be measured.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.10"></a><a name="section-5.10"></a><p></p>
<h2>5.10	<span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Kidney Stones</span></h2>
<p class="First">A total of 32/2086 (1.5%) of adults exposed to topiramate during its adjunctive <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> therapy development reported the occurrence of <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">kidney stones</span>, an incidence about 2 to 4 times greater than expected in a similar, untreated population. In the double-blind monotherapy <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> study, a total of 4/319 (1.3%) of adults exposed to topiramate reported the occurrence of <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">kidney stones</span>. As in the general population, the incidence of stone formation among topiramate-treated patients was higher in men. <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Kidney stones</span> have also been reported in pediatric patients. During long-term (up to 1 year) topiramate treatment in an open-label extension study of 284 pediatric patients 1–24 months old with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, 7% developed kidney or bladder stones that were diagnosed clinically or by sonogram. TOPAMAX<span class="Sup">®</span> is not approved for pediatric patients less than 2 years old<span class="Italics"> [see <a href="#S8.4">Use in Specific Populations (8.4)</a>].</span></p>
<p>An explanation for the association of TOPAMAX<span class="Sup">® </span>and <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">kidney stones</span> may lie in the fact that topiramate is a carbonic anhydrase inhibitor. Carbonic anhydrase inhibitors (e.g., zonisamide, acetazolamide, or dichlorphenamide) can promote stone formation by reducing urinary citrate excretion and by increasing urinary pH <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>. The concomitant use of TOPAMAX<span class="Sup">®</span> with any other drug producing <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, or potentially in patients on a ketogenic diet, may create a physiological environment that increases the risk of <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">kidney stone</span> formation, and should therefore be avoided.</p>
<p>Increased fluid intake increases the urinary output, lowering the concentration of substances involved in stone formation. Hydration is recommended to reduce new stone formation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.11"></a><a name="section-5.11"></a><p></p>
<h2>5.11	<span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">Hypothermia</span> with Concomitant Valproic Acid (VPA) Use</h2>
<p class="First" style="border-left:1px solid;"><span class="XmChange"><span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">Hypothermia</span>, defined as an unintentional drop in body core temperature to &lt;35°C (95°F), has been reported in association with topiramate use with concomitant valproic acid (VPA) both in conjunction with <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> and in the absence of <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span>. This adverse reaction in patients using concomitant topiramate and valproate can occur after starting topiramate treatment or after increasing the daily dose of topiramate <span class="Italics">[see <a href="#S7.1">Drug Interactions (7.1)</a>]</span>. Consideration should be given to stopping topiramate or valproate in patients who develop <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span>, which may be manifested by a variety of clinical abnormalities including <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, and significant alterations in other major organ systems such as the cardiovascular and respiratory systems. Clinical management and assessment should include examination of blood <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> levels.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.12"></a><a name="section-5.12"></a><p></p>
<h2>5.12	<span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span> (usually <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> of the extremities), an effect associated with the use of other carbonic anhydrase inhibitors, appears to be a common effect of TOPAMAX<span class="Sup">®</span>. <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span> was more frequently reported in the monotherapy <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> trials and <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> prophylaxis trials than in the adjunctive therapy <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> trials. In the majority of instances, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> did not lead to treatment discontinuation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.13"></a><a name="section-5.13"></a><p></p>
<h2>5.13	Adjustment of Dose in <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">Renal Failure</span></h2>
<p class="First">The major route of elimination of unchanged topiramate and its metabolites is via the kidney. Dosage adjustment may be required in patients with reduced renal function <span class="Italics">[see <a href="#S2.4">Dosage and Administration (2.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.14"></a><a name="section-5.14"></a><p></p>
<h2>5.14	Decreased Hepatic Function</h2>
<p class="First">In hepatically impaired patients, TOPAMAX<span class="Sup">®</span> should be administered with caution as the clearance of topiramate may be decreased <span class="Italics">[see <a href="#S2.7">Dosage and Administration (2.7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S5.15"></a><a name="section-5.15"></a><p></p>
<h2>5.15	Monitoring: Laboratory Tests</h2>
<p class="First">Topiramate treatment was associated with changes in several clinical laboratory analytes in randomized, double-blind, placebo-controlled studies.</p>
<p>Topiramate treatment causes non-<span class="product-label-link" type="condition" conceptid="4009397" conceptname="Anion gap">anion gap</span>, hyperchloremic <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> manifested by a decrease in serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> and an increase in serum chloride. Measurement of baseline and periodic serum <span class="product-label-link" type="condition" conceptid="4285456" conceptname="Bicarbonate">bicarbonate</span> during TOPAMAX<span class="Sup">®</span> treatment is recommended <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>.</p>
<p>Controlled trials of adjunctive topiramate treatment of adults for partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> showed an increased incidence of markedly decreased serum phosphorus (6% topiramate, 2% placebo), markedly increased serum alkaline phosphatase (3% topiramate, 1% placebo), and decreased serum potassium (0.4 % topiramate, 0.1 % placebo). The clinical significance of these abnormalities has not been clearly established.</p>
<p>Changes in several clinical laboratory values (i.e., increased creatinine, BUN, alkaline phosphatase, total protein, total eosinophil count, and decreased potassium) have been observed in a clinical investigational program in very young (&lt;2 years) pediatric patients who were treated with adjunctive topiramate for partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> [<span class="Italics">see <a href="#S8.4">Use in Specific Populations (8.4)</a></span>].</p>
<p>Topiramate treatment produced a dose-related increased shift in serum creatinine from normal at baseline to an increased value at the end of 4 months treatment in adolescent patients (ages 12–16 years) who were treated for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> prophylaxis in a double-blind, placebo-controlled study.</p>
<p>TOPAMAX<span class="Sup">®</span> treatment with or without concomitant valproic acid (VPA) can cause <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> with or without <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>
<p>The following adverse reactions are discussed in more detail in other sections of the labeling:</p>
<ul class="Disc">
<li>Acute <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">Myopia</span> and Secondary Angle Closure <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>
</li>
<li>Oligohidrosis and <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">Hyperthermia</span> <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic Acidosis</span> <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>
</li>
<li>Cognitive/Neuropsychiatric Adverse Reactions <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>
</li>
<li>Fetal Toxicity <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a> and <a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>
</li>
<li>Withdrawal of Antiepileptic Drugs (AEDs) <span class="Italics">[see <a href="#S5.7">Warnings and Precautions (5.7)</a>]</span>
</li>
<li>Sudden Unexplained <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> (SUDEP) <span class="Italics">[see <a href="#S5.8">Warnings and Precautions (5.8)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> and <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span> (Without and With Concomitant Valproic Acid [VPA] Use <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Kidney Stones</span> <span class="Italics">[see <a href="#S5.10">Warnings and Precautions (5.10)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">Hypothermia</span> with Concomitant Valproic Acid (VPA) Use <span class="Italics">[see <a href="#S5.11">Warnings and Precautions (5.11)</a>]</span>
</li>
<li><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span> <span class="Italics">[see <a href="#S5.12">Warnings and Precautions (5.12)</a>]</span>
</li>
</ul>
<p>The data described in the following sections were obtained using TOPAMAX<span class="Sup">®</span> (topiramate) Tablets.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Monotherapy <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First">Adults ≥16 Years</p>
<p>The adverse reactions in the controlled trial that occurred most commonly in adults in the 400 mg/day TOPAMAX<span class="Sup">®</span> group and at a rate higher (≥ 5 %) than in the 50 mg/day group were: <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and difficulty with memory (see <a href="#table5">Table 5</a>).</p>
<p>Approximately 21% of the 159 adult patients in the 400 mg/day group who received topiramate as monotherapy in the controlled clinical trial discontinued therapy due to adverse reactions. The most common (≥ 2% more frequent than low-dose 50 mg/day TOPAMAX<span class="Sup">® </span>) adverse reactions causing discontinuation in this trial were difficulty with memory, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">asthenia</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First">Pediatric Patients 6 to &lt;16 Years of Age</p>
<p>The adverse reactions in the controlled trial that occurred most commonly in pediatric patients in the 400 mg/day TOPAMAX<span class="Sup">®</span> group and at a rate higher (≥ 5%) than in the 50 mg/day group were <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>, mood problems, cognitive problems, <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> (see <a href="#table5">Table 5</a>).</p>
<p>Approximately 14% of the 77 pediatric patients in the 400 mg/day group who received TOPAMAX<span class="Sup">®</span> as monotherapy in the controlled clinical trial discontinued therapy due to adverse reactions. The most common (<span class="Underline">&gt; </span>2% more frequent than low-dose 50 mg/day TOPAMAX<span class="Sup">® </span>) adverse reactions resulting in discontinuation in this trial were difficulty with concentration/attention, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>.</p>
<a name="table5"></a><table width="90%">
<caption><span>Table 5: Incidence of Treatment-Emergent Adverse Reactions in Monotherapy  <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> Where the Rate Was at Least 2% in Any TOPAMAX<span class="Sup">®</span> Group and the Rate in the 400 mg/day  TOPAMAX<span class="Sup">®</span> Group Was Greater Than  the Rate in the 50 mg/day TOPAMAX<span class="Sup">®</span>  Group for Adults (≥16 Years) and Pediatric (6 to  &lt;16 Years) Patients in Study TOPMAX-EPMN-106</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center" colspan="4">Age Group</th>
</tr>
<tr>
<th align="left"></th>
<th class="Botrule" align="center" colspan="2">Pediatric<br>(6 to &lt;16 Years)</th>
<th class="Botrule" align="center" colspan="2">Adult<br>(Age ≥16 Years)</th>
</tr>
<tr>
<th align="left"></th>
<th align="center" colspan="4">TOPAMAX<span class="Sup">®</span> Daily Dosage Group (mg/day)</th>
</tr>
<tr>
<th align="left"></th>
<th class="Botrule" align="center">50</th>
<th class="Botrule" align="center">400</th>
<th class="Botrule" align="center">50</th>
<th class="Botrule" align="center">400</th>
</tr>
<tr>
<th align="left">Body System</th>
<th align="center">(N=74)</th>
<th align="center">(N=77)</th>
<th align="center">(N=160)</th>
<th align="center">(N=159)</th>
</tr>
<tr class="Last">
<th align="left">  Adverse Reaction</th>
<th align="center">%<a name="footnote-reference-2" href="#footnote-2" class="Sup">*</a>
</th>
<th align="center">%<a href="#footnote-2" class="Sup">*</a>
</th>
<th align="center">%<a href="#footnote-2" class="Sup">*</a>
</th>
<th align="center">%<a href="#footnote-2" class="Sup">*</a>
</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-2" href="#footnote-reference-2">*</a></dt>
<dd>Percentages calculated with the number of subjects in each group as denominator</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First"><td align="left" colspan="5"><span class="Bold">Body as a Whole - General Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center">0</td>
<td align="center">3</td>
<td align="center">4</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td align="center">1</td>
<td align="center">12</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Leg pain</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">2</td>
<td align="center">3</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Central &amp; Peripheral <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">3</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">13</td>
<td align="center">14</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4208994" conceptname="Increased muscle tone">Hypertonia</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">0</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoesthesia</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">4</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4189159" conceptname="Muscle fibrillation">Muscle contractions involuntary</span></td>
<td align="center">0</td>
<td align="center">3</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td align="center">3</td>
<td align="center">12</td>
<td align="center">21</td>
<td align="center">40</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></td>
<td align="center">0</td>
<td align="center">3</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Gastro-Intestinal System Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">1</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">8</td>
<td align="center">9</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">Gastritis</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">0</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal reflux</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">1</td>
<td align="center">3</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Liver and Biliary System Disorders</span></td></tr>
<tr>
<td align="left">  Gamma-GT increased</td>
<td align="center"></td>
<td align="center"></td>
<td align="center">1</td>
<td align="center">3</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Metabolic and Nutritional Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight decrease</span></td>
<td align="center">7</td>
<td align="center">17</td>
<td align="center">6</td>
<td align="center">17</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Platelet, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span> &amp; <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Clotting Disorders</span></span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td align="center">0</td>
<td align="center">4</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Psychiatric Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">4</td>
<td align="center">14</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">4</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">  Cognitive problems</td>
<td align="center">1</td>
<td align="center">6</td>
<td align="center">1</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></td>
<td align="center">0</td>
<td align="center">3</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td align="center">0</td>
<td align="center">3</td>
<td align="center">7</td>
<td align="center">9</td>
</tr>
<tr>
<td align="left">  Difficulty with concentration/attention</td>
<td align="center">7</td>
<td align="center">10</td>
<td align="center">7</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">  Difficulty with memory</td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">6</td>
<td align="center">11</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">8</td>
<td align="center">9</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">Libido decreased</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">0</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  Mood problems</td>
<td align="center">1</td>
<td align="center">8</td>
<td align="center">2</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">Personality disorder</span>(behavior problems)</td>
<td align="center">0</td>
<td align="center">3</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  Psychomotor slowing</td>
<td align="center"></td>
<td align="center"></td>
<td align="center">3</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">10</td>
<td align="center">15</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Red Blood Cell Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span></td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Reproductive Disorders, Female
                                          </span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="198195" conceptname="Ovulation bleeding">Intermenstrual Bleeding</span></td>
<td align="center">0</td>
<td align="center">3</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4129155" conceptname="Vaginal bleeding">Vaginal Hemorrhage</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">0</td>
<td align="center">3</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Resistance Mechanism Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td align="center">3</td>
<td align="center">8</td>
<td align="center">2</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="40493255" conceptname="Viral syndrome">Infection viral</span></td>
<td align="center">3</td>
<td align="center">6</td>
<td align="center">6</td>
<td align="center">8</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span></span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></td>
<td align="center">1</td>
<td align="center">5</td>
<td align="center">3</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td align="center">5</td>
<td align="center">6</td>
<td align="center">2</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td align="center">1</td>
<td align="center">4</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td align="center">16</td>
<td align="center">18</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Skin and Appendages Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="141095" conceptname="Acne">Acne</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">2</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td align="center">1</td>
<td align="center">4</td>
<td align="center">3</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">1</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span></td>
<td align="center">3</td>
<td align="center">4</td>
<td align="center">1</td>
<td align="center">4</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Special Senses Other, Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste perversion</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">3</td>
<td align="center">5</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Urinary System Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">Cystitis</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">1</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="197684" conceptname="Dysuria">Dysuria</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  Micturition frequency</td>
<td align="center">0</td>
<td align="center">3</td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Renal calculus</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">0</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">Urinary incontinence</span></td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center"></td>
<td align="center"></td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td align="center"></td>
<td align="center"></td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Vascular (Extracardiac) Disorders</span></td></tr>
<tr class="Last">
<td align="left">  <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span></td>
<td align="center">0</td>
<td align="center">5</td>
<td align="center"></td>
<td align="center"></td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Adjunctive Therapy <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span></h2>
<p class="First">The most commonly observed adverse reactions associated with the use of TOPAMAX<span class="Sup">®</span> at dosages of 200 to 400 mg/day in controlled trials in adults with partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span>, or Lennox-Gastaut syndrome, that were seen at greater frequency in TOPAMAX<span class="Sup">®</span>-treated patients and did not appear to be dose-related were <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, speech disorders and related speech problems, psychomotor slowing, <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">abnormal vision</span>, difficulty with memory, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> and <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span> (see <a href="#table6">Table 6</a>). The most common dose-related adverse reactions at dosages of 200 to 1,000 mg/day were <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, difficulty with concentration or attention, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, language problems, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, mood problems, and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span> (see <a href="#table8">Table 8</a>).</p>
<p>Adverse reactions associated with the use of TOPAMAX<span class="Sup">®</span> at dosages of 5 to 9 mg/kg/day in controlled trials in pediatric patients with partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span>, or Lennox-Gastaut syndrome, that were seen at greater frequency in TOPAMAX<span class="Sup">®</span>- treated patients were <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, difficulty with concentration/attention, difficulty with memory, <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">aggressive reaction</span>, and <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span> (see <a href="#table9">Table 9</a>).</p>
<p>In controlled clinical trials in adults, 11% of patients receiving TOPAMAX<span class="Sup">®</span> 200 to 400 mg/day as adjunctive therapy discontinued due to adverse reactions. This rate appeared to increase at dosages above 400 mg/day. Adverse reactions associated with discontinuing therapy included <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, difficulty with concentration or attention, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> and increased at dosages above 400 mg/day. None of the pediatric patients who received TOPAMAX<span class="Sup">®</span> adjunctive therapy at 5 to 9 mg/kg/day in controlled clinical trials discontinued due to adverse reactions.</p>
<p>Approximately 28% of the 1757 adults with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> who received TOPAMAX<span class="Sup">®</span> at dosages of 200 to 1,600 mg/day in clinical studies discontinued treatment because of adverse reactions; an individual patient could have reported more than one adverse reaction. These adverse reactions were psychomotor slowing (4.0%), difficulty with memory (3.2%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (3.2%), <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span> (3.1%), <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (3.2%), difficulty with concentration/attention (2.9%), <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> (2.7%), <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> (2.6%), <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (2.5%), <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span> (2.5%), <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> (2.3%), <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span> (2.1%), and <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> (2.0%). Approximately 11% of the 310 pediatric patients who received TOPAMAX<span class="Sup">®</span> at dosages up to 30 mg/kg/day discontinued due to adverse reactions. Adverse reactions associated with discontinuing therapy included aggravated <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span> (2.3%), difficulty with concentration/attention (1.6%), language problems (1.3%), <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">personality disorder</span> (1.3%), and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span> (1.3%).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.3"></a><a name="section-6.3"></a><p></p>
<h2>6.3	Incidence in <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> Controlled Clinical Trials – Adjunctive Therapy – Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>, Primary Generalized Tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">Clonic Seizures</span>, and Lennox-Gastaut Syndrome</h2>
<p class="First">Table 6 lists treatment-emergent adverse reactions that occurred in at least 1% of adults treated with 200 to 400 mg/day TOPAMAX<span class="Sup">®</span> in controlled trials that were numerically more common at this dose than in the patients treated with placebo. In general, most patients who experienced adverse reactions during the first eight weeks of these trials no longer experienced them by their last visit. Table 9 lists treatment-emergent adverse reactions that occurred in at least 1% of pediatric patients treated with 5 to 9 mg/kg TOPAMAX<span class="Sup">®</span> in controlled trials that were numerically more common than in patients treated with placebo.</p>
<p>The prescriber should be aware that these data were obtained when TOPAMAX<span class="Sup">®</span> was added to concurrent antiepileptic drug therapy and cannot be used to predict the frequency of adverse reactions in the course of usual medical practice where patient characteristics and other factors may differ from those prevailing during clinical studies. Similarly, the cited frequencies cannot be directly compared with data obtained from other clinical investigations involving different treatments, uses, or investigators. Inspection of these frequencies, however, does provide the prescribing physician with a basis to estimate the relative contribution of drug and non-drug factors to the adverse reaction incidences in the population studied.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.4"></a><a name="section-6.4"></a><p></p>
<h2>6.4	Other Adverse Reactions Observed During Double-Blind <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> Adjunctive Therapy Trials</h2>
<p class="First">Other adverse reactions that occurred in more than 1% of adults treated with 200 to 400 mg of TOPAMAX<span class="Sup">®</span> in placebo-controlled <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> trials but with equal or greater frequency in the placebo group were <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, injury, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions aggravated</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">coughing</span>, <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscle weakness</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">personality disorder</span>, <span class="product-label-link" type="condition" conceptid="194696" conceptname="Dysmenorrhea">dysmenorrhea</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span>, and <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>.</p>
<a name="table6"></a><table width="90%">
<caption><span>Table 6: Incidence of Treatment-Emergent Adverse Reactions in Placebo-Controlled, Add-On <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> Trials in Adults
                              <span class="Sup">,</span>
                               Where Incidence Was &gt;1% in Any TOPAMAX<span class="Sup">®</span> Group and Greater Than the Rate in Placebo-Treated Patients</span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<col align="center" valign="top" width="20%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center"></th>
<th class="Botrule" align="center" colspan="2">TOPAMAX<span class="Sup">®</span> Dosage (mg/day)</th>
</tr>
<tr>
<th align="left">Body System/</th>
<th align="center">Placebo</th>
<th align="center">200–400</th>
<th align="center">600–1,000</th>
</tr>
<tr class="Last">
<th align="left">  Adverse Reaction
                                 </th>
<th align="center">(N=291)</th>
<th align="center">(N=183)</th>
<th align="center">(N=414)</th>
</tr>
</thead>
<tbody>
<tr class="First"><td align="left" colspan="4"><span class="Bold">Body as a Whole-General Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">13</td>
<td align="center">15</td>
<td align="center">30</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center">1</td>
<td align="center">6</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td align="center">4</td>
<td align="center">5</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></td>
<td align="center">3</td>
<td align="center">4</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-like symptoms</td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Leg pain</span></td>
<td align="center">2</td>
<td align="center">2</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4113666" conceptname="Menopausal flushing">Hot flushes</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4178504" conceptname="Body odor">Body odor</span></td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4190045" conceptname="Rigor">Rigors</span></td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">&lt;1</td>
</tr>
<tr><td align="left" colspan="4"><span class="Bold">Central &amp; Peripheral <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">15</td>
<td align="center">25</td>
<td align="center">32</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span></td>
<td align="center">7</td>
<td align="center">16</td>
<td align="center">14</td>
</tr>
<tr>
<td align="left">  Speech disorders/Related speech problems</td>
<td align="center">2</td>
<td align="center">13</td>
<td align="center">11</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td align="center">4</td>
<td align="center">11</td>
<td align="center">19</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="378165" conceptname="Nystagmus">Nystagmus</span></td>
<td align="center">7</td>
<td align="center">10</td>
<td align="center">11</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td align="center">6</td>
<td align="center">9</td>
<td align="center">9</td>
</tr>
<tr>
<td align="left">  Language problems</td>
<td align="center">1</td>
<td align="center">6</td>
<td align="center">10</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="441417" conceptname="Incoordination">Coordination abnormal</span></td>
<td align="center">2</td>
<td align="center">4</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoesthesia</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Gait abnormal</span></td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4189159" conceptname="Muscle fibrillation">Muscle contractions involuntary</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">Stupor</span></td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">Vertigo</span></td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr><td align="left" colspan="4"><span class="Bold">Gastro-Intestinal System Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">8</td>
<td align="center">10</td>
<td align="center">12</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center">6</td>
<td align="center">7</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td align="center">4</td>
<td align="center">6</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center">2</td>
<td align="center">4</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">Gastroenteritis</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4281516" conceptname="Gingivitis">Gingivitis</span></td>
<td align="center">&lt;1</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  GI disorder</td>
<td align="center">&lt;1</td>
<td align="center">1</td>
<td align="center">0</td>
</tr>
<tr><td align="left" colspan="4"><span class="Bold">Hearing and <span class="product-label-link" type="condition" conceptid="81303" conceptname="Labyrinthine disorder">Vestibular Disorders</span></span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hearing decreased</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr><td align="left" colspan="4"><span class="Bold">Metabolic and Nutritional Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight decrease</span></td>
<td align="center">3</td>
<td align="center">9</td>
<td align="center">13</td>
</tr>
<tr><td align="left" colspan="4"><span class="Bold">Muscle-Skeletal System Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4129418" conceptname="Bone pain">Skeletal pain</span></td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">0</td>
</tr>
<tr><td align="left" colspan="4"><span class="Bold">Platelet, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, &amp; <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Clotting Disorders</span></span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr><td align="left" colspan="4"><span class="Bold">Psychiatric Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center">12</td>
<td align="center">29</td>
<td align="center">28</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
<td align="center">6</td>
<td align="center">16</td>
<td align="center">19</td>
</tr>
<tr>
<td align="left">  Psychomotor slowing</td>
<td align="center">2</td>
<td align="center">13</td>
<td align="center">21</td>
</tr>
<tr>
<td align="left">  Difficulty with memory</td>
<td align="center">3</td>
<td align="center">12</td>
<td align="center">14</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center">4</td>
<td align="center">10</td>
<td align="center">12</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></td>
<td align="center">5</td>
<td align="center">11</td>
<td align="center">14</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td align="center">5</td>
<td align="center">5</td>
<td align="center">13</td>
</tr>
<tr>
<td align="left">  Difficulty with concentration/attention</td>
<td align="center">2</td>
<td align="center">6</td>
<td align="center">14</td>
</tr>
<tr>
<td align="left">  Mood problems</td>
<td align="center">2</td>
<td align="center">4</td>
<td align="center">9</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span></td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggressive reaction</span></td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">Emotional lability</span></td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  Cognitive problems</td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">Libido decreased</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">&lt;1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4071366" conceptname="Indifference">Apathy</span></td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4085688" conceptname="Loss of identity">Depersonalization</span></td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr><td align="left" colspan="4"><span class="Bold">Reproductive Disorders, Female</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="73819" conceptname="Pain of breast">Breast pain</span></td>
<td align="center">2</td>
<td align="center">4</td>
<td align="center">0</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="443800" conceptname="Amenorrhea">Amenorrhea</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4302555" conceptname="Menorrhagia">Menorrhagia</span></td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">Menstrual disorder</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr><td align="left" colspan="4"><span class="Bold">Reproductive Disorders, Male</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="196734" conceptname="Disorder of prostate">Prostatic disorder</span></td>
<td align="center">&lt;1</td>
<td align="center">2</td>
<td align="center">0</td>
</tr>
<tr><td align="left" colspan="4"><span class="Bold">Resistance Mechanism Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="40493255" conceptname="Viral syndrome">Infection viral</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">&lt;1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">Moniliasis</span></td>
<td align="center">&lt;1</td>
<td align="center">1</td>
<td align="center">0</td>
</tr>
<tr><td align="left" colspan="4">R<span class="Bold">espiratory System Disorders</span>
</td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td align="center">2</td>
<td align="center">6</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td align="center">6</td>
<td align="center">7</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td align="center">4</td>
<td align="center">5</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr><td align="left" colspan="4"><span class="Bold">Skin and Appendages Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin disorder</span></td>
<td align="center">&lt;1</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">Sweating increased</span></td>
<td align="center">&lt;1</td>
<td align="center">1</td>
<td align="center">&lt;1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> erythematous</td>
<td align="center">&lt;1</td>
<td align="center">1</td>
<td align="center">&lt;1</td>
</tr>
<tr><td align="left" colspan="4"><span class="Bold">Special Sense Other, Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste perversion</span></td>
<td align="center">0</td>
<td align="center">2</td>
<td align="center">4</td>
</tr>
<tr><td align="left" colspan="4"><span class="Bold">Urinary System Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="75004" conceptname="Frank hematuria">Hematuria</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">&lt;1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  Micturition frequency</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">Urinary incontinence</span></td>
<td align="center">&lt;1</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4042234" conceptname="Abnormal urinalysis">Urine abnormal</span></td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">&lt;1</td>
</tr>
<tr><td align="left" colspan="4"><span class="Bold">Vision Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4265433" conceptname="Visual impairment">Vision abnormal</span></td>
<td align="center">2</td>
<td align="center">13</td>
<td align="center">10</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">Diplopia</span></td>
<td align="center">5</td>
<td align="center">10</td>
<td align="center">10</td>
</tr>
<tr><td align="left" colspan="4"><span class="Bold">White Cell and RES Disorders</span></td></tr>
<tr class="Last">
<td align="left">  <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.5"></a><a name="section-6.5"></a><p></p>
<h2>6.5	Incidence in Study 119 – Add-On Therapy– Adults with Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></h2>
<p class="First">Study 119 was a randomized, double-blind, add-on/adjunctive, placebo-controlled, parallel group study with 3 treatment arms: 1) placebo; 2) TOPAMAX<span class="Sup">®</span> 200 mg/day with a 25 mg/day starting dose, increased by 25 mg/day each week for 8 weeks until the 200 mg/day maintenance dose was reached; and 3) TOPAMAX<span class="Sup">®</span> 200 mg/day with a 50 mg/day starting dose, increased by 50 mg/day each week for 4 weeks until the 200 mg/day maintenance dose was reached. All patients were maintained on concomitant carbamazepine with or without another concomitant antiepileptic drug.</p>
<p>The incidence of adverse reactions (Table 7) did not differ significantly between the 2 TOPAMAX<span class="Sup">®</span> regimens. Because the frequencies of adverse reactions reported in this study were markedly lower than those reported in the previous <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> studies, they cannot be directly compared with data obtained in other studies.</p>
<a name="table7"></a><table width="80%">
<caption><span>Table 7:   Incidence of Treatment-Emergent Adverse Reactions in Study 119
                              <span class="Sup">,</span>
                               Where Incidence Was ≥ 2% in the TOPAMAX<span class="Sup">®</span> Group and Greater Than the Rate in Placebo-Treated Patients</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center"></th>
<th class="Botrule" align="center">TOPAMAX<span class="Sup">®</span><br> Dosage (mg/day)</th>
</tr>
<tr>
<th align="left">Body System/</th>
<th align="center">Placebo</th>
<th align="center">200</th>
</tr>
<tr class="Last">
<th align="left">  Adverse  Reaction
                                 </th>
<th align="center">(N=92)</th>
<th align="center">(N=171)</th>
</tr>
</thead>
<tbody>
<tr class="First"><td align="left" colspan="3"><span class="Bold">Body as a Whole-General  Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">4</td>
<td align="center">9</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">Chest pain</span></td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold">Cardiovascular  Disorders, General</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold">Central &amp; Peripheral  <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td align="center">2</td>
<td align="center">9</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">4</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">Tremor</span></td>
<td align="center">2</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoesthesia</span></td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">Leg cramps</span></td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  Language  problems</td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold">Gastro-Intestinal System  Disorders</span></td></tr>
<tr>
<td align="left">  Abdominal  <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td align="center">3</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center">0</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold">Hearing and Vestibular  Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span></td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold">Metabolic and  Nutritional Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight decrease</span></td>
<td align="center">4</td>
<td align="center">8</td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold">Psychiatric Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center">9</td>
<td align="center">15</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center">7</td>
<td align="center">9</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
<td align="center">2</td>
<td align="center">9</td>
</tr>
<tr>
<td align="left">  Difficulty  with concentration/attention</td>
<td align="center">0</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center">3</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  Difficulty  with memory</td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  Aggressive  reaction</td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold">Respiratory System  Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td align="center">0</td>
<td align="center">4</td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold">Urinary System Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="195588" conceptname="Cystitis">Cystitis</span></td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold">Vision Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">Diplopia</span></td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr class="Last">
<td align="left">  <span class="product-label-link" type="condition" conceptid="4265433" conceptname="Visual impairment">Vision abnormal</span></td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
</tbody>
</table>
<a name="table8"></a><table width="80%">
<caption><span>Table 8: Incidence (%) of Dose-Related Adverse Reactions From Placebo-Controlled, Add-On Trials in Adults With Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span><a name="footnote-reference-3" href="#footnote-3" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center"></th>
<th class="Botrule" align="center" colspan="3">TOPAMAX<span class="Sup">®</span> Dosage (mg/day)</th>
</tr>
<tr>
<th align="left"></th>
<th align="center">Placebo</th>
<th align="center">200</th>
<th align="center">400</th>
<th align="center">600 – 1,000</th>
</tr>
<tr class="Last">
<th align="left">Adverse Reaction</th>
<th align="center">(N = 216)</th>
<th align="center">(N = 45)</th>
<th align="center">(N = 68)</th>
<th align="center">(N = 414)</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-3" href="#footnote-reference-3">*</a></dt>
<dd>Dose-response studies were not conducted for other adult indications or for pediatric indications.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">13</td>
<td align="center">11</td>
<td align="center">12</td>
<td align="center">30</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
<td align="center">7</td>
<td align="center">13</td>
<td align="center">18</td>
<td align="center">19</td>
</tr>
<tr>
<td align="left">Difficulty with concentration/attention</td>
<td align="center">1</td>
<td align="center">7</td>
<td align="center">9</td>
<td align="center">14</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></td>
<td align="center">4</td>
<td align="center">9</td>
<td align="center">10</td>
<td align="center">14</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td align="center">6</td>
<td align="center">9</td>
<td align="center">7</td>
<td align="center">13</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center">4</td>
<td align="center">4</td>
<td align="center">6</td>
<td align="center">12</td>
</tr>
<tr>
<td align="left">Language problems</td>
<td align="center">&lt;1</td>
<td align="center">2</td>
<td align="center">9</td>
<td align="center">10</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td align="center">6</td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">10</td>
</tr>
<tr>
<td align="left">Mood problems</td>
<td align="center">2</td>
<td align="center">0</td>
<td align="center">6</td>
<td align="center">9</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight decrease</span></td>
<td align="center">3</td>
<td align="center">4</td>
<td align="center">9</td>
<td align="center">13</td>
</tr>
</tbody>
</table>
<a name="table9"></a><table width="80%">
<caption><span>Table 9: Incidence (%) of Treatment-Emergent Adverse Reactions in Placebo-Controlled, Add-On <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> Trials in Pediatric Patients (Ages 2 –16 Years)
                              <span class="Sup">,</span>
                               (Reactions That Occurred in at Least 1% of TOPAMAX<span class="Sup">®</span>-Treated Patients and Occurred More Frequently in TOPAMAX<span class="Sup">®</span>-Treated Than Placebo-Treated Patients)</span></caption>
<col align="left" valign="top" width="50%">
<col align="center" valign="top" width="25%">
<col align="center" valign="top" width="25%">
<thead>
<tr class="First">
<th align="left">Body System/</th>
<th align="center">Placebo</th>
<th align="center">TOPAMAX<span class="Sup">®</span>
</th>
</tr>
<tr class="Last">
<th align="left">  Adverse  Reaction</th>
<th align="center">(N=101)</th>
<th align="center">(N=98)</th>
</tr>
</thead>
<tbody>
<tr class="First"><td align="left" colspan="3"><span class="Bold">Body as a Whole - General Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">5</td>
<td align="center">16</td>
</tr>
<tr>
<td align="left">  Injury</td>
<td align="center">13</td>
<td align="center">14</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reaction</span></td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4260836" conceptname="Blanching of skin">Pallor</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span>, General</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold">Central &amp; Peripheral <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="437643" conceptname="Abnormal gait">Gait abnormal</span></td>
<td align="center">5</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span></td>
<td align="center">2</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4195305" conceptname="Hyperactive behavior">Hyperkinesia</span></td>
<td align="center">4</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">2</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  Speech disorders/Related speech problems</td>
<td align="center">2</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4044603" conceptname="Hyporeflexia">Hyporeflexia</span></td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="374924" conceptname="Generalized convulsive epilepsy">Convulsions grand mal</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="197675" conceptname="Incontinence of feces">Fecal incontinence</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold">Gastro-Intestinal System Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">5</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4207204" conceptname="Excessive salivation">Saliva increased</span></td>
<td align="center">4</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span></td>
<td align="center">4</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">Gastroenteritis</span></td>
<td align="center">2</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4012503" conceptname="Excessive upper gastrointestinal gas">Flatulence</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">Gastroesophageal reflux</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">Glossitis</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  Gum <span class="product-label-link" type="condition" conceptid="4296894" conceptname="Hyperplasia">hyperplasia</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold">Heart Rate and Rhythm Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">Bradycardia</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold">Metabolic and Nutritional Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight decrease</span></td>
<td align="center">1</td>
<td align="center">9</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">Thirst</span></td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="24609" conceptname="Hypoglycemia">Hypoglycemia</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">Weight increase</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold">Platelet, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, &amp; <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Clotting Disorders</span></span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4047773" conceptname="Purpura">Purpura</span></td>
<td align="center">4</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></td>
<td align="center">1</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4147001" conceptname="Hematoma">Hematoma</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4260197" conceptname="Prothrombin time increased">Prothrombin increased</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">Thrombocytopenia</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold">Psychiatric Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center">16</td>
<td align="center">26</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center">15</td>
<td align="center">24</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
<td align="center">7</td>
<td align="center">14</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="441838" conceptname="Personality disorder">Personality disorder</span> (behavior problems)</td>
<td align="center">9</td>
<td align="center">11</td>
</tr>
<tr>
<td align="left">  Difficulty with concentration/attention</td>
<td align="center">2</td>
<td align="center">10</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4021344" conceptname="Abusive behavior">Aggressive reaction</span></td>
<td align="center">4</td>
<td align="center">9</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center">7</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">  Difficulty with memory</td>
<td align="center">0</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></td>
<td align="center">3</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  Psychomotor slowing</td>
<td align="center">2</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  Appetite increased</td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="444243" conceptname="Neurosis">Neurosis</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold">Reproductive Disorders, Female</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="195873" conceptname="Leukorrhea">Leukorrhea</span></td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold">Resistance Mechanism Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="40493255" conceptname="Viral syndrome">Infection viral</span></td>
<td align="center">3</td>
<td align="center">7</td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span></span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span></td>
<td align="center">1</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory disorder</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold">Skin and Appendages Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="140842" conceptname="Changes in skin texture">Skin disorder</span></td>
<td align="center">2</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">Alopecia</span></td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Dermatitis</span></td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="443793" conceptname="Hypertrichosis">Hypertrichosis</span></td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span> erythematous</td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">Eczema</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="138821" conceptname="Seborrhea">Seborrhea</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="135030" conceptname="Discoloration of skin">Skin discoloration</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold">Urinary System Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="197672" conceptname="Urinary incontinence">Urinary incontinence</span></td>
<td align="center">2</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="40304526" conceptname="Nocturia">Nocturia</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold">Vision Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye abnormality</span></td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4265433" conceptname="Visual impairment">Vision abnormal</span></td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">Diplopia</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="379814" conceptname="Dislocation of lacrimal gland">Lacrimation abnormal</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="379805" conceptname="Myopia">Myopia</span></td>
<td align="center">0</td>
<td align="center">1</td>
</tr>
<tr><td align="left" colspan="3"><span class="Bold">White Cell and RES Disorders</span></td></tr>
<tr class="Last">
<td align="left">  <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">Leukopenia</span></td>
<td align="center">0</td>
<td align="center">2</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.6"></a><a name="section-6.6"></a><p></p>
<h2>6.6	Other Adverse Reactions Observed During All <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> Clinical Trials</h2>
<p class="First">TOPAMAX<span class="Sup">®</span> has been administered to 2246 adults and 427 pediatric patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> during all clinical studies, only some of which were placebo-controlled. During these studies, all adverse reactions were recorded by the clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals having adverse reactions, similar types of reactions were grouped into a smaller number of standardized categories using modified WHOART dictionary terminology. The frequencies presented represent the proportion of patients who experienced a reaction of the type cited on at least one occasion while receiving TOPAMAX<span class="Sup">®</span>. Reported reactions are included except those already listed in the previous tables or text, those too general to be informative, and those not reasonably associated with the use of the drug.</p>
<p>Reactions are classified within body system categories and enumerated in order of decreasing frequency using the following definitions: <span class="Italics">frequent</span> occurring in at least 1/100 patients; <span class="Italics">infrequent</span> occurring in 1/100 to 1/1000 patients; <span class="Italics">rare</span> occurring in fewer than 1/1000 patients.</p>
<p>Autonomic <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>: <span class="Italics">Infrequent:</span> vasodilation.</p>
<p>Body as a Whole: <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>. <span class="Italics">Infrequent</span>: <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">abdomen enlarged</span>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4010023" conceptname="Alcohol intolerance">alcohol intolerance</span>.</p>
<p><span class="product-label-link" type="condition" conceptid="134057" conceptname="Disorder of cardiovascular system">Cardiovascular Disorders</span>, General: <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>, <span class="product-label-link" type="condition" conceptid="321318" conceptname="Angina pectoris">angina pectoris</span>.</p>
<p>Central &amp; Peripheral <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>: <span class="Italics">Infrequent</span>: <span class="product-label-link" type="condition" conceptid="197608" conceptname="Peripheral neuritis in pregnancy">neuropathy</span>, <span class="product-label-link" type="condition" conceptid="132342" conceptname="Apraxia">apraxia</span>, <span class="product-label-link" type="condition" conceptid="4031840" conceptname="Hyperesthesia">hyperesthesia</span>, <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span>, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">scotoma</span>, <span class="product-label-link" type="condition" conceptid="373194" conceptname="Paralytic ptosis">ptosis</span>, <span class="product-label-link" type="condition" conceptid="375800" conceptname="Dystonia">dystonia</span>, <span class="product-label-link" type="condition" conceptid="377286" conceptname="Visual field defect">visual field defect</span>, <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>, <span class="product-label-link" type="condition" conceptid="4168553" conceptname="Electroencephalogram abnormal">EEG abnormal</span>. <span class="Italics">Rare:</span> upper motor neuron lesion, <span class="product-label-link" type="condition" conceptid="4046815" conceptname="Dysdiadochokinesis">cerebellar syndrome</span>, <span class="product-label-link" type="condition" conceptid="4243934" conceptname="Paralysis of tongue">tongue paralysis</span>.</p>
<p>Gastrointestinal System Disorders: <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="194382" conceptname="External hemorrhoids">hemorrhoids</span>, <span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">stomatitis</span>, <span class="product-label-link" type="condition" conceptid="193809" conceptname="Melena due to gastrointestinal hemorrhage">melena</span>, <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">gastritis</span>, <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4217627" conceptname="Edema of the tongue">tongue edema</span>.</p>
<p>Heart Rate and Rhythm Disorders: <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="316135" conceptname="Atrioventricular block">AV block</span>.</p>
<p>Liver and Biliary System Disorders: <span class="Italics">Infrequent:</span> SGPT increased, <span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span> increased.</p>
<p>Metabolic and Nutritional Disorders: <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="435796" conceptname="Dehydration">dehydration</span>, <span class="product-label-link" type="condition" conceptid="435510" conceptname="Hypocalcemia">hypocalcemia</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipemia</span>, <span class="product-label-link" type="condition" conceptid="4214376" conceptname="Hyperglycemia">hyperglycemia</span>, <span class="product-label-link" type="condition" conceptid="4180937" conceptname="Xerophthalmia">xerophthalmia</span>, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">hypernatremia</span>, <span class="product-label-link" type="condition" conceptid="4232311" conceptname="Hyponatremia">hyponatremia</span>, <span class="product-label-link" type="condition" conceptid="4266240" conceptname="Hypocholesterolemia">hypocholesterolemia</span>, creatinine increased.</p>
<p>Musculoskeletal System Disorders: <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">arthralgia</span>. <span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="73553" conceptname="Arthropathy">arthrosis</span>.</p>
<p>Neoplasms: <span class="Italics">Infrequent: </span><span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocythemia</span>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="435790" conceptname="Secondary polycythemia">polycythemia</span>.</p>
<p>Platelet, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Clotting Disorders</span>: <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4311406" conceptname="Bleeding gums">gingival bleeding</span>, <span class="product-label-link" type="condition" conceptid="440417" conceptname="Pulmonary embolism">pulmonary embolism</span>.</p>
<p>Psychiatric Disorders: <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucination</span>, <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychosis</span>, <span class="product-label-link" type="condition" conceptid="4219484" conceptname="Suicide attempt">suicide attempt</span>. <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="438737" conceptname="Acute paranoid reaction">paranoid reaction</span>, <span class="product-label-link" type="condition" conceptid="444401" conceptname="Delusions">delusion</span>, <span class="product-label-link" type="condition" conceptid="432590" conceptname="Delusional disorder">paranoia</span>, <span class="product-label-link" type="condition" conceptid="373995" conceptname="Delirium">delirium</span>, abnormal dreaming. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4237753" conceptname="Increased libido">libido increased</span>, <span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">manic reaction</span>.</p>
<p>Red Blood Cell Disorders: <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">anemia</span>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4145241" conceptname="Bone marrow depression">marrow depression</span>, <span class="product-label-link" type="condition" conceptid="432881" conceptname="Pancytopenia">pancytopenia</span>.</p>
<p>Reproductive Disorders, Male: <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4297368" conceptname="Abnormal ejaculation">ejaculation disorder</span>, <span class="product-label-link" type="condition" conceptid="4181744" conceptname="Discharge from nipple">breast discharge</span>.</p>
<p>Skin and Appendages Disorders: <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4080920" conceptname="Phytophotodermatitis">photosensitivity reaction</span>, abnormal hair texture. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4264234" conceptname="Chloasma">chloasma</span>.</p>
<p>Special Senses Other, Disorders: <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">taste loss</span>, <span class="product-label-link" type="condition" conceptid="444223" conceptname="Sense of smell altered">parosmia</span>.</p>
<p>Urinary System Disorders: <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4167250" conceptname="Renal pain">renal pain</span>, <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">albuminuria</span>, <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">polyuria</span>, <span class="product-label-link" type="condition" conceptid="4306451" conceptname="Oliguria">oliguria</span>.</p>
<p>Vascular (Extracardiac) Disorders: <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="4042396" conceptname="Deep thrombophlebitis">deep vein thrombosis</span>, <span class="product-label-link" type="condition" conceptid="318174" conceptname="Phlebitis">phlebitis</span>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4215494" conceptname="Vasospasm">vasospasm</span>.</p>
<p>Vision Disorders: <span class="Italics">Frequent:</span> <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>. <span class="Italics">Infrequent:</span> abnormal accommodation, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, <span class="product-label-link" type="condition" conceptid="4329707" conceptname="Strabismus">strabismus</span>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="4274964" conceptname="Iritis">iritis</span>.</p>
<p>White Cell and Reticuloendothelial System Disorders: <span class="Italics">Infrequent:</span> <span class="product-label-link" type="condition" conceptid="315085" conceptname="Lymphadenopathy">lymphadenopathy</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="441541" conceptname="Lymphocytopenia">lymphopenia</span>, <span class="product-label-link" type="condition" conceptid="4218497" conceptname="Granulocytopenic disorder">granulocytopenia</span>. <span class="Italics">Rare:</span> <span class="product-label-link" type="condition" conceptid="320074" conceptname="Lymphocytosis">lymphocytosis</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.7"></a><a name="section-6.7"></a><p></p>
<h2>6.7	<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span></h2>
<p class="First">In the four multicenter, randomized, double-blind, placebo-controlled, parallel group <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> prophylaxis clinical trials, most of the adverse reactions with TOPAMAX<span class="Sup">® </span>were mild or moderate in severity. Most adverse reactions occurred more frequently during the titration period than during the maintenance period.</p>
<p>Table 10 includes those adverse reactions reported for patients in the placebo-controlled trials where the incidence in any TOPAMAX<span class="Sup">®</span> treatment group was at least 2% and was greater than that for placebo patients.</p>
<a name="table10"></a><table width="90%">
<caption><span>Table 10:  Incidence of Treatment-Emergent Adverse Reactions in Placebo-Controlled, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Trials Where Incidence Was ≥2 % in Any TOPAMAX<span class="Sup">®</span> Group and Greater Than the Rate in Placebo-Treated Patients
                           </span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center"></th>
<th class="Botrule" align="center" colspan="3">TOPAMAX<span class="Sup">®</span>  Dosage (mg/day)</th>
</tr>
<tr>
<th align="left">Body System/</th>
<th align="center">Placebo</th>
<th align="center">50</th>
<th align="center">100</th>
<th align="center">200</th>
</tr>
<tr class="Last">
<th align="left">Adverse Reaction</th>
<th align="center">(N=445)</th>
<th align="center">(N=235)</th>
<th align="center">(N=386)</th>
<th align="center">(N=514)</th>
</tr>
</thead>
<tbody>
<tr class="First"><td align="left" colspan="5"><span class="Bold">Body as a Whole-General Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">11</td>
<td align="center">14</td>
<td align="center">15</td>
<td align="center">19</td>
</tr>
<tr>
<td align="left">  Injury</td>
<td align="center">7</td>
<td align="center">9</td>
<td align="center">6</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Asthenia</span></td>
<td align="center">1</td>
<td align="center">&lt;1</td>
<td align="center">2</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Fever</span></td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4266367" conceptname="Influenza">Influenza</span>-like symptoms</td>
<td align="center">&lt;1</td>
<td align="center">&lt;1</td>
<td align="center">&lt;1</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span></td>
<td align="center">&lt;1</td>
<td align="center">2</td>
<td align="center">&lt;1</td>
<td align="center">&lt;1</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Central &amp; Peripheral <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td align="center">6</td>
<td align="center">35</td>
<td align="center">51</td>
<td align="center">49</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">10</td>
<td align="center">8</td>
<td align="center">9</td>
<td align="center">12</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoesthesia</span></td>
<td align="center">2</td>
<td align="center">6</td>
<td align="center">7</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">  Language problems</td>
<td align="center">2</td>
<td align="center">7</td>
<td align="center">6</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">  Involuntary muscle contractions</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">2</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">Ataxia</span></td>
<td align="center">&lt;1</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  Speech disorders/Related speech problems</td>
<td align="center">&lt;1</td>
<td align="center">1</td>
<td align="center">&lt;1</td>
<td align="center">2</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Gastro-Intestinal System Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">8</td>
<td align="center">9</td>
<td align="center">13</td>
<td align="center">14</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">4</td>
<td align="center">9</td>
<td align="center">11</td>
<td align="center">11</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span></td>
<td align="center">5</td>
<td align="center">6</td>
<td align="center">6</td>
<td align="center">7</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td align="center">3</td>
<td align="center">4</td>
<td align="center">5</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td align="center">2</td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span></td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4101468" conceptname="Gastroenteritis">Gastroenteritis</span></td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">3</td>
<td align="center">2</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Hearing and <span class="product-label-link" type="condition" conceptid="81303" conceptname="Labyrinthine disorder">Vestibular Disorders</span></span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">Tinnitus</span></td>
<td align="center">1</td>
<td align="center">&lt;1</td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Metabolic and Nutritional Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight decrease</span></td>
<td align="center">1</td>
<td align="center">6</td>
<td align="center">9</td>
<td align="center">11</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4241197" conceptname="Thirst">Thirst</span></td>
<td align="center">&lt;1</td>
<td align="center">2</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Musculoskeletal System Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="77074" conceptname="Joint pain">Arthralgia</span></td>
<td align="center">2</td>
<td align="center">7</td>
<td align="center">3</td>
<td align="center">1</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Neoplasms</span></td></tr>
<tr>
<td align="left">  Neoplasm</td>
<td align="center">&lt;1</td>
<td align="center">2</td>
<td align="center">&lt;1</td>
<td align="center">&lt;1</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Psychiatric Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center">6</td>
<td align="center">9</td>
<td align="center">15</td>
<td align="center">14</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center">5</td>
<td align="center">8</td>
<td align="center">7</td>
<td align="center">10</td>
</tr>
<tr>
<td align="left">  Difficulty with memory</td>
<td align="center">2</td>
<td align="center">7</td>
<td align="center">7</td>
<td align="center">11</td>
</tr>
<tr>
<td align="left">  Difficulty with concentration/attention</td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">6</td>
<td align="center">10</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span></td>
<td align="center">5</td>
<td align="center">6</td>
<td align="center">7</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td align="center">3</td>
<td align="center">4</td>
<td align="center">5</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">  Mood problems</td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">6</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td align="center">4</td>
<td align="center">3</td>
<td align="center">4</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
<td align="center">2</td>
<td align="center">4</td>
<td align="center">4</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></td>
<td align="center">2</td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  Psychomotor slowing</td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">2</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="443262" conceptname="Lack or loss of sexual desire">Libido decreased</span></td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  Aggravated <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> </td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">Agitation</span></td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
<tr>
<td align="left">  Cognitive problems</td>
<td align="center">1</td>
<td align="center">&lt;1</td>
<td align="center">2</td>
<td align="center">2</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Reproductive Disorders, Female</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="196471" conceptname="Puberty bleeding">Menstrual disorder</span></td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">2</td>
<td align="center">2</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Reproductive Disorders, Male</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="434319" conceptname="Premature ejaculation">Ejaculation premature</span></td>
<td align="center">0</td>
<td align="center">3</td>
<td align="center">0</td>
<td align="center">0</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Resistance Mechanism Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">Viral infection</span> </td>
<td align="center">3</td>
<td align="center">4</td>
<td align="center">4</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">Otitis media</span></td>
<td align="center">&lt;1</td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">1</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span></span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">Upper respiratory tract infection</span></td>
<td align="center">12</td>
<td align="center">13</td>
<td align="center">14</td>
<td align="center">12</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span></td>
<td align="center">6</td>
<td align="center">10</td>
<td align="center">6</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></td>
<td align="center">4</td>
<td align="center">5</td>
<td align="center">6</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Coughing</span></td>
<td align="center">2</td>
<td align="center">2</td>
<td align="center">4</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">Bronchitis</span></td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">3</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td align="center">2</td>
<td align="center">1</td>
<td align="center">3</td>
<td align="center">2</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span></td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">2</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Skin and Appendages Disorders</span></td></tr>
<tr>
<td align="left">  Pruritis</td>
<td align="center">2</td>
<td align="center">4</td>
<td align="center">2</td>
<td align="center">2</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Special Sense Other, Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="436235" conceptname="Taste sense altered">Taste perversion</span></td>
<td align="center">1</td>
<td align="center">15</td>
<td align="center">8</td>
<td align="center">12</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">Taste loss</span></td>
<td align="center">&lt;1</td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Urinary System Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">Urinary tract infection</span></td>
<td align="center">2</td>
<td align="center">4</td>
<td align="center">2</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Renal calculus</span></td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
<tr><td align="left" colspan="5"><span class="Bold">Vision Disorders</span></td></tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4265433" conceptname="Visual impairment">Vision abnormal</span></td>
<td align="center">&lt;1</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">3</td>
</tr>
<tr>
<td align="left">  <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred vision</span> 
                                 </td>
<td align="center">2</td>
<td align="center">4</td>
<td align="center">2</td>
<td align="center">4</td>
</tr>
<tr class="Last">
<td align="left">  <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">Conjunctivitis</span></td>
<td align="center">1</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">1</td>
</tr>
</tbody>
</table>
<p>Of the 1135 patients exposed to TOPAMAX<span class="Sup">®</span> in the placebo-controlled studies, 25% discontinued due to adverse reactions, compared to 10% of the 445 placebo patients. The adverse reactions associated with discontinuing therapy in the TOPAMAX<span class="Sup">®</span> -treated patients included <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span> (7%), <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span> (4%), <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span> (4%), difficulty with concentration/attention (3%), <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span> (3%), <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span> (2%), and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> (2%).</p>
<p>Patients treated with TOPAMAX<span class="Sup">®</span> experienced mean percent reductions in body weight that were dose-dependent. This change was not seen in the placebo group. Mean changes of 0%, -2%, -3%, and -4% were seen for the placebo group, TOPAMAX<span class="Sup">®</span> 50, 100, and 200 mg groups, respectively.</p>
<p>Table 11 shows adverse reactions that were dose-dependent. Several central nervous system adverse reactions, including some that represented cognitive dysfunction, were dose-related. The most common dose-related adverse reactions were <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, difficulty with memory, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight decrease</span>, difficulty with concentration/attention, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>.</p>
<a name="table11"></a><table width="80%">
<caption><span>Table 11: Incidence (%) of Dose-Related Adverse Reactions From Placebo-Controlled, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Trials<a name="footnote-reference-4" href="#footnote-4" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="40%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<col align="center" valign="top" width="15%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="center"></th>
<th class="Botrule" align="center" colspan="3">TOPAMAX<span class="Sup">® </span>Dosage (mg/day)</th>
</tr>
<tr>
<th align="left"></th>
<th align="center">Placebo</th>
<th align="center">50</th>
<th align="center">100</th>
<th align="center">200</th>
</tr>
<tr class="Last">
<th align="left">Adverse Reaction</th>
<th align="center">(N=445)</th>
<th align="center">(N=235)</th>
<th align="center">(N=386)</th>
<th align="center">(N=514)</th>
</tr>
</thead>
<tfoot><tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-4" href="#footnote-reference-4">*</a></dt>
<dd>The incidence of adverse reactions in the 200 mg/day group was ≥ 2% than the incidence in both the placebo group and the 50 mg/day group.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left"><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span></td>
<td align="center">6</td>
<td align="center">35</td>
<td align="center">51</td>
<td align="center">49</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td align="center">11</td>
<td align="center">14</td>
<td align="center">15</td>
<td align="center">19</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td align="center">8</td>
<td align="center">9</td>
<td align="center">13</td>
<td align="center">14</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">Anorexia</span></td>
<td align="center">6</td>
<td align="center">9</td>
<td align="center">15</td>
<td align="center">14</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td align="center">10</td>
<td align="center">8</td>
<td align="center">9</td>
<td align="center">12</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">Weight decrease</span></td>
<td align="center">1</td>
<td align="center">6</td>
<td align="center">9</td>
<td align="center">11</td>
</tr>
<tr>
<td align="left">Difficulty with memory</td>
<td align="center">2</td>
<td align="center">7</td>
<td align="center">7</td>
<td align="center">11</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span></td>
<td align="center">4</td>
<td align="center">9</td>
<td align="center">11</td>
<td align="center">11</td>
</tr>
<tr>
<td align="left">Difficulty with concentration/attention</td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">6</td>
<td align="center">10</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Somnolence</span></td>
<td align="center">5</td>
<td align="center">8</td>
<td align="center">7</td>
<td align="center">10</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">Hypoesthesia</span></td>
<td align="center">2</td>
<td align="center">6</td>
<td align="center">7</td>
<td align="center">8</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">Anxiety</span></td>
<td align="center">3</td>
<td align="center">4</td>
<td align="center">5</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">Depression</span></td>
<td align="center">4</td>
<td align="center">3</td>
<td align="center">4</td>
<td align="center">6</td>
</tr>
<tr>
<td align="left">Mood problems</td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">6</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry mouth</span></td>
<td align="center">2</td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">5</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">Confusion</span></td>
<td align="center">2</td>
<td align="center">2</td>
<td align="center">3</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left">Involuntary muscle contractions</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">2</td>
<td align="center">4</td>
</tr>
<tr>
<td align="left"><span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">Abnormal vision</span></td>
<td align="center">&lt;1</td>
<td align="center">1</td>
<td align="center">2</td>
<td align="center">3</td>
</tr>
<tr class="Last">
<td align="left"><span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Renal calculus</span></td>
<td align="center">0</td>
<td align="center">0</td>
<td align="center">1</td>
<td align="center">2</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.8"></a><a name="section-6.8"></a><p></p>
<h2>6.8	Other Adverse Reactions Observed During <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Clinical Trials</h2>
<p class="First">TOPAMAX<span class="Sup">®</span>, for the treatment of prophylaxis of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span>, has been administered to 1367 patients in all clinical studies (includes double-blind and open-label extension). During these studies, all adverse reactions were recorded by the clinical investigators using terminology of their own choosing. To provide a meaningful estimate of the proportion of individuals having adverse reactions, similar types of reactions were grouped into a smaller number of standardized categories using modified WHOART dictionary terminology.</p>
<p>The following additional adverse reactions that were not described earlier were reported by greater than 1% of the 1367 TOPAMAX<span class="Sup">®</span>-treated patients in the controlled clinical trials:</p>
<p><span class="Italics">Body as a Whole:</span> <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">Pain</span>, <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>, <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</p>
<p><span class="Italics">Central &amp; Peripheral <span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>, <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4311114" conceptname="Sensory disorder">sensory disturbance</span>, <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine aggravated</span>.</p>
<p><span class="Italics">Gastrointestinal System Disorders:</span> <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">Constipation</span>, <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux</span>.</p>
<p><span class="Italics">Musculoskeletal System Disorders:</span> <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span>.</p>
<p><span class="Italics">Platelet, <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">Bleeding</span>, and <span class="product-label-link" type="condition" conceptid="432585" conceptname="Blood coagulation disorder">Clotting Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span>.</p>
<p><span class="Italics">Reproductive Disorders, Female:</span> <span class="product-label-link" type="condition" conceptid="198195" conceptname="Ovulation bleeding">Intermenstrual bleeding</span>.</p>
<p><span class="Italics">Resistance Mechanism Disorders:</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infection</span>, genital <span class="product-label-link" type="condition" conceptid="433968" conceptname="Candidiasis">moniliasis</span>.</p>
<p><span class="Italics"><span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">Respiratory System Disorders</span>:</span> <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">Pneumonia</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
<p><span class="Italics">Skin and Appendages Disorders:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>, <span class="product-label-link" type="condition" conceptid="133280" conceptname="Alopecia">alopecia</span>.</p>
<p><span class="Italics">Vision Disorders:</span> Abnormal accommodation, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S6.9"></a><a name="section-6.9"></a><p></p>
<h2>6.9	Postmarketing and Other Experience</h2>
<p class="First">In addition to the adverse experiences reported during clinical testing of TOPAMAX<span class="Sup">®</span>, the following adverse experiences have been reported worldwide in patients receiving TOPAMAX<span class="Sup">®</span> post-approval.</p>
<p>These adverse experiences have not been listed above and data are insufficient to support an estimate of their incidence or to establish causation. The listing is alphabetized: bullous <span class="product-label-link" type="condition" conceptid="4089139" conceptname="Skin reaction">skin reactions</span> (including <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson syndrome</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>), <span class="product-label-link" type="condition" conceptid="4245975" conceptname="Hepatic failure">hepatic failure</span> (including fatalities), <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">hepatitis</span>, <span class="product-label-link" type="condition" conceptid="4208223" conceptname="Disorder of macula of retina">maculopathy</span>, <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>, and <span class="product-label-link" type="condition" conceptid="135338" conceptname="Pemphigus">pemphigus</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="S7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First"><span class="Italics">In vitro </span>studies indicate that topiramate does not inhibit enzyme activity for CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1, and CYP3A4/5 isozymes. <span class="Italics">In vitro </span>studies indicate that topiramate is a mild inhibitor of CYP2C19 and a mild inducer of CYP3A4. Drug interactions with some antiepileptic drugs, CNS depressants and oral contraceptives are described here. For other drug interactions, please refer to <span class="Italics"><a href="#S12.3">Clinical Pharmacology (12.3)</a></span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.1"></a><a name="section-7.1"></a><p></p>
<h2>7.1	Antiepileptic Drugs</h2>
<p class="First">Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. Concomitant administration of phenytoin or carbamazepine with topiramate decreased plasma concentrations of topiramate by 48% and 40%, respectively when compared to TOPAMAX<span class="Sup">®</span> given alone <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>.]</span></p>
<p>Concomitant administration of valproic acid and TOPAMAX<span class="Sup">®</span> has been associated with <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> with and without <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>. Concomitant administration of TOPAMAX<span class="Sup">®</span> with valproic acid has also been associated with <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span> (with and without <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span>) in patients who have tolerated either drug alone. It may be prudent to examine blood <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> levels in patients in whom the onset of <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span> has been reported  <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>, <a href="#S5.11">(5.11)</a> or <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.2"></a><a name="section-7.2"></a><p></p>
<h2>7.2	CNS Depressants</h2>
<p class="First">Concomitant administration of TOPAMAX<span class="Sup">®</span> and alcohol or other CNS depressant drugs has not been evaluated in clinical studies. Because of the potential of topiramate to cause <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, as well as other cognitive and/or neuropsychiatric adverse reactions, TOPAMAX<span class="Sup">®</span> should be used with extreme caution if used in combination with alcohol and other CNS depressants.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.3"></a><a name="section-7.3"></a><p></p>
<h2>7.3	Oral Contraceptives</h2>
<p class="First">Exposure to ethinyl estradiol was statistically significantly decreased at doses of 200, 400, and 800 mg/day (18%, 21%, and 30%, respectively) when TOPAMAX<span class="Sup">®</span> was given as adjunctive therapy in patients taking valproic acid. However, norethindrone exposure was not significantly affected. In another <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> study in healthy volunteers with a concomitantly administered combination oral contraceptive product containing 1 mg norethindrone (NET) plus 35 mcg ethinyl estradiol (EE), TOPAMAX<span class="Sup">®</span>,  given in the absence of other medications at doses of 50 to 200 mg/day, was not associated with statistically significant changes in mean exposure (AUC) to either component of the oral contraceptive. The possibility of decreased contraceptive efficacy and increased breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> should be considered in patients taking combination oral contraceptive products with TOPAMAX<span class="Sup">®</span>. Patients taking estrogen-containing contraceptives should be asked to report any change in their <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> patterns. Contraceptive efficacy can be decreased even in the absence of breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.4"></a><a name="section-7.4"></a><p></p>
<h2>7.4	Metformin</h2>
<p class="First">Topiramate treatment can frequently cause <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, a condition for which the use of metformin is contraindicated [<span class="Italics">see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.5"></a><a name="section-7.5"></a><p></p>
<h2>7.5	Lithium</h2>
<p class="First">In patients, lithium levels were unaffected during treatment with topiramate at doses of 200 mg/day; however, there was an observed increase in systemic exposure of lithium (27% for C<span class="Sub">max</span> and 26% for AUC) following topiramate doses of up to 600 mg/day. Lithium levels should be monitored when co-administered with high-dose TOPAMAX<span class="Sup">®</span><span class="Italics"> [see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S7.6"></a><a name="section-7.6"></a><p></p>
<h2>7.6	Other Carbonic Anhydrase Inhibitors</h2>
<p class="First">Concomitant use of topiramate, a carbonic anhydrase inhibitor, with any other carbonic anhydrase inhibitor (e.g., zonisamide, acetazolamide, or dichlorphenamide) may increase the severity of <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> and may also increase the risk of <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">kidney stone</span> formation. Therefore, if TOPAMAX<span class="Sup">®</span> is given concomitantly with another carbonic anhydrase inhibitor, the patient should be monitored for the appearance or worsening of <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Category D. <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a>]</span></span></p>
<p>TOPAMAX<span class="Sup">®</span> (topiramate) can cause fetal harm when administered to a pregnant woman. Data from pregnancy registries indicate that infants exposed to topiramate <span class="Italics">in utero</span> have an increased risk for <span class="product-label-link" type="condition" conceptid="133861" conceptname="Cleft lip">cleft lip</span> and/or <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> (oral clefts). When multiple species of pregnant animals received topiramate at clinically relevant doses, structural malformations, including craniofacial defects, and reduced fetal weights occurred in offspring. TOPAMAX<span class="Sup">®</span> should be used during pregnancy only if the potential benefit outweighs the potential risk. If this drug is used during pregnancy, or if the patient becomes pregnant while taking this drug, the patient should be apprised of the potential hazard to a fetus <span class="Italics">[see <a href="#S8.9">Use in Specific Populations (8.9)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.2"></a><p></p>
<p class="First"><span class="Bold">Pregnancy Registry</span></p>
<p>Patients should be encouraged to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry if they become pregnant. This registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll-free number 1-888-233-2334. Information about the North American Drug Pregnancy Registry can be found at <span class="Italics">http://www.massgeneral.org/aed/</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.2.1"></a><p></p>
<p class="First">Human Data</p>
<p>Data from the NAAED Pregnancy Registry indicate an increased risk of oral clefts in infants exposed to topiramate monotherapy during the first trimester of pregnancy. The prevalence of oral clefts was 1.2% compared to a prevalence of 0.39% – 0.46% in infants exposed to other AEDs, and a prevalence of 0.12% in infants of mothers without <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> or treatment with other AEDs. For comparison, the Centers for Disease Control and Prevention (CDC) reviewed available data on oral clefts in the United States and found a similar background rate of 0.17%. The relative risk of oral clefts in topiramate-exposed pregnancies in the NAAED Pregnancy Registry was 9.6 (95% Confidence Interval = CI 3.6 – 25.7) as compared to the risk in a background population of untreated women. The UK <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> and Pregnancy Register reported a similarly increased prevalence of oral clefts of 3.2% among infants exposed to topiramate monotherapy. The observed rate of oral clefts was 16 times higher than the background rate in the UK, which is approximately 0.2%.</p>
<p>TOPAMAX<span class="Sup">®</span> treatment can cause <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>. The effect of topiramate-induced <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> has not been studied in pregnancy; however, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> in pregnancy (due to other causes) can cause decreased fetal growth, decreased fetal oxygenation, and <span class="product-label-link" type="condition" conceptid="4079844" conceptname="Fetal death">fetal death</span>, and may affect the fetus' ability to tolerate labor. Pregnant patients should be monitored for <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> and treated as in the nonpregnant state <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>. Newborns of mothers treated with TOPAMAX<span class="Sup">®</span> should be monitored for <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> because of transfer of topiramate to the fetus and possible occurrence of transient <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> following birth.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.1.2.2"></a><p></p>
<p class="First">Animal Data</p>
<p>Topiramate has demonstrated selective developmental toxicity, including <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>, in multiple animal species at clinically relevant doses. When oral doses of 20, 100, or 500 mg/kg were administered to pregnant mice during the period of organogenesis, the incidence of <span class="product-label-link" type="condition" conceptid="4079975" conceptname="Congenital malformation">fetal malformations</span> (primarily craniofacial defects) was increased at all doses. The low dose is approximately 0.2 times the recommended human dose (RHD) 400 mg/day on a mg/m<span class="Sup">2</span> basis. Fetal body weights and skeletal ossification were reduced at 500 mg/kg in conjunction with decreased maternal body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>.</p>
<p>In rat studies (oral doses of 20, 100, and 500 mg/kg or 0.2, 2.5, 30, and 400 mg/kg), the frequency of <span class="product-label-link" type="condition" conceptid="134741" conceptname="Congenital anomaly of limb">limb malformations</span> (ectrodactyly, <span class="product-label-link" type="condition" conceptid="73307" conceptname="Transverse deficiency of lower limb">micromelia</span>, and amelia) was increased among the offspring of dams treated with 400 mg/kg (10 times the RHD on a mg/m<span class="Sup">2</span> basis) or greater during the organogenesis period of pregnancy. Embryotoxicity (reduced fetal body weights, increased incidence of structural variations) was observed at doses as low as 20 mg/kg (0.5 times the RHD on a mg/m<span class="Sup">2</span> basis). Clinical signs of maternal toxicity were seen at 400 mg/kg and above, and maternal body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> was reduced during treatment with 100 mg/kg or greater.</p>
<p>In rabbit studies (20, 60, and 180 mg/kg or 10, 35, and 120 mg/kg orally during organogenesis), embryo/fetal mortality was increased at 35 mg/kg (2 times the RHD on a mg/m<span class="Sup">2</span> basis) or greater, and teratogenic effects (primarily rib and vertebral malformations) were observed at 120 mg/kg (6 times the RHD on a mg/m<span class="Sup">2</span> basis). Evidence of maternal toxicity (decreased body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, clinical signs, and/or mortality) was seen at 35 mg/kg and above.</p>
<p>When female rats were treated during the latter part of gestation and throughout lactation (0.2, 4, 20, and 100 mg/kg or 2, 20, and 200 mg/kg), offspring exhibited decreased viability and delayed physical development at 200 mg/kg (5 times the RHD on a mg/m<span class="Sup">2</span> basis) and reductions in pre- and/or postweaning body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> at 2 mg/kg (0.05 times the RHD on a mg/m<span class="Sup">2</span> basis) and above. Maternal toxicity (decreased body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>, clinical signs) was evident at 100 mg/kg or greater.</p>
<p>In a rat embryo/fetal development study with a postnatal component (0.2, 2.5, 30, or 400 mg/kg during organogenesis; noted above), pups exhibited delayed physical development at 400 mg/kg (10 times the RHD on a mg/m<span class="Sup">2</span> basis) and persistent reductions in body <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span> at 30 mg/kg (1 times the RHD on a mg/m<span class="Sup">2</span> basis) and higher.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="S8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2	Labor and Delivery</h2>
<p class="First">Although the effect of TOPAMAX<span class="Sup">®</span> on labor and delivery in humans has not been established, the development of topiramate-induced <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> in the mother and/or in the fetus might affect the fetus' ability to tolerate labor <span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">Limited data on 5 breastfeeding infants exposed to topiramate showed infant plasma topiramate levels equal to 10–20% of the maternal plasma level. The effects of this exposure on infants are unknown. Caution should be exercised when administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.1"></a><p></p>
<p class="First">Adjunctive Treatment for Partial Onset <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> in Infants and Toddlers (1 to 24 months)</p>
<p>Safety and effectiveness in patients below the age of 2 years have not been established for the adjunctive therapy treatment of partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span>, or <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with Lennox-Gastaut syndrome. In a single randomized, double-blind, placebo-controlled investigational trial, the efficacy, safety, and tolerability of topiramate oral liquid and sprinkle formulations as an adjunct to concurrent antiepileptic drug therapy in infants 1 to 24 months of age with refractory partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> were assessed. After 20 days of double-blind treatment, topiramate (at fixed doses of 5, 15, and 25 mg/kg/day) did not demonstrate efficacy compared with placebo in controlling <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p>In general, the adverse reaction profile in this population was similar to that of older pediatric patients, although results from the above controlled study and an open-label, long-term extension study in these infants/toddlers (1 to 24 months old) suggested some adverse reactions/toxicities (not previously observed in older pediatric patients and adults; i.e., growth/length retardation, certain clinical laboratory abnormalities, and other adverse reactions/toxicities that occurred with a greater frequency and/or greater severity than had been recognized previously from studies in older pediatric patients or adults for various indications.</p>
<p>These very young pediatric patients appeared to experience an increased risk for <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> (any topiramate dose 12%, placebo 0%) and of <span class="product-label-link" type="condition" conceptid="320136" conceptname="Disorder of respiratory system">respiratory disorders</span> (any topiramate dose 40%, placebo 16%). The following adverse reactions were observed in at least 3% of patients on topiramate and were 3% to 7% more frequent than in patients on placebo: <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infection</span>, <span class="product-label-link" type="condition" conceptid="256451" conceptname="Bronchitis">bronchitis</span>, <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span>, <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>, <span class="product-label-link" type="condition" conceptid="372328" conceptname="Otitis media">otitis media</span>, <span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory infection</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, and <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>. A generally similar profile was observed in older children <span class="Italics">[see <a href="#S6">Adverse Reactions (6)</a>]</span>.</p>
<p>Topiramate resulted in an increased incidence of patients with increased creatinine (any topiramate dose 5%, placebo 0%), BUN (any topiramate dose 3%, placebo 0%), and protein (any topiramate dose 34%, placebo 6%), and an increased incidence of decreased potassium (any topiramate dose 7%, placebo 0%). This increased frequency of abnormal values was not dose-related. Creatinine was the only analyte showing a noteworthy increased incidence (topiramate 25 mg/kg/day 5%, placebo 0%) of a markedly abnormal increase <span class="Italics">[see <a href="#S5.15">Warnings and Precautions (5.15)</a>]</span>. The significance of these findings is uncertain.</p>
<p>Topiramate treatment also produced a dose-related increase in the percentage of patients who had a shift from normal at baseline to high/increased (above the normal reference range) in total eosinophil count at the end of treatment. The incidence of these abnormal shifts was 6 % for placebo, 10% for 5 mg/kg/day, 9% for 15 mg/kg/day, 14% for 25 mg/kg/day, and 11% for any topiramate dose <span class="Italics">[see <a href="#S5.15">Warnings and Precautions (5.15)</a>]</span>. There was a mean dose-related increase in alkaline phosphatase. The significance of these findings is uncertain.</p>
<p>Topiramate produced a dose-related increased incidence of treatment-emergent <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>]</span>.</p>
<p>Treatment with topiramate for up to 1 year was associated with reductions in Z SCORES for length, weight, and head circumference <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a> and <a href="#S6">Adverse Reactions (6)</a>]</span>.</p>
<p>In open-label, uncontrolled experience, increasing impairment of adaptive behavior was documented in behavioral testing over time in this population. There was a suggestion that this effect was dose-related. However, because of the absence of an appropriate control group, it is not known if this decrement in function was treatment-related or reflects the patient's underlying disease (e.g., patients who received higher doses may have more severe underlying disease) <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>.</p>
<p>In this open-label, uncontrolled study, the mortality was 37 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>/1000 patient years. It is not possible to know whether this mortality rate is related to topiramate treatment, because the background mortality rate for a similar, significantly refractory, young pediatric population (1–24 months) with <span class="product-label-link" type="condition" conceptid="374915" conceptname="Localization-related epilepsy">partial epilepsy</span> is not known.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.2"></a><p></p>
<p class="First">Monotherapy Treatment in Partial Onset <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> in Patients &lt;2 Years Old</p>
<p>Safety and effectiveness in patients below the age of 2 years have not been established for the monotherapy treatment of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.3"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Prophylaxis in Pediatrics</p>
<p>Safety and effectiveness in pediatric patients have not been established for the prophylaxis treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span>.</p>
<p>Topiramate treatment produced a dose-related increased shift in serum creatinine from normal at baseline to an increased value at the end of 4 months treatment in adolescent patients (ages 12–16 years) who were treated for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> prophylaxis in a double-blind, placebo-controlled study. The incidence of these abnormal shifts was 4% for placebo, 4% for 50 mg, and 18% for 100 mg <span class="Italics">[see <a href="#S5.15">Warnings and Precautions (5.15)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-8.4.4"></a><p></p>
<p class="First">Juvenile Animal Studies</p>
<p>When topiramate (30, 90, or 300 mg/kg/day) was administered orally to rats during the juvenile period of development (postnatal days 12 to 50), bone growth plate thickness was reduced in males at the highest dose, which is approximately 5–8 times the maximum recommended pediatric dose (9 mg/kg/day) on a body surface area (mg/m<span class="Sup">2</span>) basis.</p>
</div>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">In clinical trials, 3% of patients were over 60. No age-related differences in effectiveness or adverse effects were evident. However, clinical studies of topiramate did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently than younger subjects. Dosage adjustment may be necessary for elderly with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (creatinine clearance rate &lt;70 mL/min/1.73 m<span class="Sup">2</span>) due to reduced clearance of topiramate <span class="Italics">[see <a href="#S12.3">Clinical Pharmacology (12.3)</a> and <a href="#S2.5">Dosage and Administration (2.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.6"></a><a name="section-8.6"></a><p></p>
<h2>8.6	Race and Gender Effects</h2>
<p class="First">Evaluation of effectiveness and safety in clinical trials has shown no race- or gender-related effects.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.7"></a><a name="section-8.7"></a><p></p>
<h2>8.7	<span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<p class="First">The clearance of topiramate was reduced by 42% in moderately renally impaired (creatinine clearance 30 to 69 mL/min/1.73m<span class="Sup">2</span>) and by 54% in severely renally impaired subjects (creatinine clearance &lt;30 mL/min/1.73m<span class="Sup">2</span>) compared to normal renal function subjects (creatinine clearance &gt;70 mL/min/1.73m<span class="Sup">2</span>). One-half the usual starting and maintenance dose is recommended in patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see <a href="#S2.6">Dosage and Administration (2.6)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.8"></a><a name="section-8.8"></a><p></p>
<h2>8.8	Patients Undergoing Hemodialysis</h2>
<p class="First">Topiramate is cleared by hemodialysis at a rate that is 4 to 6 times greater than in a normal individual. Accordingly, a prolonged period of dialysis may cause topiramate concentration to <span class="product-label-link" type="condition" conceptid="436583" conceptname="Fall">fall</span> below that required to maintain an anti-<span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> effect. To avoid rapid drops in topiramate plasma concentration during hemodialysis, a supplemental dose of TOPAMAX<span class="Sup">®</span> may be required.</p>
<p>The actual adjustment should take into account the duration of dialysis period, the clearance rate of the dialysis system being used, and the effective renal clearance of topiramate in the patient being dialyzed <span class="Italics">[see <a href="#S2.4">Dosage and Administration (2.4)</a> and <a href="#S12.3">Clinical Pharmacology (12.3)</a>]</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S8.9"></a><a name="section-8.9"></a><p></p>
<h2>8.9	Women of Childbearing Potential</h2>
<p class="First">Data from pregnancy registries indicate that infants exposed to TOPAMAX<span class="Sup">®</span><span class="Italics"> in utero</span> have an increased risk for <span class="product-label-link" type="condition" conceptid="133861" conceptname="Cleft lip">cleft lip</span> and/or <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> (oral clefts) <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a> and <a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>. Consider the benefits and the risks of TOPAMAX<span class="Sup">®</span> when prescribing this drug to women of childbearing potential, particularly when TOPAMAX<span class="Sup">®</span> is considered for a condition not usually associated with permanent injury or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>. Because of the risk of oral clefts to the fetus, which occur in the first trimester of pregnancy before many women know they are pregnant, all women of childbearing potential should be apprised of the potential hazard to the fetus from exposure to TOPAMAX<span class="Sup">®</span>. If the decision is made to use TOPAMAX<span class="Sup">®</span>, women who are not planning a pregnancy should use effective contraception <span class="Italics">[see <a href="#S7.3">Drug Interactions (7.3)</a>]</span>. Women who are planning a pregnancy should be counseled regarding the relative risks and benefits of TOPAMAX<span class="Sup">®</span> use during pregnancy, and alternative therapeutic options should be considered for these patients <span class="Italics">[see <a href="#S17.6">Patient Counseling Information (17.6)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="S9"></a><a name="section-9"></a><p></p>
<h1>9 DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<div class="Section" data-sectionCode="34085-1">
<a name="S9.1"></a><a name="section-9.1"></a><p></p>
<h2>9.1 Controlled Substance</h2>
<p class="First">TOPAMAX<span class="Sup">®</span> (topiramate) is not a controlled substance.</p>
</div>
<div class="Section" data-sectionCode="34086-9">
<a name="S9.2"></a><a name="section-9.2"></a><p></p>
<h2>9.2 Abuse</h2>
<p class="First">The abuse and <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> potential of TOPAMAX<span class="Sup">®</span> has not been evaluated in human studies.</p>
</div>
<div class="Section" data-sectionCode="34087-7">
<a name="S9.3"></a><a name="section-9.3"></a><p></p>
<h2>9.3 <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">Dependence</span></h2>
<p class="First">TOPAMAX<span class="Sup">® </span>has not been systematically studied in animals or humans for its potential for tolerance or physical <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="S10"></a><a name="section-10"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdoses</span> of TOPAMAX<span class="Sup">®</span> have been reported. Signs and symptoms included <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, speech disturbance, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, mentation impaired, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, abnormal coordination, <span class="product-label-link" type="condition" conceptid="4229897" conceptname="Stupor">stupor</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>. The clinical consequences were not severe in most cases, but <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> have been reported after poly-drug <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdoses</span> involving TOPAMAX<span class="Sup">®</span>.</p>
<p>Topiramate <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> has resulted in severe <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a>]</span>.</p>
<p>A patient who ingested a dose between 96 and 110 g topiramate was admitted to a hospital with a <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span> lasting 20 to 24 hours followed by full recovery after 3 to 4 days.</p>
<p>In acute TOPAMAX<span class="Sup">®</span> <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, if the ingestion is recent, the stomach should be emptied immediately by lavage or by induction of <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span>. Activated charcoal has been shown to adsorb topiramate <span class="Italics">in vitro</span>. Treatment should be appropriately supportive. Hemodialysis is an effective means of removing topiramate from the body.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-11"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">Topiramate is a sulfamate-substituted monosaccharide. TOPAMAX<span class="Sup">®</span> (topiramate) Tablets are available as 25 mg, 50 mg, 100 mg, and 200 mg round tablets for oral administration. TOPAMAX<span class="Sup">® </span>(topiramate capsules) Sprinkle Capsules are available as 15 mg and 25 mg sprinkle capsules for oral administration as whole capsules or opened and sprinkled onto soft food.</p>
<p>Topiramate is a white crystalline powder with a bitter taste. Topiramate is most soluble in alkaline solutions containing sodium hydroxide or sodium phosphate and having a pH of 9 to 10. It is freely soluble in acetone, chloroform, dimethylsulfoxide, and ethanol. The solubility in water is 9.8 mg/mL. Its saturated solution has a pH of 6.3. Topiramate has the molecular formula C<span class="Sub">12</span>H<span class="Sub">21</span>NO<span class="Sub">8</span>S and a molecular weight of 339.36. Topiramate is designated chemically as 2,3:4,5-Di-<span class="Italics">O</span>-isopropylidene-β-D-fructopyranose sulfamate and has the following structural formula:</p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cea5f748-3127-4d36-83af-9ab3cf58503c&amp;name=topamax-01.jpg"></div>
<p>TOPAMAX<span class="Sup">®</span> Tablets contain the following inactive ingredients: lactose monohydrate, pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, purified water, carnauba wax, hypromellose, titanium dioxide, polyethylene glycol, synthetic iron oxide, and polysorbate 80.</p>
<p>TOPAMAX<span class="Sup">®</span> Sprinkle Capsules contain topiramate-coated beads in a hard gelatin capsule. The inactive ingredients are sugar spheres (sucrose and starch), povidone, cellulose acetate, gelatin, sorbitan monolaurate, sodium lauryl sulfate, titanium dioxide, and black pharmaceutical ink.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-12"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-12.1"></a><p></p>
<h2>12.1	Mechanism of Action</h2>
<p class="First">The precise mechanisms by which topiramate exerts its anticonvulsant and <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> prophylaxis effects are unknown; however, preclinical studies have revealed four properties that may contribute to topiramate's efficacy for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> prophylaxis. Electrophysiological and biochemical evidence suggests that topiramate, at pharmacologically relevant concentrations, blocks voltage-dependent sodium channels, augments the activity of the neurotransmitter gamma-aminobutyrate at some subtypes of the GABA-A receptor, antagonizes the AMPA/kainate subtype of the glutamate receptor, and inhibits the carbonic anhydrase enzyme, particularly isozymes II and IV.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="S12.2"></a><a name="section-12.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First">Topiramate has anticonvulsant activity in rat and mouse maximal electroshock <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> (MES) tests. Topiramate is only weakly effective in blocking <span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span> induced by the GABA<span class="Sub">A</span> receptor antagonist, pentylenetetrazole. Topiramate is also effective in rodent models of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, which include tonic and absence-like <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> in the spontaneous epileptic rat (SER) and tonic and <span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span> induced in rats by kindling of the amygdala or by global <span class="product-label-link" type="condition" conceptid="4200991" conceptname="Ischemia">ischemia</span>.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="S12.3"></a><a name="section-12.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First">The sprinkle formulation is bioequivalent to the immediate-release tablet formulation and, therefore, may be substituted as a therapeutic equivalent.</p>
<p>Absorption of topiramate is rapid, with peak plasma concentrations occurring at approximately 2 hours following a 400 mg oral dose. The relative bioavailability of topiramate from the tablet formulation is about 80% compared to a solution. The bioavailability of topiramate is not affected by food.</p>
<p>The pharmacokinetics of topiramate are linear with dose proportional increases in plasma concentration over the dose range studied (200 to 800 mg/day). The mean plasma elimination half-life is 21 hours after single or multiple doses. Steady-state is thus reached in about 4 days in patients with normal renal function. Topiramate is 15% to 41% bound to human plasma proteins over the blood concentration range of 0.5 to 250 µg/mL. The fraction bound decreased as blood concentration increased.</p>
<p>Carbamazepine and phenytoin do not alter the binding of topiramate. Sodium valproate, at 500 µg/mL (a concentration 5 to 10 times higher than considered therapeutic for valproate) decreased the protein binding of topiramate from 23% to 13%. Topiramate does not influence the binding of sodium valproate.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.1"></a><p></p>
<p class="First"><span class="Bold">Metabolism and Excretion</span></p>
<p>Topiramate is not extensively metabolized and is primarily eliminated unchanged in the urine (approximately 70% of an administered dose). Six metabolites have been identified in humans, none of which constitutes more than 5% of an administered dose. The metabolites are formed via hydroxylation, hydrolysis, and glucuronidation. There is evidence of renal tubular reabsorption of topiramate. In rats, given probenecid to inhibit tubular reabsorption, along with topiramate, a significant increase in renal clearance of topiramate was observed. This interaction has not been evaluated in humans. Overall, oral plasma clearance (CL/F) is approximately 20 to 30 mL/min in adults following oral administration.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.2"></a><p></p>
<p class="First"><span class="Bold">Special Populations</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.2.1"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></p>
<p>The clearance of topiramate was reduced by 42% in moderately renally impaired (creatinine clearance 30 to 69 mL/min/1.73m<span class="Sup">2</span>) and by 54% in severely renally impaired subjects (creatinine clearance &lt;30 mL/min/1.73m<span class="Sup">2</span>) compared to normal renal function subjects (creatinine clearance &gt;70 mL/min/1.73m<span class="Sup">2</span>). Since topiramate is presumed to undergo significant tubular reabsorption, it is uncertain whether this experience can be generalized to all situations of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. It is conceivable that some forms of <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> could differentially affect glomerular filtration rate and tubular reabsorption resulting in a clearance of topiramate not predicted by creatinine clearance. In general, however, use of one-half the usual starting and maintenance dose is recommended in patients with moderate or severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> <span class="Italics">[see <a href="#S2.4">Dosage and Administration (2.4)</a> and <a href="#S2.5">(2.5)</a> and <a href="#S5.13">Warnings and Precautions (5.13)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.2.2"></a><p></p>
<p class="First">Hemodialysis</p>
<p>Topiramate is cleared by hemodialysis. Using a high-efficiency, counterflow, single pass-dialysate hemodialysis procedure, topiramate dialysis clearance was 120 mL/min with blood flow through the dialyzer at 400 mL/min. This high clearance (compared to 20 to 30 mL/min total oral clearance in healthy adults) will remove a clinically significant amount of topiramate from the patient over the hemodialysis treatment period. Therefore, a supplemental dose may be required <span class="Italics">[see <a href="#S2.6">Dosage and Administration (2.6)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.2.3"></a><p></p>
<p class="First"><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></p>
<p>In hepatically impaired subjects, the clearance of topiramate may be decreased; the mechanism underlying the decrease is not well understood <span class="Italics">[see <a href="#S2.7">Dosage and Administration (2.7)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.2.4"></a><p></p>
<p class="First">Age, Gender, and Race</p>
<p>The pharmacokinetics of topiramate in elderly subjects (65 to 85 years of age, N=16) were evaluated in a controlled clinical study. The elderly subject population had reduced renal function (creatinine clearance [-20%]) compared to young adults. Following a single oral 100 mg dose, maximum plasma concentration for elderly and young adults was achieved at approximately 1 to 2 hours. Reflecting the primary renal elimination of topiramate, topiramate plasma and renal clearance were reduced 21% and 19%, respectively, in elderly subjects, compared to young adults. Similarly, topiramate half-life was longer (13%) in the elderly. Reduced topiramate clearance resulted in slightly higher maximum plasma concentration (23%) and AUC (25%) in elderly subjects than observed in young adults. Topiramate clearance is decreased in the elderly only to the extent that renal function is reduced. As recommended for all patients, dosage adjustment may be indicated in the elderly patient when <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> (creatinine clearance rate ≤70 mL/min/1.73 m<span class="Sup">2</span>) is evident. It may be useful to monitor renal function in the elderly patient <span class="Italics">[see <a href="#S2.4">Dosage and Administration (2.4)</a> and <a href="#S5.13">Warnings and Precautions (5.13)</a>]</span>.</p>
<p>Clearance of topiramate in adults was not affected by gender or race.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.2.5"></a><p></p>
<p class="First">Pediatric Pharmacokinetics</p>
<p>Pharmacokinetics of topiramate were evaluated in patients aged 2 to &lt;16 years. Patients received either no or a combination of other antiepileptic drugs. A population pharmacokinetic model was developed on the basis of pharmacokinetic data from relevant topiramate clinical studies. This dataset contained data from 1217 subjects including 258 pediatric patients aged 2 to &lt;16 years (95 pediatric patients &lt;10 years of age).</p>
<p>Pediatric patients on adjunctive treatment exhibited a higher oral clearance (L/h) of topiramate compared to patients on monotherapy, presumably because of increased clearance from concomitant enzyme-inducing antiepileptic drugs. In comparison, topiramate clearance per kg is greater in pediatric patients than in adults and in young pediatric patients (down to 2 years) than in older pediatric patients. Consequently, the plasma drug concentration for the same mg/kg/day dose would be lower in pediatric patients compared to adults and also in younger pediatric patients compared to older pediatric patients. Clearance was independent of dose.</p>
<p>As in adults, hepatic enzyme-inducing antiepileptic drugs decrease the steady state plasma concentrations of topiramate.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3"></a><p></p>
<p class="First"><span class="Bold">Drug-Drug Interactions</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.1"></a><p></p>
<p class="First">Antiepileptic Drugs</p>
<p>Potential interactions between topiramate and standard AEDs were assessed in controlled clinical pharmacokinetic studies in patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>. The effects of these interactions on mean plasma AUCs are summarized in Table 12.</p>
<p>In Table 12, the second column (AED concentration) describes what happens to the concentration of the AED listed in the first column when topiramate is added. The third column (topiramate concentration) describes how the co-administration of a drug listed in the first column modifies the concentration of topiramate in experimental settings when TOPAMAX<span class="Sup">®</span>  was given alone.</p>
<a name="table12"></a><table width="80%">
<caption><span>Table 12:  Summary of AED Interactions with TOPAMAX<span class="Sup">®</span></span></caption>
<col align="left" valign="top" width="31%">
<col align="left" valign="top" width="38%">
<col align="left" valign="top" width="31%">
<thead><tr class="First Last">
<th align="left">AED<br>Co-administered</th>
<th align="left">AED<br>Concentration</th>
<th align="left">Topiramate<br>Concentration</th>
</tr></thead>
<tfoot>
<tr class="First"><td align="left" colspan="3">NC = Less than 10% change in plasma concentration.</td></tr>
<tr><td align="left" colspan="3">AED = Antiepileptic drug.</td></tr>
<tr><td align="left" colspan="3">NE = Not Evaluated.</td></tr>
<tr class="Last"><td align="left" colspan="3">TPM = Topiramate</td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left">Phenytoin</td>
<td align="left">NC or 25% increase
                                             </td>
<td align="left">48% decrease</td>
</tr>
<tr>
<td align="left">Carbamazepine (CBZ)</td>
<td align="left">NC</td>
<td align="left">40% decrease</td>
</tr>
<tr>
<td align="left">CBZ epoxide
                                             </td>
<td align="left">NC</td>
<td align="left">NE</td>
</tr>
<tr>
<td align="left">Valproic acid</td>
<td align="left">11% decrease</td>
<td align="left">14% decrease</td>
</tr>
<tr>
<td align="left">Phenobarbital</td>
<td align="left">NC</td>
<td align="left">NE</td>
</tr>
<tr>
<td align="left">Primidone</td>
<td align="left">NC</td>
<td align="left">NE</td>
</tr>
<tr class="Last">
<td align="left">Lamotrigine</td>
<td align="left">NC at TPM doses up to 400 mg/day</td>
<td align="left">13% decrease</td>
</tr>
</tbody>
</table>
<p>In addition to the <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> described in the above table, concomitant administration of valproic acid and TOPAMAX<span class="Sup">®</span>  has been associated with <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> with and without <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> and <span class="product-label-link" type="condition" conceptid="435371" conceptname="Hypothermia">hypothermia</span> <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>, <a href="#S5.11">(5.11)</a> and <a href="#S7.1">Drug Interactions (7.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.2"></a><p></p>
<p class="First">CNS Depressants</p>
<p>Concomitant administration of TOPAMAX<span class="Sup">®</span>  and alcohol or other CNS depressant drugs has not been evaluated in clinical studies. Because of the potential of TOPAMAX<span class="Sup">®</span> to cause <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">CNS depression</span>, as well as other cognitive and/or neuropsychiatric adverse reactions, TOPAMAX<span class="Sup">®</span> should be used with extreme caution if used in combination with alcohol and other CNS depressants <span class="Italics">[see <a href="#S7.2">Drug Interactions (7.2)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.3"></a><p></p>
<p class="First">Oral Contraceptives</p>
<p>In a <span class="product-label-link" type="condition" conceptid="4196500" conceptname="Drug interaction">pharmacokinetic interaction</span> study in healthy volunteers with a concomitantly administered combination oral contraceptive product containing 1 mg norethindrone (NET) plus 35 mcg ethinyl estradiol (EE), TOPAMAX<span class="Sup">®</span>,  given in the absence of other medications at doses of 50 to 200 mg/day, was not associated with statistically significant changes in mean exposure (AUC) to either component of the oral contraceptive. In another study, exposure to EE was statistically significantly decreased at doses of 200, 400, and 800 mg/day (18%, 21%, and 30%, respectively) when given as adjunctive therapy in patients taking valproic acid. In both studies, TOPAMAX<span class="Sup">®</span> (50 mg/day to 800 mg/day) did not significantly affect exposure to NET. Although there was a dose-dependent decrease in EE exposure for doses between 200 and 800 mg/day, there was no significant dose-dependent change in EE exposure for doses of 50 to 200 mg/day. The clinical significance of the changes observed is not known. The possibility of decreased contraceptive efficacy and increased breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> should be considered in patients taking combination oral contraceptive products with TOPAMAX<span class="Sup">®</span>. Patients taking estrogen-containing contraceptives should be asked to report any change in their <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> patterns. Contraceptive efficacy can be decreased even in the absence of breakthrough <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> <span class="Italics">[see <a href="#S7.3">Drug Interactions (7.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.4"></a><p></p>
<p class="First">Digoxin</p>
<p>In a single-dose study, serum digoxin AUC was decreased by 12% with concomitant TOPAMAX<span class="Sup">®</span>  administration. The clinical relevance of this observation has not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.5"></a><p></p>
<p class="First">Hydrochlorothiazide</p>
<p>A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of hydrochlorothiazide (HCTZ) (25 mg q24h) and topiramate (96 mg q12h) when administered alone and concomitantly. The results of this study indicate that topiramate Cmax increased by 27% and AUC increased by 29% when HCTZ was added to topiramate. The clinical significance of this change is unknown. The addition of HCTZ to topiramate therapy may require an adjustment of the topiramate dose. The steady-state pharmacokinetics of HCTZ were not significantly influenced by the concomitant administration of topiramate. Clinical laboratory results indicated decreases in serum potassium after topiramate or HCTZ administration, which were greater when HCTZ and topiramate were administered in combination.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.6"></a><p></p>
<p class="First">Metformin</p>
<p>Topiramate treatment can frequently cause <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>, a condition for which the use of metformin is contraindicated.</p>
<p>A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of metformin (500 mg every 12 hr) and topiramate in plasma when metformin was given alone and when metformin and topiramate (100 mg every 12 hr) were given simultaneously. The results of this study indicated that the mean metformin C<span class="Sub">max</span> and AUC<span class="Sub">0–12h</span> increased by 17% and 25%, respectively, when topiramate was added. Topiramate did not affect metformin t<span class="Sub">max</span>. The clinical significance of the effect of topiramate on metformin pharmacokinetics is not known. Oral plasma clearance of topiramate appears to be reduced when administered with metformin. The clinical significance of the effect of metformin on topiramate pharmacokinetics is unclear <span class="Italics">[see <a href="#S7.4">Drug Interactions (7.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.7"></a><p></p>
<p class="First">Pioglitazone</p>
<p>A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of topiramate and pioglitazone when administered alone and concomitantly. A 15% decrease in the AUC<span class="Sub">τ,ss</span> of pioglitazone with no alteration in C<span class="Sub">max,ss</span> was observed. This finding was not statistically significant. In addition, a 13% and 16% decrease in C<span class="Sub">max,ss</span> and AUC<span class="Sub">τ,ss</span> respectively, of the active hydroxy-metabolite was noted as well as a 60% decrease in Cmax,ss and AUC<span class="Sub">τ,ss</span> of the active keto-metabolite. The clinical significance of these findings is not known. When TOPAMAX<span class="Sup">®</span>  is added to pioglitazone therapy or pioglitazone is added to TOPAMAX<span class="Sup">®</span>  therapy, careful attention should be given to the routine monitoring of patients for adequate control of their diabetic disease state.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.8"></a><p></p>
<p class="First">Glyburide</p>
<p>A drug-drug interaction study conducted in patients with type 2 <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> evaluated the steady-state pharmacokinetics of glyburide (5 mg/day) alone and concomitantly with topiramate (150 mg/day). There was a 22% decrease in C<span class="Sub">max</span> and a 25% reduction in AUC<span class="Sub">24</span> for glyburide during topiramate administration. Systemic exposure (AUC) of the active metabolites, 4-<span class="Italics">trans</span>-hydroxy-glyburide (M1) and 3-<span class="Italics">cis</span>-hydroxyglyburide (M2), was also reduced by 13% and 15%, and C<span class="Sub">max</span> was reduced by 18% and 25%, respectively. The steady-state pharmacokinetics of topiramate were unaffected by concomitant administration of glyburide.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.9"></a><p></p>
<p class="First">Lithium</p>
<p>In patients, the pharmacokinetics of lithium were unaffected during treatment with topiramate at doses of 200 mg/day; however, there was an observed increase in systemic exposure of lithium (27% for C<span class="Sub">max</span> and 26% for AUC) following topiramate doses up to 600 mg/day. Lithium levels should be monitored when co-administered with high-dose TOPAMAX<span class="Sup">®</span><span class="Italics">[see <a href="#S7.5">Drug Interactions (7.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.10"></a><p></p>
<p class="First">Haloperidol</p>
<p>The pharmacokinetics of a single dose of haloperidol (5 mg) were not affected following multiple dosing of topiramate (100 mg every 12 hr) in 13 healthy adults (6 males, 7 females).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.11"></a><p></p>
<p class="First">Amitriptyline</p>
<p>There was a 12% increase in AUC and C<span class="Sub">max</span> for amitriptyline (25 mg per day) in 18 normal subjects (9 males, 9 females) receiving 200 mg/day of topiramate. Some subjects may experience a large increase in amitriptyline concentration in the presence of topiramate and any adjustments in amitriptyline dose should be made according to the patient's clinical response and not on the basis of plasma levels.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.12"></a><p></p>
<p class="First">Sumatriptan</p>
<p>Multiple dosing of topiramate (100 mg every 12 hrs) in 24 healthy volunteers (14 males, 10 females) did not affect the pharmacokinetics of single-dose sumatriptan either orally (100 mg) or subcutaneously (6 mg).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.13"></a><p></p>
<p class="First">Risperidone</p>
<p>When administered concomitantly with topiramate at escalating doses of 100, 250, and 400 mg/day, there was a reduction in risperidone systemic exposure (16% and 33% for steady-state AUC at the 250 and 400 mg/day doses of topiramate). No alterations of 9-hydroxyrisperidone levels were observed. Co-administration of topiramate 400 mg/day with risperidone resulted in a 14% increase in C<span class="Sub">max</span> and a 12% increase in AUC<span class="Sub">12 </span>of topiramate. There were no clinically significant changes in the systemic exposure of risperidone plus 9-hydroxyrisperidone or of topiramate; therefore, this interaction is not likely to be of clinical significance.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.14"></a><p></p>
<p class="First">Propranolol</p>
<p>Multiple dosing of topiramate (200 mg/day) in 34 healthy volunteers (17 males, 17 females) did not affect the pharmacokinetics of propranolol following daily 160 mg doses. Propranolol doses of 160 mg/day in 39 volunteers (27 males, 12 females) had no effect on the exposure to topiramate, at a dose of 200 mg/day of topiramate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.15"></a><p></p>
<p class="First">Dihydroergotamine</p>
<p>Multiple dosing of topiramate (200 mg/day) in 24 healthy volunteers (12 males, 12 females) did not affect the pharmacokinetics of a 1 mg subcutaneous dose of dihydroergotamine. Similarly, a 1 mg subcutaneous dose of dihydroergotamine did not affect the pharmacokinetics of a 200 mg/day dose of topiramate in the same study.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.16"></a><p></p>
<p class="First">Diltiazem</p>
<p>Co-administration of diltiazem (240 mg Cardizem CD<span class="Sup">®</span>) with topiramate (150 mg/day) resulted in a 10% decrease in C<span class="Sub">max</span> and a 25% decrease in diltiazem AUC, a 27% decrease in C<span class="Sub">max</span> and an 18% decrease in des-acetyl diltiazem AUC, and no effect on N-desmethyl diltiazem. Co-administration of topiramate with diltiazem resulted in a 16% increase in C<span class="Sub">max</span> and a 19% increase in AUC<span class="Sub">12 </span>of topiramate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.17"></a><p></p>
<p class="First">Venlafaxine</p>
<p>Multiple dosing of topiramate (150 mg/day) in healthy volunteers did not affect the pharmacokinetics of venlafaxine or O-desmethyl venlafaxine. Multiple dosing of venlafaxine (150 mg Effexor XR<span class="Sup">®</span>) did not affect the pharmacokinetics of topiramate.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.3.3.18"></a><p></p>
<p class="First">Other Carbonic Anhydrase Inhibitors</p>
<p>Concomitant use of topiramate, a carbonic anhydrase inhibitor, with any other carbonic anhydrase inhibitor (e.g., zonisamide, acetazolamide, or dichlorphenamide) may increase the severity of <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> and may also increase the risk of <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">kidney stone</span> formation. Therefore, if TOPAMAX<span class="Sup">® </span>is given concomitantly with another carbonic anhydrase inhibitor, the patient should be monitored for the appearance or worsening of <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> [<span class="Italics">see <a href="#S7.6">Drug Interactions (7.6)</a></span>].</p>
</div>
</div>
<div class="Section" data-sectionCode="34074-5">
<a name="section-12.3.4"></a><p></p>
<p class="First"><span class="Bold">Drug/Laboratory Tests Interactions</span></p>
<p>There are no known interactions of topiramate with commonly used laboratory tests.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-13"></a><p></p>
<h1>13 NON-CLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-13.1"></a><p></p>
<h2>13.1	Carcinogenesis, Mutagenesis, and Impairment of Fertility</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.1"></a><p></p>
<p class="First"><span class="Bold Italics">Carcinogenesis</span></p>
<p>An increase in urinary bladder tumors was observed in mice given topiramate (20, 75, and 300 mg/kg) in the diet for 21 months. The elevated bladder tumor incidence, which was statistically significant in males and females receiving 300 mg/kg, was primarily due to the increased occurrence of a smooth muscle tumor considered histomorphologically unique to mice. Plasma exposures in mice receiving 300 mg/kg were approximately 0.5 to 1 times steady-state exposures measured in patients receiving topiramate monotherapy at the recommended human dose (RHD) of 400 mg, and 1.5 to 2 times steady-state topiramate exposures in patients receiving 400 mg of topiramate plus phenytoin. The relevance of this finding to human carcinogenic risk is uncertain. No evidence of carcinogenicity was seen in rats following oral administration of topiramate for 2 years at doses up to 120 mg/kg (approximately 3 times the RHD on a mg/m<span class="Sup">2</span> basis).</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.2"></a><p></p>
<p class="First"><span class="Bold Italics">Mutagenesis</span></p>
<p>Topiramate did not demonstrate genotoxic potential when tested in a battery of <span class="Italics">in vitro</span> and <span class="Italics">in vivo</span> assays. Topiramate was not mutagenic in the Ames test or the <span class="Italics">in vitro</span> mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay; it did not increase unscheduled DNA synthesis in rat hepatocytes <span class="Italics">in vitro</span>; and it did not increase chromosomal aberrations in human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> <span class="Italics">in vitro</span> or in rat bone marrow <span class="Italics">in vivo</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1.3"></a><p></p>
<p class="First"><span class="Bold Italics">Impairment of Fertility</span></p>
<p>No adverse effects on male or female fertility were observed in rats at doses up to 100 mg/kg (2.5 times the RHD on a mg/m<span class="Sup">2</span> basis).</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-14"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The studies described in the following sections were conducted using TOPAMAX<span class="Sup">®</span> (topiramate) Tablets.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.1"></a><a name="section-14.1"></a><p></p>
<h2>14.1	Monotherapy <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> Controlled Trial</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1.1"></a><p></p>
<p class="First">Patients with Partial Onset or Primary Generalized Tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">Clonic Seizures</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1.1.1"></a><p></p>
<p class="First"><span class="Italics">Adults and Pediatric Patients 10 Years of Age and Older</span></p>
<p>The effectiveness of topiramate as initial monotherapy in adults and children 10 years of age and older with partial onset or primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span> was established in a multicenter, randomized, double-blind, parallel-group trial.</p>
<p>The trial was conducted in 487 patients diagnosed with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> (6 to 83 years of age) who had 1 or 2 well-documented <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> during the 3-month retrospective baseline phase who then entered the study and received topiramate 25 mg/day for 7 days in an open-label fashion. Forty-nine percent of subjects had no prior AED treatment and 17% had a diagnosis of <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> for greater than 24 months. Any AED therapy used for temporary or emergency purposes was discontinued prior to randomization. In the double-blind phase, 470 patients were randomized to titrate up to 50 mg/day or 400 mg/day. If the target dose could not be achieved, patients were maintained on the maximum tolerated dose. Fifty-eight percent of patients achieved the maximal dose of 400 mg/day for &gt;2 weeks, and patients who did not tolerate 150 mg/day were discontinued. The primary efficacy assessment was a between-group comparison of time to first <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> during the double-blind phase. Comparison of the Kaplan-Meier survival curves of time to first <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> favored the topiramate 400 mg/day group over the topiramate 50 mg/day group (p=0.0002, log rank test; Figure 1). The treatment effects with respect to time to first <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> were consistent across various patient subgroups defined by age, sex, geographic region, baseline body weight, baseline <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> type, time since diagnosis, and baseline AED use.</p>
<a name="i396ce56e-d903-4c91-8395-f8cebf0d8e3e"></a><table width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless">
<tr class="First Toprule"><td align="center">
<span class="Bold">Figure 1:</span> 	Kaplan-Meier Estimates of Cumulative Rates for Time to First <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span></td></tr>
<tr class="Botrule Last"><td align="center"><img alt="Figure 1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cea5f748-3127-4d36-83af-9ab3cf58503c&amp;name=topamax-02.jpg"></td></tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.1.1.2"></a><p></p>
<p class="First"><span class="Italics">Children 2 to &lt;10 Years of Age</span></p>
<p>The conclusion that topiramate is effective as initial monotherapy in children 2 to &lt;10 years of age with partial onset or primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span> was based on a pharmacometric bridging approach using data from the controlled <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> trials described in labeling. This approach consisted of first showing a similar exposure response relationship between pediatric patients down to 2 years of age and adults when topiramate was given as adjunctive therapy. Similarity of exposure-response was also demonstrated in pediatric patients ages 6 to &lt;16 years and adults when topiramate was given as initial monotherapy. Specific dosing in children 2 to &lt;10 years of age was derived from simulations utilizing plasma exposure ranges observed in pediatric and adult patients treated with topiramate initial monotherapy <span class="Italics">[see <a href="#S2.1">Dosage and Administration (2.1)</a>]</span><span class="Bold">.</span></p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.2"></a><a name="section-14.2"></a><p></p>
<h2>14.2	Adjunctive Therapy <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> Controlled Trials</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.2.1"></a><p></p>
<p class="First">Adult Patients With Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></p>
<p>The effectiveness of topiramate as an adjunctive treatment for adults with partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> was established in six multicenter, randomized, double-blind, placebo-controlled trials, two comparing several dosages of topiramate and placebo and four comparing a single dosage with placebo, in patients with a history of partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, with or without secondarily generalized <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p>Patients in these studies were permitted a maximum of two antiepileptic drugs (AEDs) in addition to TOPAMAX<span class="Sup">®</span> tablets or placebo. In each study, patients were stabilized on optimum dosages of their concomitant AEDs during baseline phase lasting between 4 and 12 weeks. Patients who experienced a prespecified minimum number of partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, with or without secondary generalization, during the baseline phase (12 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> for 12-week baseline, 8 for 8-week baseline or 3 for 4-week baseline) were randomly assigned to placebo or a specified dose of TOPAMAX<span class="Sup">®</span> tablets in addition to their other AEDs.</p>
<p>Following randomization, patients began the double-blind phase of treatment. In five of the six studies, patients received active drug beginning at 100 mg per day; the dose was then increased by 100 mg or 200 mg/day increments weekly or every other week until the assigned dose was reached, unless intolerance prevented increases. In the sixth study (119), the 25 or 50 mg/day initial doses of topiramate were followed by respective weekly increments of 25 or 50 mg/day until the target dose of 200 mg/day was reached. After titration, patients entered a 4, 8 or 12-week stabilization period. The numbers of patients randomized to each dose and the actual mean and median doses in the stabilization period are shown in Table 13.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.2.2"></a><p></p>
<p class="First">Pediatric Patients Ages 2 to 16 Years with Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></p>
<p>The effectiveness of topiramate as an adjunctive treatment for pediatric patients ages 2 to 16 years with partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> was established in a multicenter, randomized, double-blind, placebo-controlled trial, comparing topiramate and placebo in patients with a history of partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, with or without secondarily generalized <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</p>
<p>Patients in this study were permitted a maximum of two antiepileptic drugs (AEDs) in addition to TOPAMAX<span class="Sup">®</span> tablets or placebo. In this study, patients were stabilized on optimum dosages of their concomitant AEDs during an 8-week baseline phase. Patients who experienced at least six partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, with or without secondarily generalized <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, during the baseline phase were randomly assigned to placebo or TOPAMAX<span class="Sup">®</span> tablets in addition to their other AEDs.</p>
<p>Following randomization, patients began the double-blind phase of treatment. Patients received active drug beginning at 25 or 50 mg/day; the dose was then increased by 25 mg to 150 mg/day increments every other week until the assigned dosage of 125, 175, 225, or 400 mg/day based on patients' weight to approximate a dosage of 6 mg/kg/day  was reached, unless intolerance prevented increases. After titration, patients entered an 8-week stabilization period.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.2.3"></a><p></p>
<p class="First">Patients With Primary Generalized Tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">Clonic Seizures</span></p>
<p>The effectiveness of topiramate as an adjunctive treatment for primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span> in patients 2 years old and older was established in a multicenter, randomized, double-blind, placebo-controlled trial, comparing a single dosage of topiramate and placebo.</p>
<p>Patients in this study were permitted a maximum of two antiepileptic drugs (AEDs) in addition to TOPAMAX<span class="Sup">®</span> or placebo. Patients were stabilized on optimum dosages of their concomitant AEDs during an 8-week baseline phase. Patients who experienced at least three primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span> during the baseline phase were randomly assigned to placebo or TOPAMAX<span class="Sup">®</span> in addition to their other AEDs.</p>
<p>Following randomization, patients began the double-blind phase of treatment. Patients received active drug beginning at 50 mg/day for four weeks; the dose was then increased by 50 mg to 150 mg/day increments every other week until the assigned dose of 175, 225, or 400 mg/day based on patients' body weight to approximate a dosage of 6 mg/kg/day was reached, unless intolerance prevented increases. After titration, patients entered a 12-week stabilization period.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14.2.4"></a><p></p>
<p class="First">Patients With Lennox-Gastaut Syndrome</p>
<p>The effectiveness of topiramate as an adjunctive treatment for <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with Lennox-Gastaut syndrome was established in a multicenter, randomized, double-blind, placebo-controlled trial comparing a single dosage of topiramate with placebo in patients 2 years of age and older.</p>
<p>Patients in this study were permitted a maximum of two antiepileptic drugs (AEDs) in addition to TOPAMAX<span class="Sup">®</span> or placebo. Patients who were experiencing at least 60 <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> per month before study entry were stabilized on optimum dosages of their concomitant AEDs during a 4-week baseline phase. Following baseline, patients were randomly assigned to placebo or TOPAMAX<span class="Sup">®</span> in addition to their other AEDs. Active drug was titrated beginning at 1 mg/kg/day  for a week; the dose was then increased to 3 mg/kg/day  for one week, then to 6 mg/kg/day. After titration, patients entered an 8-week stabilization period. The primary measures of effectiveness were the percent reduction in drop attacks and a parental global rating of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> severity.</p>
<a name="table13"></a><table width="100%">
<caption><span>Table 13: Topiramate Dose Summary During the Stabilization Periods of Each of Six Double-Blind, Placebo-Controlled, Add-On Trials in Adults with Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span><a name="footnote-reference-7" href="#footnote-7" class="Sup">*</a></span></caption>
<col align="left" valign="top" width="12%">
<col align="left" valign="top" width="16%">
<col align="left" valign="top" width="12%">
<col align="left" valign="top" width="12%">
<col align="left" valign="top" width="12%">
<col align="left" valign="top" width="12%">
<col align="left" valign="top" width="12%">
<col align="left" valign="top" width="12%">
<thead>
<tr class="First">
<th align="left"></th>
<th align="left"></th>
<th align="left"></th>
<th class="Botrule" align="center" colspan="5">Target Topiramate Dosage (mg/day)</th>
</tr>
<tr class="Last">
<th align="left">Protocol</th>
<th align="left">Stabilization Dose</th>
<th align="left">Placebo<a name="footnote-reference-8" href="#footnote-8" class="Sup">†</a>
</th>
<th align="left">200</th>
<th align="left">400</th>
<th align="left">600</th>
<th align="left">800</th>
<th align="left">1,000</th>
</tr>
</thead>
<tfoot><tr><td colspan="8" align="left"><dl class="Footnote">
<dt><a name="footnote-7" href="#footnote-reference-7">*</a></dt>
<dd>Dose-response studies were not conducted for other indications or pediatric partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">†</a></dt>
<dd>Placebo dosages are given as the number of tablets. Placebo target dosages were as follows: Protocol Y1, 4 tablets/day; Protocols YD and Y2, 6 tablets/day; Protocols Y3 and 119, 8 tablets/day; Protocol YE, 10 tablets/day.</dd>
</dl></td></tr></tfoot>
<tbody>
<tr class="First">
<td align="left" rowspan="3">YD</td>
<td align="left">N</td>
<td align="left">42</td>
<td align="left">42</td>
<td align="left">40</td>
<td align="left">41</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left">Mean Dose</td>
<td align="left">5.9</td>
<td align="left">200</td>
<td align="left">390</td>
<td align="left">556</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left">Median Dose</td>
<td align="left">6.0</td>
<td align="left">200</td>
<td align="left">400</td>
<td align="left">600</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left" rowspan="3">YE</td>
<td align="left">N</td>
<td align="left">44</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">40</td>
<td align="left">45</td>
<td align="left">40</td>
</tr>
<tr>
<td align="left">Mean Dose</td>
<td align="left">9.7</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">544</td>
<td align="left">739</td>
<td align="left">796</td>
</tr>
<tr>
<td align="left">Median Dose</td>
<td align="left">10.0</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">600</td>
<td align="left">800</td>
<td align="left">1,000</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left" rowspan="3">Y1</td>
<td align="left">N</td>
<td align="left">23</td>
<td align="left">--</td>
<td align="left">19</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left">Mean Dose</td>
<td align="left">3.8</td>
<td align="left">--</td>
<td align="left">395</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left">Median Dose</td>
<td align="left">4.0</td>
<td align="left">--</td>
<td align="left">400</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left" rowspan="3">Y2</td>
<td align="left">N</td>
<td align="left">30</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">28</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left">Mean Dose</td>
<td align="left">5.7</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">522</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left">Median Dose</td>
<td align="left">6.0</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">600</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left" rowspan="3">Y3</td>
<td align="left">N</td>
<td align="left">28</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">25</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left">Mean Dose</td>
<td align="left">7.9</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">568</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left">Median Dose</td>
<td align="left">8.0</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">600</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left"> </td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">119</td>
<td align="left">N</td>
<td align="left">90</td>
<td align="left">157</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left"></td>
<td align="left">Mean Dose</td>
<td align="left">8</td>
<td align="left">200</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr class="Last">
<td align="left"></td>
<td align="left">Median Dose</td>
<td align="left">8</td>
<td align="left">200</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
</tbody>
</table>
<p>In all add-on trials, the reduction in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> rate from baseline during the entire double-blind phase was measured. The median percent reductions in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> rates and the responder rates (fraction of patients with at least a 50% reduction) by treatment group for each study are shown below in Table 14. As described above, a global improvement in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> severity was also assessed in the Lennox-Gastaut trial.</p>
<a name="table14"></a><table width="100%">
<caption><span>Table 14: Efficacy Results in Double-Blind, Placebo-Controlled, Add-On <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">Epilepsy</span> Trials</span></caption>
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="15%">
<col align="left" valign="top" width="13%">
<col align="left" valign="top" width="9%">
<col align="left" valign="top" width="9%">
<col align="left" valign="top" width="9%">
<col align="left" valign="top" width="9%">
<col align="left" valign="top" width="9%">
<col align="left" valign="top" width="12%">
<thead>
<tr class="First">
<th align="left" colspan="2"></th>
<th align="left"></th>
<th class="Botrule" align="center" colspan="6">Target Topiramate Dosage (mg/day)</th>
</tr>
<tr class="Last">
<th align="left" colspan="2">Protocol Efficacy Results</th>
<th align="left">Placebo</th>
<th align="left">200</th>
<th align="left">400</th>
<th align="left">600</th>
<th align="left">800</th>
<th align="left">1,000</th>
<th align="left">≈6 mg/kg/day<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a>
</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="9">Comparisons with placebo:</td></tr>
<tr><td colspan="9" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>For Protocols YP and YTC, protocol-specified target dosages (&lt;9.3 mg/kg/day) were assigned based on subject's weight to approximate a dosage of 6 mg/kg per day; these dosages corresponded to mg/day dosages of 125, 175, 225, and 400 mg/day.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">†</a></dt>
<dd>p≤0.001;</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">‡</a></dt>
<dd>p≤0.050;</dd>
<dt><a name="footnote-12" href="#footnote-reference-12">§</a></dt>
<dd>p≤0.005;</dd>
<dt><a name="footnote-13" href="#footnote-reference-13">¶</a></dt>
<dd>Median % reduction and % responders are reported for PGTC <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span>;</dd>
<dt><a name="footnote-14" href="#footnote-reference-14">#</a></dt>
<dd>Median % reduction and % responders for drop attacks, i.e., tonic or atonic <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>;</dd>
<dt><a name="footnote-15" href="#footnote-reference-15">Þ</a></dt>
<dd>p=0.071;</dd>
<dt><a name="footnote-16" href="#footnote-reference-16">ß</a></dt>
<dd>Percent of subjects who were minimally, much, or very much improved from baseline</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="First">
<td align="left" colspan="2">Partial Onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizures</span></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left" colspan="2">Studies in Adults</td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">YD</td>
<td align="left">N</td>
<td align="left">45</td>
<td align="left">45</td>
<td align="left">45</td>
<td align="left">46</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left" colspan="2">Median % Reduction</td>
<td align="left">11.6</td>
<td align="left">27.2
                                       </td>
<td align="left">47.5
                                       </td>
<td align="left">44.7<a name="footnote-reference-10" href="#footnote-10" class="Sup">†</a>
</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left" colspan="2">% Responders</td>
<td align="left">18</td>
<td align="left">24</td>
<td align="left">44<a name="footnote-reference-11" href="#footnote-11" class="Sup">‡</a>
</td>
<td align="left">46<a href="#footnote-11" class="Sup">‡</a>
</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left">YE</td>
<td align="left">N</td>
<td align="left">47</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">48</td>
<td align="left">48</td>
<td align="left">47</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left" colspan="2">Median % Reduction</td>
<td align="left">1.7</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">40.8<a href="#footnote-10" class="Sup">†</a>
</td>
<td align="left">41.0<a href="#footnote-10" class="Sup">†</a>
</td>
<td align="left">36.0<a href="#footnote-10" class="Sup">†</a>
</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left" colspan="2">% Responders</td>
<td align="left">9</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">40<a href="#footnote-10" class="Sup">†</a>
</td>
<td align="left">41<a href="#footnote-10" class="Sup">†</a>
</td>
<td align="left">36<a href="#footnote-11" class="Sup">‡</a>
</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left">Y1</td>
<td align="left">N</td>
<td align="left">24</td>
<td align="left">--</td>
<td align="left">23</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left" colspan="2">Median % Reduction</td>
<td align="left">1.1</td>
<td align="left">--</td>
<td align="left">40.7
                                       </td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left" colspan="2">% Responders</td>
<td align="left">8</td>
<td align="left">--</td>
<td align="left">35<a href="#footnote-11" class="Sup">‡</a>
</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left">Y2</td>
<td align="left">N</td>
<td align="left">30</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">30</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left" colspan="2">Median % Reduction</td>
<td align="left">-12.2</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">46.4<a name="footnote-reference-12" href="#footnote-12" class="Sup">§</a>
</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left" colspan="2">% Responders</td>
<td align="left">10</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">47<a href="#footnote-10" class="Sup">†</a>
</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left">Y3</td>
<td align="left">N</td>
<td align="left">28</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">28</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left" colspan="2">Median % Reduction</td>
<td align="left">-20.6</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">24.3<a href="#footnote-10" class="Sup">†</a>
</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left" colspan="2">% Responders</td>
<td align="left">0</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">43<a href="#footnote-10" class="Sup">†</a>
</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left" colspan="2">119 N</td>
<td align="left">91</td>
<td align="left">168</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left" colspan="2">Median % Reduction</td>
<td align="left">20.0</td>
<td align="left">44.2<a href="#footnote-10" class="Sup">†</a>
</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left" colspan="2">% Responders</td>
<td align="left">24</td>
<td align="left">45<a href="#footnote-10" class="Sup">†</a>
</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
</tr>
<tr>
<td align="left" colspan="2">Studies in Pediatric Patients</td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">YP</td>
<td align="left">N</td>
<td align="left">45</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">41</td>
</tr>
<tr>
<td align="left" colspan="2">Median % Reduction</td>
<td align="left">10.5</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">33.1<a href="#footnote-11" class="Sup">‡</a>
</td>
</tr>
<tr>
<td align="left" colspan="2">% Responders</td>
<td align="left">20</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">39</td>
</tr>
<tr>
<td align="left" colspan="2">Primary Generalized Tonic-Clonic<a name="footnote-reference-13" href="#footnote-13" class="Sup">¶</a>
</td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">YTC</td>
<td align="left">N</td>
<td align="left">40</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">39</td>
</tr>
<tr>
<td align="left" colspan="2">Median % Reduction</td>
<td align="left">9.0</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">56.7<a href="#footnote-11" class="Sup">‡</a>
</td>
</tr>
<tr>
<td align="left" colspan="2">% Responders</td>
<td align="left">20</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">56<a href="#footnote-10" class="Sup">†</a>
</td>
</tr>
<tr>
<td align="left" colspan="2">Lennox-Gastaut Syndrome<a name="footnote-reference-14" href="#footnote-14" class="Sup">#</a>
</td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
<td align="left"></td>
</tr>
<tr>
<td align="left">YL</td>
<td align="left">N</td>
<td align="left">49</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">46</td>
</tr>
<tr>
<td align="left" colspan="2">Median % Reduction</td>
<td align="left">-5.1</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">14.8<a href="#footnote-11" class="Sup">‡</a>
</td>
</tr>
<tr>
<td align="left" colspan="2">% Responders</td>
<td align="left">14</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">28<a name="footnote-reference-15" href="#footnote-15" class="Sup">Þ</a>
</td>
</tr>
<tr class="Last">
<td align="left" colspan="2">Improvement in <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span> Severity<a name="footnote-reference-16" href="#footnote-16" class="Sup">ß</a>
</td>
<td align="left">28</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">--</td>
<td align="left">52<a href="#footnote-11" class="Sup">‡</a>
</td>
</tr>
</tbody>
</table>
<p>Subset analyses of the antiepileptic efficacy of TOPAMAX<span class="Sup">® </span>tablets in these studies showed no differences as a function of gender, race, age, baseline <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> rate, or concomitant AED.</p>
<p>In clinical trials for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span>, daily dosages were decreased in weekly intervals by 50 to 100 mg/day in adults and over a 2- to 8-week period in children; transition was permitted to a new antiepileptic regimen when clinically indicated.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S14.3"></a><a name="section-14.3"></a><p></p>
<h2>14.3	<span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine</span> Prophylaxis</h2>
<p class="First">The results of 2 multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trials established the effectiveness of TOPAMAX<span class="Sup">®</span> in the <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> treatment of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span>. The design of both trials (one study was conducted in the U.S. and one study was conducted in the U.S. and Canada) was identical, enrolling patients with a history of <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span>, with or without <span class="product-label-link" type="condition" conceptid="4091160" conceptname="Aura">aura</span>, for at least 6 months, according to the International <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> Society diagnostic criteria. Patients with a history of <span class="product-label-link" type="condition" conceptid="381278" conceptname="Cluster headache">cluster headaches</span> or basilar, ophthalmoplegic, hemiplegic, or transformed <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> were excluded from the trials. Patients were required to have completed up to a 2-week washout of any prior <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> preventive medications before starting the baseline phase.</p>
<p>Patients who experienced 3 to 12 <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> over the 4 weeks in the baseline phase were equally randomized to either TOPAMAX<span class="Sup">®</span> 50 mg/day, 100 mg/day, 200 mg/day,  or placebo and treated for a total of 26 weeks (8-week titration period and 18-week maintenance period). Treatment was initiated at 25 mg/day for one week, and then the daily dosage was increased by 25 mg increments each week until reaching the assigned target dose or maximum tolerated dose (administered twice daily).</p>
<p>Effectiveness of treatment was assessed by the reduction in <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> frequency, as measured by the change in 4-week <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine</span> rate from the baseline phase to double-blind treatment period in each TOPAMAX<span class="Sup">®</span> treatment group compared to placebo in the Intent-To-Treat (ITT) population.</p>
<p>In the first study, a total of 469 patients (416 females, 53 males), ranging in age from 13 to 70 years, were randomized and provided efficacy data. Two hundred sixty-five patients completed the entire 26-week double-blind phase. The median average daily dosages were 47.8 mg/day, 88.3 mg/day, and 132.1 mg/day in the target dose groups of TOPAMAX<span class="Sup">®</span> 50, 100, and 200 mg/day, respectively.</p>
<p>The mean <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> frequency rate at baseline was approximately 5.5 <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span>/28 days and was similar across treatment groups. The change in the mean 4-week <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> frequency from baseline to the double-blind phase was -1.3, -2.1, and -2.2 in the TOPAMAX<span class="Sup">®</span> 50, 100, and 200 mg/day groups, respectively, versus -0.8 in the placebo group (see <a href="#figure2">Figure 2</a>). The differences between the TOPAMAX<span class="Sup">®</span> 100 and 200 mg/day groups versus placebo were statistically significant (p&lt;0.001 for both comparisons).</p>
<p>In the second study, a total of 468 patients (406 females, 62 males), ranging in age from 12 to 65 years, were randomized and provided efficacy data. Two hundred fifty-five patients completed the entire 26-week double-blind phase. The median average daily dosages were 46.5 mg/day, 85.6 mg/day, and 150.2 mg/day in the target dose groups of TOPAMAX<span class="Sup">®</span> 50, 100, and 200 mg/day, respectively.</p>
<p>The mean <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> frequency rate at baseline was approximately 5.5 <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span>/28 days and was similar across treatment groups. The change in the mean 4-week <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span> period frequency from baseline to the double-blind phase was -1.4, -2.1, and -2.4 in the TOPAMAX<span class="Sup">®</span> 50, 100, and 200 mg/day groups, respectively, versus -1.1 in the placebo group (see <a href="#figure2">Figure 2</a>). The differences between the TOPAMAX<span class="Sup">®</span> 100 and 200 mg/day groups versus placebo were statistically significant (p=0.008 and p &lt;0.001, respectively).</p>
<p>In both studies, there were no apparent differences in treatment effect within age or gender subgroups. Because most patients were Caucasian, there were insufficient numbers of patients from different races to make a meaningful comparison of race.</p>
<p>For patients withdrawing from TOPAMAX<span class="Sup">®</span>, daily dosages were decreased in weekly intervals by 25 to 50 mg/day.</p>
<a name="i6c26e0ea-8426-426a-8246-68805942bf64"></a><table width="100%">
<col align="center" valign="middle" width="100%">
<tbody class="Headless">
<tr class="First Toprule"><td align="center">
<span class="Bold">Figure 2:</span>	Reduction in 4-Week <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">Migraine Headache</span> Frequency<br> (Studies TOPMAT-MIGR-001 and TOPMAT-MIGR-002)</td></tr>
<tr class="Botrule Last"><td align="center">
<a name="figure2"></a><img alt="Figure 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cea5f748-3127-4d36-83af-9ab3cf58503c&amp;name=topamax-03.jpg">
</td></tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-15"></a><p></p>
<h1>16	HOW SUPPLIED/STORAGE AND HANDLING</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.1"></a><p></p>
<p class="First"><span class="Bold">TOPAMAX<span class="Sup">®</span> Tablets</span></p>
<p>TOPAMAX<span class="Sup">®</span> (topiramate) Tablets are available as debossed, coated, round tablets in the following strengths and colors:</p>
<p>25 mg cream tablet (debossed "OMN" on one side; "25" on the other) and are available in bottles of 60 count with desiccant (NDC 50458-639-65)</p>
<p>50 mg light yellow tablet (debossed "OMN" on one side; "50" on the other) and are available in bottles of 60 count with desiccant (NDC 50458-640-65)</p>
<p>100 mg yellow tablet (debossed "OMN" on one side; "100" on the other) and are available in bottles of 60 count with desiccant (NDC 50458-641-65)</p>
<p>200 mg salmon tablet (debossed "OMN" on one side; "200" on the other) and are available in bottles of 60 count with desiccant (NDC 50458-642-65)</p>
<p><span class="Bold">TOPAMAX<span class="Sup">®</span> Sprinkle Capsules</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-15.2"></a><p></p>
<p class="First">TOPAMAX<span class="Sup">®</span> (topiramate capsules) Sprinkle Capsules contain small, white to off-white spheres. The gelatin capsules are white and clear and are marked as follows:</p>
<p>15 mg capsule with "TOP" and "15 mg" on the side and are available in bottles of 60 (NDC 50458-647-65)</p>
<p>25 mg capsule with "TOP" and "25 mg" on the side and are available in bottles of 60 (NDC 50458-645-65)</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-15.3"></a><p></p>
<p class="First"><span class="Bold">Storage and Handling</span></p>
<p>TOPAMAX<span class="Sup">®</span> Tablets should be stored in tightly-closed containers at controlled room temperature (59° to 86°F, 15° to 30°C). Protect from moisture.</p>
<p>TOPAMAX<span class="Sup">®</span> Sprinkle Capsules should be stored in tightly-closed containers at or below 25°C (77°F). Protect from moisture.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-16"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Patients and their caregivers should be informed of the availability of a Medication Guide, and they should be instructed to read the Medication Guide prior to taking TOPAMAX<span class="Sup">®</span>. Patients should be instructed to take TOPAMAX<span class="Sup">®</span> only as prescribed. See <a href="#MEDGUIDE">FDA-approved Medication Guide</a>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.1"></a><a name="section-16.1"></a><p></p>
<h2>17.1	<span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></h2>
<p class="First">Patients taking TOPAMAX<span class="Sup">®</span> should be told to seek immediate medical attention if they experience <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>, or <span class="product-label-link" type="condition" conceptid="4201702" conceptname="Sore eye">periorbital pain</span> <span class="Italics">[see <a href="#S5.1">Warnings and Precautions (5.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.2"></a><a name="section-16.2"></a><p></p>
<h2>17.2	Oligohydrosis and <span class="product-label-link" type="condition" conceptid="4178904" conceptname="Body temperature above reference range">Hyperthermia</span></h2>
<p class="First">Patients, especially pediatric patients, treated with TOPAMAX<span class="Sup">®</span> should be monitored closely for evidence of decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> and increased body temperature, especially in hot weather. Patients should be counseled to contact their healthcare professionals immediately if they develop these symptoms <span class="Italics">[see <a href="#S5.2">Warnings and Precautions (5.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.3"></a><a name="section-16.3"></a><p></p>
<h2>17.3	<span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic Acidosis</span></h2>
<p class="First">Patients should be warned about the potential significant risk for <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> that may be asymptomatic and may be associated with adverse effects on kidneys (e.g., <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">kidney stones</span>, <span class="product-label-link" type="condition" conceptid="4171974" conceptname="Nephrocalcinosis">nephrocalcinosis</span>), bones (e.g., <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span>, and/or <span class="product-label-link" type="condition" conceptid="4189941" conceptname="Rickets">rickets</span> in children), and growth (e.g., growth delay/retardation) in pediatric patients, and on the fetus <span class="Italics">[see <a href="#S5.3">Warnings and Precautions (5.3)</a> and <a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.4"></a><a name="section-16.4"></a><p></p>
<h2>17.4	<span class="product-label-link" type="condition" conceptid="4322252" conceptname="Suicidal behavior">Suicidal Behavior</span> and Ideation</h2>
<p class="First">Patients, their caregivers, and families should be counseled that AEDs, including TOPAMAX<span class="Sup">®</span>, may increase the risk of suicidal thoughts and behavior and should be advised of the need to be alert for the emergence or worsening of the signs and symptoms of <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, any unusual changes in mood or behavior or the emergence of suicidal thoughts, or behavior or thoughts about self-harm. Behaviors of concern should be reported immediately to healthcare providers <span class="Italics">[see <a href="#S5.4">Warnings and Precautions (5.4)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.5"></a><a name="section-16.5"></a><p></p>
<h2>17.5	Interference with Cognitive and Motor Performance</h2>
<p class="First">Patients should be warned about the potential for <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">somnolence</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, difficulty concentrating, or visual effects and should be advised not to drive or operate machinery until they have gained sufficient experience on TOPAMAX<span class="Sup">®</span> to gauge whether it adversely affects their mental performance, motor performance, and/or vision <span class="Italics">[see <a href="#S5.5">Warnings and Precautions (5.5)</a>]</span>.</p>
<p>Even when taking TOPAMAX<span class="Sup">®</span> or other anticonvulsants, some patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> will continue to have unpredictable <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. Therefore, all patients taking TOPAMAX<span class="Sup">®</span> for <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> should be told to exercise appropriate caution when engaging in any activities where <span class="product-label-link" type="condition" conceptid="372448" conceptname="Loss of consciousness">loss of consciousness</span> could result in serious danger to themselves or those around them (including swimming, driving a car, climbing in high places, etc.). Some patients with refractory <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> will need to avoid such activities altogether. Physicians should discuss the appropriate level of caution with their patients, before patients with <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> engage in such activities.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.6"></a><a name="section-16.6"></a><p></p>
<h2>17.6	Fetal Toxicity</h2>
<p class="First">Inform pregnant women and women of childbearing potential that use of TOPAMAX<span class="Sup">®</span> during pregnancy can cause fetal harm, including an increased risk for <span class="product-label-link" type="condition" conceptid="133861" conceptname="Cleft lip">cleft lip</span> and/or <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> (oral clefts), which occur early in pregnancy before many women know they are pregnant. There may also be risks to the fetus from chronic <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> with use of TOPAMAX<span class="Sup">®</span> during pregnancy <span class="Italics">[see <a href="#S5.6">Warnings and Precautions (5.6)</a> and <a href="#S8.1">Use in Specific Populations (8.1)</a>, <a href="#S8.9">(8.9)</a>]</span>. When appropriate, prescribers should counsel pregnant women and women of childbearing potential about alternative therapeutic options. This is particularly important when TOPAMAX<span class="Sup">®</span> use is considered for a condition not usually associated with permanent injury or <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>.</p>
<p>Prescribers should advise women of childbearing potential who are not planning a pregnancy to use effective contraception while using TOPAMAX<span class="Sup">®</span>, keeping in mind that there is a potential for decreased contraceptive efficacy when using estrogen-containing birth control with topiramate <span class="Italics">[see <a href="#S7.3">Drug Interactions (7.3)</a>]</span>.</p>
<p>Encourage pregnant women using TOPAMAX<span class="Sup">®</span>, to enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. The registry is collecting information about the safety of antiepileptic drugs during pregnancy. To enroll, patients can call the toll-free number, 1-888-233-2334. Information about the North American Drug Pregnancy Registry can be found at <span class="Italics">http://www.massgeneral.org/aed/ </span><span class="Italics">[see <a href="#S8.1">Use in Specific Populations (8.1)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.7"></a><a name="section-16.7"></a><p></p>
<h2>17.7	<span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">Hyperammonemia</span> and <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">Encephalopathy</span></h2>
<p class="First">Patients should be warned about the possible development of <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> with or without <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span>. Although <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> may be asymptomatic, clinical symptoms of <span class="product-label-link" type="condition" conceptid="4143108" conceptname="Hyperammonemic encephalopathy">hyperammonemic encephalopathy</span> often include acute alterations in level of consciousness and/or cognitive function with <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span> or <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. This <span class="product-label-link" type="condition" conceptid="4246681" conceptname="Hyperammonemia">hyperammonemia</span> and <span class="product-label-link" type="condition" conceptid="372887" conceptname="Disorder of brain">encephalopathy</span> can develop with TOPAMAX<span class="Sup">®</span> treatment alone or with TOPAMAX<span class="Sup">®</span> treatment with concomitant valproic acid (VPA).</p>
<p>Patients should be instructed to contact their physician if they develop unexplained <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or changes in mental status <span class="Italics">[see <a href="#S5.9">Warnings and Precautions (5.9)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="S17.8"></a><a name="section-16.8"></a><p></p>
<h2>17.8	<span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Kidney Stones</span></h2>
<p class="First">Patients, particularly those with predisposing factors, should be instructed to maintain an adequate fluid intake in order to minimize the risk of <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">kidney stone</span> formatio<span class="Italics">n [see <a href="#S5.10">Warnings and Precautions (5.10)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-17"></a><p></p>
<p class="First">Manufactured by: Janssen Ortho, LLC, Gurabo, Puerto Rico 00778</p>
<p>Manufactured for: Janssen Pharmaceuticals, Inc. Titusville, NJ 08560</p>
<p>© Janssen Pharmaceuticals, Inc. 2009</p>
<p>Revised January 2012</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="MEDGUIDE"></a><a name="section-18"></a><p></p>
<p class="First"><span class="Bold">MEDICATION GUIDE</span></p>
<p><span class="Bold">TOPAMAX</span><span class="Sup">®</span><span class="Bold"> (TOE-PA-MAX)<br> (topiramate)<br> Tablets and Sprinkle Capsules</span></p>
<p>Read this Medication Guide before you start taking TOPAMAX<span class="Sup">®</span> and each time you get a refill. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or treatment. If you have any questions about TOPAMAX<span class="Sup">®</span>, talk to your healthcare provider or pharmacist.</p>
<p><span class="Bold">What is the most important information I should know about TOPAMAX<span class="Sup">®</span>?</span></p>
<p><span class="Bold">TOPAMAX</span><span class="Sup">®</span><span class="Bold"> may cause eye problems.</span> Serious eye problems include:</p>
<ul class="Disc">
<li>any sudden decrease in vision with or without <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">eye pain</span> and <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">redness</span>,</li>
<li>a blockage of fluid in the eye causing increased pressure in the eye (secondary <span class="product-label-link" type="condition" conceptid="432312" conceptname="Chronic angle-closure glaucoma">angle closure glaucoma</span>).</li>
<li>These eye problems can lead to permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> if not treated. You should call your healthcare provider right away if you have any new eye symptoms.</li>
</ul>
<p><span class="Bold">TOPAMAX</span><span class="Sup">®</span><span class="Bold"> may cause decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> and increased body temperature (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>).</span> People, especially children, should be watched for signs of decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, especially in hot temperatures. Some people may need to be hospitalized for this condition.  Call your healthcare provider right away if you have a <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> or decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>.</p>
<p><span class="Bold">TOPAMAX<span class="Sup">®</span> can increase the level of acid in your blood (<span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>).</span> If left untreated, <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> can cause brittle or soft bones (<span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, <span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span>, <span class="product-label-link" type="condition" conceptid="4195039" conceptname="Osteopenia">osteopenia</span>), <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">kidney stones</span>, can slow the rate of growth in children, and may possibly harm your baby if you are pregnant. <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic acidosis</span> can happen with or without symptoms.</p>
<p>Sometimes people with <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> will:</p>
<ul class="Disc">
<li> feel tired</li>
<li> not feel hungry (loss of appetite)</li>
<li> feel changes in heartbeat</li>
<li> have trouble thinking clearly</li>
</ul>
<p>Your healthcare provider should do a blood test to measure the level of acid in your blood before and during your treatment with TOPAMAX<span class="Sup">®</span>. If you are pregnant, you should talk to your healthcare provider about whether you have <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span>.</p>
<p><span class="Bold">Like other antiepileptic drugs, TOPAMAX<span class="Sup">®</span> may cause suicidal thoughts or actions in a very small number of people, about 1 in 500.</span></p>
<p><span class="Bold">Call a healthcare provider right away if you have any of these symptoms, especially if they are new, worse, or <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">worry</span> you:</span></p>
<ul class="Disc">
<li>thoughts about <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span> or dying</li>
<li>attempts to commit <span class="product-label-link" type="condition" conceptid="440925" conceptname="Suicide">suicide</span></li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span></li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span></li>
<li>feeling <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitated</span> or <span class="product-label-link" type="condition" conceptid="4012381" conceptname="Restlessness">restless</span></li>
<li><span class="product-label-link" type="condition" conceptid="4021498" conceptname="Panic attack">panic attacks</span></li>
<li>trouble sleeping (<span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>)</li>
<li>new or worse <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">irritability</span></li>
<li>acting aggressive, being angry, or violent</li>
<li>acting on dangerous impulses</li>
<li>an extreme increase in activity and talking (<span class="product-label-link" type="condition" conceptid="4333677" conceptname="Mania">mania</span>)</li>
<li>other unusual changes in behavior or mood</li>
</ul>
<p><span class="Bold">Do not stop TOPAMAX</span><span class="Sup">®</span><span class="Bold"> without first talking to a healthcare provider.</span></p>
<ul class="Disc">
<li>Stopping TOPAMAX<span class="Sup">®</span> suddenly can cause serious problems.</li>
<li>Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your healthcare provider may check for other causes.</li>
</ul>
<p><span class="Bold">How can I watch for early symptoms of suicidal thoughts and actions?</span></p>
<ul class="Disc">
<li>Pay attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings.</li>
<li>Keep all follow-up visits with your healthcare provider as scheduled.</li>
<li>Call your healthcare provider between visits as needed, especially if you are worried about symptoms.</li>
</ul>
<p><span class="Bold">TOPAMAX</span><span class="Sup">®</span><span class="Bold"> can harm your unborn baby.</span></p>
<ul class="Disc">
<li>If you take TOPAMAX<span class="Sup">®</span> during pregnancy, your baby has a higher risk for <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span> called <span class="product-label-link" type="condition" conceptid="133861" conceptname="Cleft lip">cleft lip</span> and <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span>. These defects can begin early in pregnancy, even before you know you are pregnant.</li>
<li><span class="product-label-link" type="condition" conceptid="133861" conceptname="Cleft lip">Cleft lip</span> and <span class="product-label-link" type="condition" conceptid="135923" conceptname="Cleft palate">cleft palate</span> may happen even in children born to women who are not taking any medicines and do not have other risk factors.</li>
<li>There may be other medicines to treat your condition that have a lower chance of <span class="product-label-link" type="condition" conceptid="4029540" conceptname="Congenital anomaly">birth defects</span>.</li>
<li>All women of childbearing age should talk to their healthcare providers about using other possible treatments instead of TOPAMAX<span class="Sup">®</span>. If the decision is made to use TOPAMAX<span class="Sup">®</span>, you should use effective birth control (contraception) unless you are planning to become pregnant. You should talk to your doctor about the best kind of birth control to use while you are taking TOPAMAX<span class="Sup">®</span>.</li>
<li>Tell your healthcare provider right away if you become pregnant while taking TOPAMAX<span class="Sup">®</span>. You and your healthcare provider should decide if you will continue to take TOPAMAX<span class="Sup">®</span> while you are pregnant.</li>
<li><span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic acidosis</span> may have harmful effects on your baby. Talk to your healthcare provider if TOPAMAX<span class="Sup">®</span> has caused <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> during your pregnancy.</li>
<li>Pregnancy Registry: If you become pregnant while taking TOPAMAX<span class="Sup">®</span>, talk to your healthcare provider about registering with the North American Antiepileptic Drug Pregnancy Registry. You can enroll in this registry by calling 1-888-233-2334. The purpose of this registry is to collect information about the safety of antiepileptic drugs during pregnancy.</li>
</ul>
<p><span class="Bold">What is TOPAMAX</span><span class="Sup">®</span><span class="Bold">?</span></p>
<p>TOPAMAX<span class="Sup">®</span> is a prescription medicine used:</p>
<ul class="Disc">
<li>to treat certain types of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> and primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span>) in adults and children 2 years and older,</li>
<li>with other medicines to treat certain types of <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> (partial onset <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, primary generalized tonic-<span class="product-label-link" type="condition" conceptid="4265182" conceptname="Clonic seizure">clonic seizures</span>, and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> associated with Lennox-Gastaut syndrome) in adults and children 2 years and older,</li>
<li>to prevent <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headaches</span> in adults.</li>
</ul>
<p><span class="Bold">What should I tell my healthcare provider before taking TOPAMAX</span><span class="Sup">®</span><span class="Bold">?</span></p>
<p>Before taking TOPAMAX<span class="Sup">®</span>, tell your healthcare provider about all your medical conditions, including if you:</p>
<ul class="Disc">
<li>have or have had <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, mood problems, or suicidal thoughts or behavior</li>
<li>have kidney problems, have <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">kidney stones</span>, or are getting kidney dialysis</li>
<li>have a history of <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">metabolic acidosis</span> (too much acid in the blood)</li>
<li>have liver problems</li>
<li>have weak, brittle, or soft bones (<span class="product-label-link" type="condition" conceptid="432594" conceptname="Osteomalacia">osteomalacia</span>, <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>, <span class="product-label-link" type="condition" conceptid="4195039" conceptname="Osteopenia">osteopenia</span>, or decreased bone density)</li>
<li>have lung or breathing problems</li>
<li>have eye problems, especially <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span></li>
<li>have <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>have a growth problem</li>
<li>are on a diet high in fat and low in carbohydrates, which is called a ketogenic diet</li>
<li>are having surgery</li>
<li>are pregnant or plan to become pregnant</li>
<li>are breastfeeding. TOPAMAX<span class="Sup">®</span> passes into breast milk. It is not known if the TOPAMAX<span class="Sup">®</span> that passes into breast milk can harm your baby. Talk to your healthcare provider about the best way to feed your baby if you take TOPAMAX<span class="Sup">®</span>.</li>
</ul>
<p>Tell your healthcare provider about all the medicines you take, including prescription and non-prescription medicines, vitamins, and herbal supplements. TOPAMAX<span class="Sup">®</span> and other medicines may affect each other causing side effects.</p>
<p>Especially tell your healthcare provider if you take:</p>
<ul class="Disc">
<li>Valproic acid (such as DEPAKENE<span class="Sup">®</span> or DEPAKOTE<span class="Sup">®</span>)</li>
<li>any medicines that impair or decrease your thinking, concentration, or muscle coordination</li>
<li>birth control pills. TOPAMAX<span class="Sup">®</span> may make your birth control pills less effective. Tell your healthcare provider if your menstrual <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> changes while you are taking birth control pills and TOPAMAX<span class="Sup">®</span>.</li>
</ul>
<p>Ask your healthcare provider if you are not sure if your medicine is listed above.</p>
<p>Know the medicines you take. Keep a list of them to show your healthcare provider and pharmacist each time you get a new medicine. Do not start a new medicine without talking with your healthcare provider.</p>
<p><span class="Bold">How should I take TOPAMAX</span><span class="Sup">®</span><span class="Bold">?</span></p>
<ul class="Disc">
<li>Take TOPAMAX<span class="Sup">®</span> exactly as prescribed.</li>
<li>Your healthcare provider may change your dose. Do not change your dose without talking to your healthcare provider.</li>
<li>TOPAMAX<span class="Sup">®</span> Tablets should be swallowed whole. Do not chew the tablets. They may leave a bitter taste.</li>
<li>TOPAMAX<span class="Sup">®</span> Sprinkle Capsules may be swallowed whole or may be opened and sprinkled on a teaspoon of soft food. Drink fluids right after eating the food and medicine mixture to make sure it is all swallowed.</li>
<li>Do not store any medicine and food mixture for later use.</li>
<li>TOPAMAX<span class="Sup">®</span> can be taken before, during, or after a meal. Drink plenty of fluids during the day. This may help prevent <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">kidney stones</span> while taking TOPAMAX<span class="Sup">®</span>.</li>
<li>If you take too much TOPAMAX<span class="Sup">®</span>, call your healthcare provider or poison control center right away or go to the nearest emergency room.</li>
<li>If you miss a single dose of TOPAMAX<span class="Sup">®</span>, take it as soon as you can. However, if you are within 6 hours of taking your next scheduled dose, wait until then to take your usual dose of TOPAMAX<span class="Sup">®</span>, and skip the missed dose. Do not double your dose. If you have missed more than one dose, you should call your healthcare provider for advice.</li>
<li>Do not stop taking TOPAMAX<span class="Sup">®</span> without talking to your healthcare provider. Stopping TOPAMAX<span class="Sup">®</span> suddenly may cause serious problems. If you have <span class="product-label-link" type="condition" conceptid="380378" conceptname="Epilepsy">epilepsy</span> and you stop taking TOPAMAX<span class="Sup">®</span> suddenly, you may have <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span> that do not stop. Your healthcare provider will tell you how to stop taking TOPAMAX<span class="Sup">®</span> slowly.</li>
<li>Your healthcare provider may do blood tests while you take TOPAMAX<span class="Sup">®</span>.</li>
</ul>
<p><span class="Bold">What should I avoid while taking TOPAMAX</span><span class="Sup">®</span><span class="Bold">?</span></p>
<ul class="Disc">
<li>Do not drink alcohol while taking TOPAMAX<span class="Sup">®</span>. TOPAMAX<span class="Sup">®</span> and alcohol can affect each other causing side effects such as <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</li>
<li>Do not drive a car or operate heavy machinery until you know how TOPAMAX<span class="Sup">®</span> affects you. TOPAMAX<span class="Sup">®</span> can slow your thinking and motor skills, and may affect vision.</li>
</ul>
<p><span class="Bold">What are the possible side effects of TOPAMAX</span><span class="Sup">®</span><span class="Bold">?</span></p>
<p>TOPAMAX<span class="Sup">®</span> may cause serious side effects including:</p>
<p>See "<a href="#What_is_the_most_important">What is the most important information I should know about TOPAMAX</a><span class="Sup">®</span>?"</p>
<ul class="Disc">
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic acidosis</span>.</span> <span class="product-label-link" type="condition" conceptid="4245042" conceptname="Metabolic acidosis">Metabolic acidosis</span> can cause:<ul class="Circle">
<li><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span></li>
<li>loss of appetite</li>
<li>irregular heartbeat</li>
<li>impaired consciousness</li>
</ul>
</li>
<li>
<span class="Bold">High blood <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> levels.</span> High <span class="product-label-link" type="condition" conceptid="4184927" conceptname="Ammonia">ammonia</span> in the blood can affect your mental activities, slow your alertness, make you feel tired, or cause <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>. This has happened when TOPAMAX<span class="Sup">®</span> is taken with a medicine called valproic acid (DEPAKENE<span class="Sup">®</span> and DEPAKOTE<span class="Sup">®</span>).</li>
<li>
<span class="Bold">Low body temperature.</span> Taking TOPAMAX<span class="Sup">®</span> when you are also taking valproic acid can cause a drop in body temperature to less than 95°F, feeling tired, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, or <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>.</li>
<li>
<span class="Bold"><span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">Kidney stones</span>.</span> Drink plenty of fluids when taking TOPAMAX<span class="Sup">®</span> to decrease your chances of getting <span class="product-label-link" type="condition" conceptid="201620" conceptname="Kidney stone">kidney stones</span>.</li>
<li>
<span class="Bold">Effects on thinking and alertness. </span>TOPAMAX<span class="Sup">®</span> may affect how you think and cause <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, problems with concentration, attention, memory, or speech. TOPAMAX<span class="Sup">®</span> may cause <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span> or mood problems, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">tiredness</span>, and <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">sleepiness</span>.</li>
<li><span class="Bold"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> or loss of muscle coordination.</span></li>
</ul>
<p>Call your healthcare provider right away if you have any of the symptoms above.</p>
<p>The most common side effects of TOPAMAX<span class="Sup">®</span> include:</p>
<ul class="Disc">
<li><span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span> of the arms and legs (<span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesia</span>)</li>
<li>not feeling hungry</li>
<li><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span></li>
<li>a change in the way foods taste</li>
<li><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li><span class="product-label-link" type="condition" conceptid="4134010" conceptname="Weight decreased">weight loss</span></li>
<li><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span></li>
<li><span class="product-label-link" type="condition" conceptid="4181583" conceptname="Upper respiratory infection">upper respiratory tract infection</span></li>
</ul>
<p>Tell your healthcare provider about any side effect that bothers you or that does not go away.</p>
<p>These are not all the possible side effects of TOPAMAX<span class="Sup">®</span>. For more information, ask your healthcare provider or pharmacist.</p>
<p>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.</p>
<p>You may also report side effects to Janssen Pharmaceuticals, Inc. at 1-800-JANSSEN (1-800-526-7736).</p>
<p><span class="Bold">How should I store TOPAMAX</span><span class="Sup">®</span><span class="Bold">?</span></p>
<ul class="Disc">
<li>Store TOPAMAX<span class="Sup">®</span> Tablets at room temperature, 59°F to 86°F (15°C to 30°C).</li>
<li>Store TOPAMAX<span class="Sup">®</span> Sprinkle Capsules at or below 77°F (25°C).</li>
<li>Keep TOPAMAX<span class="Sup">®</span> in a tightly closed container.</li>
<li>Keep TOPAMAX<span class="Sup">®</span> dry and away from moisture.</li>
<li>
<span class="Bold">Keep TOPAMAX</span><span class="Sup">®</span><span class="Bold"> and all medicines out of the reach of children.</span>
</li>
</ul>
<p><span class="Bold">General information about TOPAMAX</span><span class="Sup">®</span><span class="Bold">.</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use TOPAMAX<span class="Sup">®</span> for a condition for which it was not prescribed. Do not give TOPAMAX<span class="Sup">®</span> to other people, even if they have the same symptoms that you have. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about TOPAMAX<span class="Sup">®</span>. If you would like more information, talk with your healthcare provider. You can ask your pharmacist or healthcare provider for information about TOPAMAX<span class="Sup">®</span> that is written for health professionals.</p>
<p>For more information, go to www.topamax.com or call 1-800-JANSSEN (1-800-526-7736).</p>
<p><span class="Bold">What are the ingredients in TOPAMAX</span><span class="Sup">®</span><span class="Bold">?</span></p>
<p><span class="Bold">Active ingredient: </span>topiramate</p>
<p><span class="Bold">Inactive ingredients:</span></p>
<ul class="Disc">
<li>
<span class="Bold">Tablets - </span>lactose monohydrate, pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, purified water, carnauba wax, hypromellose, titanium dioxide, polyethylene glycol, synthetic iron oxide, and polysorbate 80.</li>
<li>
<span class="Bold">Sprinkle Capsules - </span>sugar spheres (sucrose and starch), povidone, cellulose acetate, gelatin, sorbitan monolaurate, sodium lauryl sulfate, titanium dioxide, and black pharmaceutical ink.</li>
</ul>
<p>Revised January 2012</p>
<p><span class="Bold">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
<p>Manufactured by: Janssen Ortho, LLC, Gurabo, Puerto Rico 00778</p>
<p>Manufactured for: Janssen Pharmaceuticals, Inc., Titusville, NJ 08560</p>
<p>© Janssen Pharmaceuticals, Inc. 2009</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-19"></a><p></p>
<p class="First"><span class="Bold">PRINCIPAL DISPLAY PANEL - 50 mg Tablet Bottle Label</span></p>
<p><span class="Bold"><br></span></p>
<p><span class="Bold">TopAMAX</span><span class="Sup">®</span><br><span class="Bold">(topiramate) Tablets</span></p>
<p><span class="Bold">50 mg</span></p>
<p><span class="Bold">CAUTION: Verify Prescription<br>Before Dispensing</span></p>
<p><span class="Bold">ATTENTION PHARMACIST:<br>Dispense Accompanying<br>Medication Guide to Each<br>Patient</span></p>
<p>Rx only<br>60 tablets</p>
<div class="Figure"><img alt="55289433 Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=cea5f748-3127-4d36-83af-9ab3cf58503c&amp;name=55289433.jpg"></div>
<br>PDRx Label<br>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>TOPAMAX 		
					</strong><br><span class="contentTableReg">topiramate tablet, coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55289-433(NDC:50458-640)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>topiramate</strong> (topiramate) </td>
<td class="formItem">topiramate</td>
<td class="formItem">50 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>lactose monohydrate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium starch glycolate type A potato</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>carnauba wax</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycols</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polysorbate 80</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">YELLOW (light yellow) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">8mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">OMN;50</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55289-433-30</td>
<td class="formItem">30  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA020505</td>
<td class="formItem">01/01/1997</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>PD-Rx Pharmaceuticals, Inc.
							(156893695)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant - </span>PD-Rx Pharmaceuticals, Inc. (156893695)</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">PD-Rx Pharmaceuticals, Inc.</td>
<td class="formItem"></td>
<td class="formItem">156893695</td>
<td class="formItem">repack</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 1/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>843d6b92-e1ae-409f-b1e5-a2f2e03fe719</div>
<div>Set id: cea5f748-3127-4d36-83af-9ab3cf58503c</div>
<div>Version: 7</div>
<div>Effective Time: 20120118</div>
</div>
</div> <div class="DistributorName">PD-Rx Pharmaceuticals, Inc.</div></p>
</body></html>
